<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003993.pub3" GROUP_ID="GYNAECA" ID="790502021512310905" MERGED_FROM="" MODIFIED="2017-05-15 13:00:47 +0100" MODIFIED_BY="Clare Jess" REVIEW_NO="F007" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2017-05-15 13:00:44 +0100" MODIFIED_BY="Clare Jess">
<TITLE MODIFIED="2011-01-18 11:24:33 +0000" MODIFIED_BY="Clare Jess">Thymic peptides for treatment of cancer patients</TITLE>
<CONTACT MODIFIED="2017-05-15 13:00:44 +0100" MODIFIED_BY="Clare Jess"><PERSON ID="13696" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Markus</FIRST_NAME><LAST_NAME>Horneber</LAST_NAME><POSITION>Senior Registrar</POSITION><EMAIL_1>markus.horneber@klinikum-nuernberg.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine, Division of Oncology and Hematology</DEPARTMENT><ORGANISATION>Paracelsus Medical University, Klinikum Nuremberg</ORGANISATION><ADDRESS_1>Prof.-Ernst-Nathan-Str. 1</ADDRESS_1><CITY>Nuremberg</CITY><ZIP>D-90419</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 911 398 3056</PHONE_1><FAX_1>+49 911 398 2724</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-05-15 13:00:44 +0100" MODIFIED_BY="Clare Jess"><PERSON ID="9B0C173282E26AA20165AC2E6574C44D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elke</FIRST_NAME><LAST_NAME>Wolf</LAST_NAME><POSITION>Medical Doctor</POSITION><ADDRESS><DEPARTMENT>Medizinische Klinik 5-Schwerpunkt Onkologie/Haematologie</DEPARTMENT><ORGANISATION>Klinikum Nord</ORGANISATION><ADDRESS_1>Prof.-Ernst-Nathan-Str. 1</ADDRESS_1><CITY>Nuernberg</CITY><ZIP>90340</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 911 398 3088</PHONE_1><FAX_1>+49 911 398 2724</FAX_1></ADDRESS><FOOTNOTE>Deceased</FOOTNOTE></PERSON><PERSON ID="FBC0939382E26AA201D44AE91D9448F5" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Stefania</FIRST_NAME><LAST_NAME>Milazzo</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>stesincro@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine, Division of Oncology and Hematology</DEPARTMENT><ORGANISATION>Paracelsus Medical University, Klinikum Nuernberg</ORGANISATION><ADDRESS_1>Prof.-Ernst-Nathan-Str. 1</ADDRESS_1><CITY>Nuernberg</CITY><ZIP>D-90419</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 911 398 3056</PHONE_1><FAX_1>+49 911 398 2724</FAX_1></ADDRESS></PERSON><PERSON ID="16400" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Boehm</LAST_NAME><SUFFIX>phil</SUFFIX><POSITION>AG Biologische Krebstherapie</POSITION><EMAIL_1>drkatjaboehm@googlemail.com</EMAIL_1><URL>www.med5-nbg.de</URL><ADDRESS><DEPARTMENT>Medizinische Klinik 5-Schwerpunkt Onkologie/Haematologie</DEPARTMENT><ORGANISATION>Klinikum Nord</ORGANISATION><ADDRESS_1>Prof.-Ernst-Nathan-Str. 1</ADDRESS_1><CITY>Nuernberg</CITY><ZIP>D-90419</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 911 398 3056</PHONE_1></ADDRESS></PERSON><PERSON ID="3F0E190482E26AA200DAFFB94E3956B9" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Marcel</FIRST_NAME><LAST_NAME>Zwahlen</LAST_NAME><EMAIL_1>marcel.zwahlen@ispm.unibe.ch</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Social and Preventive Medicine</DEPARTMENT><ORGANISATION>University of Bern</ORGANISATION><ADDRESS_1>Finkelhubelweg11</ADDRESS_1><CITY>Bern</CITY><ZIP>3012</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY></ADDRESS></PERSON><PERSON ID="13696" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Markus</FIRST_NAME><LAST_NAME>Horneber</LAST_NAME><POSITION>Senior Registrar</POSITION><EMAIL_1>markus.horneber@klinikum-nuernberg.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine, Division of Oncology and Hematology</DEPARTMENT><ORGANISATION>Paracelsus Medical University, Klinikum Nuremberg</ORGANISATION><ADDRESS_1>Prof.-Ernst-Nathan-Str. 1</ADDRESS_1><CITY>Nuremberg</CITY><ZIP>D-90419</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 911 398 3056</PHONE_1><FAX_1>+49 911 398 2724</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-05-15 12:54:57 +0100" MODIFIED_BY="Clare Jess">
<UP_TO_DATE>
<DATE DAY="19" MONTH="3" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="3" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2009"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2017-05-15 12:51:25 +0100" MODIFIED_BY="Clare Jess">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-05-15 12:51:25 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="15" MONTH="5" YEAR="2017"/>
<DESCRIPTION>
<P>Intervention is no longer clinically important.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-04-01 14:15:40 +0100" MODIFIED_BY="Tracey Bishop">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-04-01 14:15:40 +0100" MODIFIED_BY="Tracey Bishop">
<DATE DAY="24" MONTH="2" YEAR="2015"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-24 10:10:20 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="11" MONTH="2" YEAR="2015"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-11 12:44:27 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="27" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-03-27 11:59:14 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="12" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Author details amended.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR" MODIFIED="2010-05-25 10:20:44 +0100" MODIFIED_BY="Elke Wolf">
<DATE DAY="1" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Authors: Reviewer team has changed</P>
<P>Objectives: Text was rephrased and the population under study was restricted to cancer patients with thymus extracts during chemo- or radiotherapy</P>
<P>Types of interventions: Interventional treatment under study was restricted to thymus extracts given during chemo- or radiotherapy and interventions in the control group were restricted to no treatment, or placebo treatment.</P>
<P>Types of outcome measures: Text was rephrased</P>
<P>Acknowledgments/Contributions of authors: the review team has changed and the text were rephrased/amended accordingly</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-05-25 10:17:49 +0100" MODIFIED_BY="Elke Wolf">
<DATE DAY="16" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-06-17 14:10:11 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-06-17 14:09:30 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-10-01 14:14:44 +0100" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-06-17 14:10:11 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-10-01 14:13:23 +0100" MODIFIED_BY="[Empty name]">
<NAME>AG Biologische Krebstherapie, Deutsche Krebshilfe (70-301)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-03-17 08:54:38 +0000" MODIFIED_BY="[Empty name]">
<NAME>Dr. Ernst und Anita Bauer-Stiftung, Nürnberg</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-06-17 14:10:11 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Gynecologic Cancer Group, Bath</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-05-15 12:52:26 +0100" MODIFIED_BY="Clare Jess">
<SUMMARY MODIFIED="2010-12-18 08:14:01 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-12-17 10:29:08 +0000" MODIFIED_BY="[Empty name]">Thymic peptides for treatment of cancer patients in addition to chemotherapy or radiotherapy, or both</TITLE>
<SUMMARY_BODY MODIFIED="2010-12-18 08:14:01 +0000" MODIFIED_BY="[Empty name]">
<P>The immune system plays a key role in the body&#8217;s own defences against cancer cells. The thymus gland plays a central part in this and modifies T-cells, a subset of lymphocytes. Studies with thymic peptides have shown a variety of effects on the immune system. There are two groups of thymic peptides available for use in treatment: purified extracts from animal (mostly calf) thymus glands and synthetically produced thymus gland peptides.<BR/>This review aims to answer the question whether having thymic peptides can improve the response to and tolerability of standard chemotherapy or radiotherapy, or combined treatment. Further questions are whether the peptides inhibit or reduce the progression and recurrence of disease, whether they prolong the life of cancer patients and whether quality of life is improved.</P>
<P>This review looked at the evidence from 26 clinical trials with a total of 2736 adult cancer patients. Many of the trials were small and of moderate quality. Only three studies were less than 10 years old. Thymosin &#945;<SUB>1 </SUB>is a synthetic peptide that shows some promise as a treatment option for patients with metastatic melanoma when used in addition to chemotherapy. Severe problems occur during chemotherapy and radiotherapy due to low white blood cell counts and infections. These were reduced by using purified thymus extracts. However, the use of purified thymus extracts should be investigated more thoroughly before the extracts are used routinely in patients. The findings were not conclusive and caution is advised. Overall, thymic peptides seem to be well tolerated.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-01-18 11:21:00 +0000" MODIFIED_BY="Clare Jess">
<ABS_BACKGROUND MODIFIED="2010-12-08 17:20:08 +0000" MODIFIED_BY="[Empty name]">
<P>Purified thymus extracts (pTE) and synthetic thymic peptides (sTP) are thought to enhance the immune system of cancer patients in order to fight the growth of tumour cells and to resist infections due to immunosuppression induced by the disease and antineoplastic therapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-06-15 12:24:13 +0100" MODIFIED_BY="Clare Jess">
<P>To evaluate the effectiveness of pTE and sTP for the management of cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-12-20 11:53:24 +0000" MODIFIED_BY="Clare Jess">
<P>We searched CENTRAL (<I>The Cochrane Library </I>2010, Issue 3), MEDLINE, EMBASE, AMED, BIOETHICSLINE, BIOSIS, CATLINE, CISCOM, HEALTHSTAR, HTA, SOMED and LILACS (to February 2010).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-12-17 10:09:33 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trials of pTE or sTP in addition to chemotherapy or radiotherapy, or both, compared to the same regimen with placebo or no additional treatment in adult cancer patients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-12-18 08:22:43 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data from published trials. We derived odds ratios (OR) from overall survival (OS) and disease-free survival (DFS) rates, tumour response (TR) rates, and rates of adverse effects (AE) related to antineoplastic treatments. We used a random-effects model for meta-analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-01-18 11:21:00 +0000" MODIFIED_BY="Clare Jess">
<P>We identified 26 trials (2736 patients). Twenty trials investigated pTE (thymostimulin or thymosin fraction 5) and six trials investigated sTP (thymopentin or thymosin &#945;<SUB>1</SUB>). Twenty-one trials reported results for OS, six for DFS, 14 for TR, nine for AE and 10  for safety of pTE and sTP. Addition of pTE conferred no benefit on OS (RR 1.00, 95% CI 0.79 to 1.25); DFS (RR 0.97, 95% CI 0.82 to 1.16); or TR (RR 1.07, 95% CI 0.92 to 1.25). Heterogeneity was moderate to high for all these outcomes. For thymosin &#945;<SUB>1</SUB> the pooled RR for OS was 1.21 (95% CI 0.94 to 1.56, P = 0.14), with low heterogeneity; and 3.37 (95% CI 0.66 to 17.30, P = 0.15) for DFS, with moderate heterogeneity. The pTE reduced the risk of severe infectious complications (RR 0.54, 95% CI 0.38 to 0.78, P = 0.0008; I² = 0%). The RR for severe neutropenia in patients treated with thymostimulin was 0.55 (95% CI 0.25 to 1.23,  P = 0.15). Tolerability of pTE and sTP was good. Most of the trials had at least a moderate risk of bias.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-12-17 10:27:37 +0000" MODIFIED_BY="[Empty name]">
<P>Overall, we found neither evidence that the addition of pTE to antineoplastic treatment reduced the risk of death or disease progression nor that it improved the rate of tumour responses to antineoplastic treatment. For thymosin &#945;<SUB>1</SUB>, there was a trend for a reduced risk of dying and of improved DFS. There was preliminary evidence that pTE lowered the risk of severe infectious complications in patients undergoing chemotherapy or radiotherapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-01-18 11:26:16 +0000" MODIFIED_BY="Clare Jess">
<BACKGROUND MODIFIED="2010-12-18 09:23:36 +0000" MODIFIED_BY="[Empty name]">
<P>By the late 1950s and early 1960s the role of the thymus as a lymphoid organ became clearer based on observations of a decreased immune response and consequent lowered resistance to infectious disease that resulted from damage to or experimental removal of the gland (<LINK REF="REF-Seybold-1950" TYPE="REFERENCE">Seybold 1950</LINK>). It is now well established that the thymus gland is a central lymphoid organ in which bone marrow-derived T-cell precursors undergo differentiation within the context of a specific cellular and extracellular microenvironment. The thymus gland is also responsible for the production of various peptides with hormone-like activity and purified extracts from animal thymus glands have been used to treat primary immunodeficient states (<LINK REF="REF-Goldstein-2009" TYPE="REFERENCE">Goldstein 2009</LINK>).</P>
<P>The role of the immune system to recognize and destroy tumour cells has been hypothesized since the early 1950s and is now generally accepted (<LINK REF="REF-Dunn-2002" TYPE="REFERENCE">Dunn 2002</LINK>). One of the approaches to treat cancer is via stimulation or modulation of the immune system with extracts and peptides from the thymus gland, which was first introduced in the 1970s (<LINK REF="REF-Costanzi-1977" TYPE="REFERENCE">Costanzi 1977</LINK>).</P>
<P>Thymus derived pharmaceuticals can be divided into two groups:</P>
<OL>
<LI>purified extracts from animal thymus glands containing peptide mixtures; and</LI>
<LI>synthetically produced single thymic peptides.</LI>
</OL>
<P>Historically these two groups represent two steps in the investigation of thymic peptides involved in T-cell maturation and activation. The first step is to produce cell-free extracts, the second is to characterize and analyse single components of these extracts.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="5">Purified thymus extracts</HEADING>
<P>Extracts from calf thymus glands were further processed in different steps of purification, fractionation and filtration to result in peptide mixtures. The exact composition and character of the peptides are not completely known and are subject to biological variation. Different preparations are not defined by their components but by the respective standardization of the extraction procedure. Two purified thymus extracts (pTE) were investigated in clinical trials and are included in this review, thymosin fraction 5 and thymostimulin (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">Thymosin fraction 5</HEADING>
<P>Thymosin fraction 5 was produced by US investigators in 1966. Goldstein et al extracted a so called 'lymphocytopoietic factor' from calf thymus, referring to its capacity to stimulate proliferation of lymphocytes both in vitro and in animal models, and termed it thymosin, which was initially thought to be a single polypeptide (<LINK REF="REF-Goldstein-1966" TYPE="REFERENCE">Goldstein 1966</LINK>). A further 5-step purification led to 'thymosin fraction 5', then identified as a mixture of 30 to 40 small polypeptide components with a molecular weight ranging from 1 to 15 kilodalton (<LINK REF="REF-Goldstein-1977" TYPE="REFERENCE">Goldstein 1977</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Thymostimulin</HEADING>
<P>Thymostimulin, also extracted from calf thymus, was first produced by Italian investigators in 1976. It consists of a group of peptides with molecular weights ranging from 1 to 12 kilodalton (<LINK REF="REF-Falchetti-1977" TYPE="REFERENCE">Falchetti 1977</LINK>). The way of processing differs from that of thymosin fraction 5 in several steps, which presumably results in a different composition of peptides (reviewed in <LINK REF="REF-Schulof-1985a" TYPE="REFERENCE">Schulof 1985a</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Synthetic thymic peptides</HEADING>
<P>Synthetically produced thymic peptides (sTP) are derivatives of peptides that have been isolated from thymus extracts and sequenced. Two synthetically produced thymic peptides were used in clinical trials included in this review, thymosin &#945;<SUB>1</SUB> and thymopentin (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">Thymosin &#945;<SUB>1</SUB>
</HEADING>
<P>Thymosin &#945;<SUB>1</SUB> is a peptide of 28 amino acids that was first isolated from thymosin fraction 5 in 1977 (<LINK REF="REF-Goldstein-1977" TYPE="REFERENCE">Goldstein 1977</LINK>). It is highly conserved among species and the amino acid sequence of human and bovine thymosin &#945;<SUB>1</SUB> are identical (reviewed in <LINK REF="REF-Hannappel-2003" TYPE="REFERENCE">Hannappel 2003</LINK>). Thymosin &#945;<SUB>1</SUB> has been sequenced and produced synthetically. Nowadays it is approved, mainly in countries of Asia and South America, for the treatment of chronic hepatitis B and C as a vaccine enhancer and in few countries of Southeast Asia for the treatment of cancer (<LINK REF="REF-Billich-2002" TYPE="REFERENCE">Billich 2002</LINK>). Pharmacokinetic studies in healthy volunteers showed good absorption after subcutaneous injection with a peak serum level at between one and two hours and a half live of less than three hours (<LINK REF="REF-Rost-1999" TYPE="REFERENCE">Rost 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Thymopentin</HEADING>
<P>Thymopentin is a fragment of a larger peptide called thymopoietin. Thymopoietin was initially isolated from calf thymus and consists of 49 amino acids. It had been shown to induce differentiation of T-cell precursors both in vitro and in vivo (<LINK REF="REF-Schlesinger-1975" TYPE="REFERENCE">Schlesinger 1975</LINK>). In the search for a smaller peptide with the same immunologic properties that was suitable for large-scale synthesis, the five amino-acid peptide thymopentin was identified (<LINK REF="REF-Goldstein-1979" TYPE="REFERENCE">Goldstein 1979</LINK>). Pharmacokinetic studies in humans showed a short half live of 30 seconds (reviewed in <LINK REF="REF-Singh-1998" TYPE="REFERENCE">Singh 1998</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Preclinical and clinical studies with pTE and sTP</HEADING>
<P>Preclinical studies with pTE and sTP showed a variety of modulatory effects on the immune system (<LINK REF="REF-Bodey-2000" TYPE="REFERENCE">Bodey 2000</LINK>; <LINK REF="REF-Chretien-1978" TYPE="REFERENCE">Chretien 1978</LINK>; <LINK REF="REF-Goldstein-2009" TYPE="REFERENCE">Goldstein 2009</LINK>; <LINK REF="REF-Schulof-1985a" TYPE="REFERENCE">Schulof 1985a</LINK>). They were tested with other substances in the Biological Response Modifiers Program of the National Cancer Institute for their efficacy in the treatment of human cancers in the 1980s (<LINK REF="REF-Schulof-1985a" TYPE="REFERENCE">Schulof 1985a</LINK>). Surveys from the late 1990s showed ample dissemination of information on the treatment of cancer with purified thymus extracts as part of a 'complementary and alternative treatment' of cancer (<LINK REF="REF-Grothey-1998" TYPE="REFERENCE">Grothey 1998</LINK>; <LINK REF="REF-Hardell-1998" TYPE="REFERENCE">Hardell 1998</LINK>; <LINK REF="REF-Kullmer-1999" TYPE="REFERENCE">Kullmer 1999</LINK>; <LINK REF="REF-Moschen-2001" TYPE="REFERENCE">Moschen 2001</LINK>; <LINK REF="REF-Sehouli-2000" TYPE="REFERENCE">Sehouli 2000</LINK>; <LINK REF="REF-Soellner-1997" TYPE="REFERENCE">Soellner 1997</LINK>). Clinical studies investigated the effects on various clinical endpoints as well as immunological effects in a broad range of malignant diseases. The findings of controlled trials of pTE and sTP in cancer have not been conclusive. The height of research activity was in the 1980s and early 1990s and then seemed to wane but very recently published studies with thymosin &#945;<SUB>1</SUB> indicate that it is still topical (<LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>).</P>
<P>The purpose of this review was to summarize the available evidence from clinical trials which investigated pTE and sTP in combination with chemotherapy or radiotherapy, or both, in order to determine whether the addition of thymic peptides had a beneficial effect on survival outcomes and quality of life in cancer patients as well as whether it improved the response to and tolerability of conventional cancer therapies. Given the diversity of pTE and sTP we also intended to elucidate their probable differential effects.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-12-18 09:24:09 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and tolerability of purified thymus extracts (pTE) and synthetically produced thymic peptides (sTP) for the treatment of cancer patients during chemotherapy or radiotherapy. The objectives of the review were to assess the following.</P>
<UL>
<LI>The effects of thymic peptides on:</LI>
</UL>
<UL>
<UL>
<LI>overall survival (OS) and disease-free survival (DFS) or progression-free survival (PFS),</LI>
<LI>tumour response,</LI>
<LI>adverse effects of chemotherapy and radiotherapy,</LI>
<LI>patient-reported quality of life.</LI>
</UL>
</UL>
<UL>
<LI>Adverse effects of pTE and sTP;</LI>
</UL>
<P>and to make recommendations for future research.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-01-18 11:26:16 +0000" MODIFIED_BY="Clare Jess">
<SELECTION_CRITERIA MODIFIED="2010-12-18 09:30:01 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-12-18 09:20:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) or quasi-RCTs (for example trials which used alternation, allocation by date of birth, etc.).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-12-18 09:20:45 +0000" MODIFIED_BY="[Empty name]">
<P>Adult patients with histologically proven malignant diseases of all stages who were submitted to treatment with chemotherapy, chemo-immunotherapy or radiotherapy (that is standard care).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-12-18 09:25:37 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intervention group</HEADING>
<P>Standard care plus treatment with any kind of parenterally applied pTE or sTP.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control group</HEADING>
<P>Standard care plus placebo treatment or no additional treatment. Standard care was required to be similar between groups.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-12-18 09:30:01 +0000" MODIFIED_BY="[Empty name]">
<P>The outcomes of interest were:<BR/>
</P>
<UL>
<LI>OS;</LI>
<LI>DFS and PFS;</LI>
<LI>tumour response (parameters for response had to be defined or follow standard criteria (WHO (<LINK REF="REF-Miller-1981" TYPE="REFERENCE">Miller 1981</LINK>), RECIST (<LINK REF="REF-Therasse-2000" TYPE="REFERENCE">Therasse 2000</LINK>));</LI>
<LI>hematologic toxicities or infectious complications related to antineoplastic treatment (chemotherapy, radiotherapy) of at least grade 3, scored using standardized criteria (CTC version 2 or later) (<LINK REF="REF-CTC-2009" TYPE="REFERENCE">CTC 2009</LINK>);</LI>
<LI>adverse events related to pTE and sTP.</LI>
</UL>
<P>Quality of life (QoL), measured with validated instruments, was an outcome for which data were sought but no data for this outcome were found in any of the included RCTs. Trials which only reported physiological measures (for example immune parameters etc.) were excluded.</P>
<P>For a glossary of terms please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>
</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-01-18 11:26:16 +0000" MODIFIED_BY="Clare Jess">
<P>The last systematic search was performed in February 2010.</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-01-18 11:26:16 +0000" MODIFIED_BY="Clare Jess">
<P>We searched the following databases without language restrictions: Cochrane Complementary Medicine Field Registry of randomised clinical trials and controlled clinical trials, Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2010, Issue 3), MEDLINE, EMBASE, PubMed, AMED, BIOETHICSLINE, BIOSIS, CATLINE, CISCOM, HEALTHSTAR, INTERNATIONAL HEALTH TECHNOLOGY ASSESSMENT, SOMED, LILACS. Synonyms of the specific terms were identified by looking up the thesaurus of each database, if available. Search strategies and terms are listed in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. All databases were searched from inception to February 2010.</P>
<P>Duplicates were removed from the search results and bibliographies from retrieved articles were searched for additional studies. The search strategies used were developed and executed by the author team.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-12-18 09:34:47 +0000" MODIFIED_BY="[Empty name]">
<P>To minimize the impact of publication bias, we searched conference abstracts and unpublished material. Inquiries were sent to the investigators or institutions of included studies and respective manufacturers of pTE and sTP requesting information on additional trials. Our own files were searched for further studies.<BR/>
</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-12-18 09:59:27 +0000" MODIFIED_BY="[Empty name]">
<P>All discrepancies between two authors in the process of data collection and analysis were discussed and, if not agreed upon, the opinion of a third review author was sought.</P>
<STUDY_SELECTION MODIFIED="2010-12-18 09:38:41 +0000" MODIFIED_BY="[Empty name]">
<P>All publications identified by the search were screened by one review author (SM), who excluded those that were clearly irrelevant (for example diseases other than cancer, reviews, etc.). The titles and abstracts of the remaining articles were independently checked by two review authors (KB, MH, SM, EW). When articles could not be excluded with certainty, full text material was obtained. At least two review authors (KB, MH, SM, EW) of the team independently assessed full text material by means of a standard eligibility form that applied the inclusion and exclusion criteria. All results of the selection process were documented and disagreements resolved by discussion with a third review author (MH, EW).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-12-18 09:47:21 +0000" MODIFIED_BY="[Empty name]">
<P>Data extraction was performed non-blinded to the study authors and independently by at least two review authors using a pretested extraction form. For included studies, data were extracted as recommended in <LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>. This included data on the following.</P>
<UL>
<LI>Author, year of publication (if published), journal citation and language.</LI>
<LI>Country.</LI>
<LI>Setting.</LI>
<LI>Study design, methodology.</LI>
<LI>Study population: total number enrolled, patient characteristics (inclusion and exclusion criteria, age, stage, histological cell type, co-morbidity, previous treatment), number enrolled in each arm.</LI>
<LI>Intervention and control details: no treatment, composition of placebo.</LI>
<LI>Standard care: type of chemotherapy, number of cycles and dose; timing and dose of radiotherapy.</LI>
<LI>Risk of bias in study: see below.</LI>
<LI>Duration of follow up.</LI>
<LI>Deviations from protocol.</LI>
<LI>Outcomes, where data on all outcomes were extracted for:</LI>
<UL>
<LI>time to event data, we extracted the median or mean survival times and their spread or confidence interval;</LI>
<LI>dichotomous outcomes (e.g. adverse events, deaths, disease recurrence, disease progression, tumour response), we extracted the number of patients in each treatment arm who experienced the outcome of interest and the number of patients assessed at the endpoint in order to estimate a risk ratio (RR). If necessary, data were extracted from Kaplan-Meier curves;</LI>
<LI>adverse events, type of event and grade of toxicity.</LI>
</UL>
</UL>
<P>The time points at which outcomes were collected and reported were noted. Data were entered from the forms into a Microsoft Access database and double-checked using descriptive database methods and plausibility checks by two review authors (MH, EW).</P>
<P>If more than one report from a study was available, the most recent was considered as the primary publication and was used primarily for data extraction; information from other reports were extracted if not reported in the primary reference. Data from non-english articles were extracted with the help of a native speaker.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-12-18 09:50:43 +0000" MODIFIED_BY="[Empty name]">
<P>The assessment of risk of bias was carried out according to the approach of The Cochrane Collaboration (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). In a first step, information relating to study quality that was essential for the judgment of risk of bias was extracted onto a prespecified form. Two review authors (MH, EW) then independently judged the risk of bias for each criterion as being low, high or unclear. Disagreements were resolved by discussion. The 'blinding' item was split up in order to allow for differential assessment of the outcomes dependent or independent of outcome assessors. The risk of bias was scored 'low' to 'high' with three intermediates ('low to moderate', 'moderate', and 'moderate to high'), with 'high' indicating the highest risk of bias.</P>
</QUALITY_ASSESSMENT>
<MISSING_DATA MODIFIED="2010-12-18 09:52:36 +0000" MODIFIED_BY="[Empty name]">
<P>Where information was missing in the study reports, lacked detail or there was a discrepancy between different reports, we tried to obtain the required information from the study authors. Contacting study authors helped to clarify our questions for only one publication (<LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-12-18 09:53:40 +0000" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was assessed according to the standard method using the I<SUP>2</SUP> statistic, calculated for each comparison on each outcome. I<SUP>2</SUP> values above 50% indicated high heterogeneity, between 25% and 50% moderate heterogeneity, and below 25% low heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-12-18 09:58:46 +0000" MODIFIED_BY="[Empty name]">
<P>For both survival outcomes, OS and DFS, we analysed the number of patients in each treatment arm who experienced deaths from all causes or relapse or progression of their cancer disease at one year ± four months. Tumour response was analysed if studies reported events of complete or partial, or both, responses. Pooled random-effects model estimates and their 95% confidence intervals (CI) were calculated. Analyses were run separately for pTE and sTP trials.<BR/>
<BR/>A decision regarding whether to combine treatment-related symptoms was made depending on how this information was collected in each trial. Results were expressed as relative risks or risk ratios (RR) with 95% CIs. In survival and tumour response analyses a RR higher than 1.0 favoured the intervention group, indicating that patients in the intervention group (pTE or sTP) had a greater chance of survival or for having a response to treatment. In the analysis of adverse effects of chemotherapy and radiotherapy, RR less than 1.0 favoured the intervention group, indicating that fewer patients experienced adverse events in the intervention groups than in the control group.<BR/>
<BR/>In studies reporting the median survival time, we recalculated the number of events up to median survival time in the intervention group for both the intervention and the control group assuming one-parametric exponential survival time. This assumption is equivalent to assuming a constant event hazard &#654;. Therefore, the formulae developed by <LINK REF="REF-Kirkwood-2003" TYPE="REFERENCE">Kirkwood 2003</LINK> were used (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
<P>Due to the variable study methods, all meta-analyses were considered as being explorative and pooled effects sizes have to be interpreted with great caution.<BR/>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-12-08 17:40:52 +0000" MODIFIED_BY="[Empty name]">
<P>Subgroup analyses were performed according to type of pTE or sTP if at least three studies reported data on the respective outcome and carried out sensitivity analyses as described below.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-12-18 09:59:27 +0000" MODIFIED_BY="[Empty name]">
<P>We performed sensitivity analyses taking account of different intervention treatments within one study (that is low dose or high dose of thymic peptides).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-12-18 10:39:08 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-12-18 10:20:51 +0000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2010-12-18 10:02:38 +0000" MODIFIED_BY="[Empty name]">
<P>From electronic searches and handsearches we retrieved 326 relevant publications. Out of 326 publications, 23 publications were unclear or the abstracts were not retrievable and 251 publications were ineligible for this systematic review. Reasons for ineligibility were: trial design other than RCT (for example historical control group); participants other than adult cancer patients (for example children, other disease conditions); no thymic peptides; application mode other than subcutaneous or intramuscular (for example oral or topical) or combination with other substances; no control for thymic peptides; and no chemotherapy or radiotherapy or different regimes in the control and intervention groups.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-12-18 10:19:52 +0000" MODIFIED_BY="[Empty name]">
<P>Twenty-six randomised controlled trials were included in this review. Thirteen were conducted in Italy (<LINK REF="STD-Airoldi-1987" TYPE="STUDY">Airoldi 1987</LINK>; <LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988</LINK>; <LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>; <LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>; <LINK REF="STD-GISOT-1987" TYPE="STUDY">GISOT 1987</LINK>; <LINK REF="STD-Gonnelli-1995" TYPE="STUDY">Gonnelli 1995</LINK>; <LINK REF="STD-Iaffaioli-1994" TYPE="STUDY">Iaffaioli 1994</LINK>; <LINK REF="STD-Luzi-1984" TYPE="STUDY">Luzi 1984</LINK>; <LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>; <LINK REF="STD-Mantovani-1988" TYPE="STUDY">Mantovani 1988</LINK>; <LINK REF="STD-Mustacchi-1994" TYPE="STUDY">Mustacchi 1994</LINK>; <LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK>; <LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>), six in the USA (<LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>; <LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>; <LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>; <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>; <LINK REF="STD-Wara-1981" TYPE="STUDY">Wara 1981</LINK>), four in Spain (<LINK REF="STD-Canovas-1988" TYPE="STUDY">Canovas 1988</LINK>; <LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>; <LINK REF="STD-De-Serdio-1997" TYPE="STUDY">De Serdio 1997</LINK>; <LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK>), one in Argentina (<LINK REF="STD-Guzman-1988" TYPE="STUDY">Guzman 1988</LINK>), one in China (<LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>), and one study recruited patients from several countries (<LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>). Studies with thymosin fraction 5 were published between 1979 and 1988, with thymostimulin between 1984 and 1997, with thymopentin between 1987 and 1994, and with thymosin &#945;<SUB>1 </SUB>between 1985 and 2010.</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>A total of 2931 adult patients were randomised (and 2744 evaluated) in the studies (median 49, range 28 to 650). The studies included the following number of randomised (and evaluated) cancer patients:</P>
<UL>
<LI>four studies with 427 (372 evaluated) breast cancer patients (<LINK REF="STD-Gonnelli-1995" TYPE="STUDY">Gonnelli 1995</LINK>; <LINK REF="STD-Mantovani-1988" TYPE="STUDY">Mantovani 1988</LINK>; <LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK>; <LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK>),</LI>
<LI>five with 314 (304) non-small cell lung cancer patients (<LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>; <LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988;</LINK> <LINK REF="STD-Iaffaioli-1994" TYPE="STUDY">Iaffaioli 1994</LINK>; <LINK REF="STD-Luzi-1984" TYPE="STUDY">Luzi 1984</LINK>; <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>),</LI>
<LI>four with 220 (192) small cell lung cancer patients (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>; <LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>; <LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>),</LI>
<LI>three with 236 (207) lymphoma patients (<LINK REF="STD-Canovas-1988" TYPE="STUDY">Canovas 1988</LINK>; <LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>; <LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>),</LI>
<LI>three with 160 (159) head and neck cancer patients (<LINK REF="STD-Airoldi-1987" TYPE="STUDY">Airoldi 1987</LINK>; <LINK REF="STD-De-Serdio-1997" TYPE="STUDY">De Serdio 1997</LINK>; <LINK REF="STD-Wara-1981" TYPE="STUDY">Wara 1981</LINK>),</LI>
<LI>two with 267 (243) colorectal cancer (<LINK REF="STD-Guzman-1988" TYPE="STUDY">Guzman 1988</LINK>; <LINK REF="STD-Mustacchi-1994" TYPE="STUDY">Mustacchi 1994</LINK>),</LI>
<LI>two with 69 (66) hepatocellular carcinoma patients (<LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>; <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>),</LI>
<LI>two with 750 (705) patients with various types of cancer (<LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>; <LINK REF="STD-GISOT-1987" TYPE="STUDY">GISOT 1987</LINK>), and</LI>
<LI>one with 488 (488) melanoma patients (<LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatments</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Intervention</HEADING>
<P>In 20 studies pTE was used as interventional treatment: 16 used thymostimulin and four used thymosin fraction 5. Thymostimulin was applied intramuscularly and single doses ranged from 25 mg to 150 mg. Most study authors (n = 9) used a dose of 1 mg/kg body weight. Thymosin fraction 5 was applied subcutaneously with single doses of 60 mg in all trials. However, treatment schedules varied considerably among trials. <LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK> had two interventional arms with different doses of thymosin fraction 5 (20 mg and 60 mg).</P>
<P>Six study authors used sTP as the interventional treatment: four used thymosin &#945;<SUB>1 </SUB>and two used thymopentin. Thymosin &#945;<SUB>1</SUB> was applied subcutaneously with single doses of 1.6 mg in three trials and 0.9 mg/m² in one trial. Treatment schedules varied among these trials. <LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK> compared different doses of thymosin &#945;<SUB>1 </SUB>(1.6, 3.2 and 6.4 mg); <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK> compared a 14-day 'loading' dose of thymosin &#945;<SUB>1</SUB> with a maintenance therapy for up to one year; thymopentin was given intramuscularly in <LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK> and subcutaneously in <LINK REF="STD-GISOT-1987" TYPE="STUDY">GISOT 1987</LINK>, both studies using single doses of 50 mg.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Control</HEADING>
<P>Twenty studies had two arms and two of these studies used a placebo control (<LINK REF="STD-Iaffaioli-1994" TYPE="STUDY">Iaffaioli 1994</LINK>; <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>). Three studies had three arms (<LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>; <LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>). <LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK> compared two different thymosin fraction 5 doses with no treatment; <LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK> compared intrahepatic chemotherapy, with or without thymosin &#945;<SUB>1</SUB>, with no intrahepatic chemotherapy; and <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK> compared two different regimen of thymosin &#945;<SUB>1</SUB> with placebo. <LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK> had four arms and compared thymopentin with or without granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF. <LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK> had five arms: three compared different doses of thymosin &#945;<SUB>1</SUB> in addition to chemotherapy plus interferon &#945;, one arm had 3.2 mg thymosin &#945;<SUB>1</SUB> in addition to chemotherapy alone and the fifth arm had only chemotherapy plus interferon &#945;. The comparison between 3.2 mg thymosin &#945;<SUB>1</SUB> and interferon &#945; was not included in the analysis as interferon &#945; was not a control treatment in accordance with our protocol.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Basic treatment</HEADING>
<P>The chemotherapy or radiotherapy regimen was described in all but one of the studies (<LINK REF="STD-GISOT-1987" TYPE="STUDY">GISOT 1987</LINK>). In 23 studies patients received chemotherapy alone, in combination with radiotherapy or immunotherapy, or applied as transcatheter arterial embolization. In two studies patients received radiotherapy alone (<LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>; <LINK REF="STD-Wara-1981" TYPE="STUDY">Wara 1981</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Survival</HEADING>
<P>Twenty-one studies reported OS. One author did not present estimates but described the results narratively (<LINK REF="STD-Iaffaioli-1994" TYPE="STUDY">Iaffaioli 1994</LINK>). Six studies reported DFS (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-De-Serdio-1997" TYPE="STUDY">De Serdio 1997</LINK>; <LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>; <LINK REF="STD-Guzman-1988" TYPE="STUDY">Guzman 1988</LINK>; <LINK REF="STD-Mantovani-1988" TYPE="STUDY">Mantovani 1988</LINK>; <LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>), although none gave a definition of how this was measured. Nine studies reported on PFS (<LINK REF="STD-Airoldi-1987" TYPE="STUDY">Airoldi 1987</LINK>; <LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>; <LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>; <LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>; <LINK REF="STD-Mustacchi-1994" TYPE="STUDY">Mustacchi 1994</LINK>; <LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK>; <LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>; <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>; <LINK REF="STD-Wara-1981" TYPE="STUDY">Wara 1981</LINK>) although none gave a definition of how this was measured. Terminology of the measures of relapse and recurrence differed considerably between trials (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Tumour response</HEADING>
<P>Seventeen studies reported on tumour response and 14 of them referred to defined response criteria mostly in accordance with standard criteria. In <LINK REF="STD-Iaffaioli-1994" TYPE="STUDY">Iaffaioli 1994</LINK> tumour response data were not reported but the author summarised the results in the text. <LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK> reported data on an 'overall response rate' but did not define it any further and <LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK> presented data on response referring to the first cycle of chemotherapy only (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Toxicity (adverse effects of chemotherapy and radiotherapy)</HEADING>
<P>The two outcomes which were reported in a way that allowed us to include them in our analyses were severe neutropenia and infectious complications. Nine studies (<LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>; <LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988</LINK>; <LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>; <LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>; <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>; <LINK REF="STD-Iaffaioli-1988" TYPE="STUDY">Iaffaioli 1988</LINK>; <LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>; <LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK>; <LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>) reported on one or both of these outcomes according to the National Cancer Institute Common Toxicity Criteria (<LINK REF="REF-CTC-2009" TYPE="REFERENCE">CTC 2009</LINK>) or gave a sufficient description of the outcomes, which allowed us to apply grading criteria. Three of them reported on the incidence of grade 3 to 4 neutropenia per patient, one per chemotherapy cycle; and seven on the incidence of grade 3 to 4 infectious complications (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Safety (adverse effects of purified thymus extracts (pTE) and synthetic thymic peptides (sTP)</HEADING>
<P>Ten trials commented on the 'tolerability' of pTE or sTP (<LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>; <LINK REF="STD-Canovas-1988" TYPE="STUDY">Canovas 1988</LINK>; <LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>; <LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988</LINK>; <LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>; <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>; <LINK REF="STD-Luzi-1984" TYPE="STUDY">Luzi 1984</LINK>; <LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>; <LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK>). The numbers of patients with local or systemic adverse effects were given in three studies (<LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>; <LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>; <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>) (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>, <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>None of the included studies reported on patient-reported QoL.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-12-18 10:20:51 +0000" MODIFIED_BY="[Empty name]">
<P>Of the remaining 52 publications considered to be of possible relevance, nine papers were duplicates and 17 did not fulfil inclusion criteria. Reasons for exclusion of studies are described in the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-12-18 10:24:45 +0000" MODIFIED_BY="[Empty name]">
<P>The quality of the included studies and the subsequent risk of bias were assessed separately for the different outcomes of interest using the criteria defined in the Cochrane Handbook (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). The assessments and grades given are shown in <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> and <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>. The studies are grouped below by the grades for risk of bias. The grading is a basic judgement and does not account for the complexity of many of the trials studied.</P>
<SUBSECTION>
<HEADING LEVEL="3">Mortality outcomes</HEADING>
<P>Studies with pTE were judged as having the following risk of bias concerning OS:</P>
<UL>
<LI>low to moderate: <LINK REF="STD-Mustacchi-1994" TYPE="STUDY">Mustacchi 1994</LINK>; <LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>,</LI>
<LI>moderate: <LINK REF="STD-Airoldi-1987" TYPE="STUDY">Airoldi 1987</LINK>; <LINK REF="STD-Canovas-1988" TYPE="STUDY">Canovas 1988</LINK>; <LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>; <LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK>,</LI>
<LI>moderate to high: <LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>; <LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>; <LINK REF="STD-Guzman-1988" TYPE="STUDY">Guzman 1988</LINK>; <LINK REF="STD-Luzi-1984" TYPE="STUDY">Luzi 1984</LINK>,</LI>
<LI>high: <LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988</LINK>; <LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>; <LINK REF="STD-Mantovani-1988" TYPE="STUDY">Mantovani 1988</LINK>; <LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>.</LI>
</UL>
<P>Studies with sTP were judged as having the following risk of bias concerning OS:</P>
<UL>
<LI>low: <LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>,</LI>
<LI>low to moderate: <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>,</LI>
<LI>moderate: <LINK REF="STD-GISOT-1987" TYPE="STUDY">GISOT 1987</LINK>; <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>,</LI>
<LI>high: <LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome assessor-related outcomes</HEADING>
<P>Studies with pTE were judged as having the following risk of bias concerning DFS and toxicity outcomes:</P>
<UL>
<LI>moderate: <LINK REF="STD-Iaffaioli-1994" TYPE="STUDY">Iaffaioli 1994</LINK>,</LI>
<LI>moderate to high: <LINK REF="STD-Airoldi-1987" TYPE="STUDY">Airoldi 1987</LINK>; <LINK REF="STD-Canovas-1988" TYPE="STUDY">Canovas 1988</LINK>; <LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>; <LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-De-Serdio-1997" TYPE="STUDY">De Serdio 1997</LINK>; <LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>; <LINK REF="STD-Mustacchi-1994" TYPE="STUDY">Mustacchi 1994</LINK>; <LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK>; <LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK>; <LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>; <LINK REF="STD-Wara-1981" TYPE="STUDY">Wara 1981</LINK>,</LI>
<LI>high: <LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>; <LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988</LINK>; <LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>; <LINK REF="STD-Gonnelli-1995" TYPE="STUDY">Gonnelli 1995</LINK>; <LINK REF="STD-Guzman-1988" TYPE="STUDY">Guzman 1988</LINK>; <LINK REF="STD-Luzi-1984" TYPE="STUDY">Luzi 1984</LINK>; <LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>; <LINK REF="STD-Mantovani-1988" TYPE="STUDY">Mantovani 1988</LINK>; <LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>.</LI>
</UL>
<P>Studies with sTP were judged as having the following risk of bias concerning DFS and toxicity outcomes:</P>
<UL>
<LI>low to moderate: <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>; <LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>,</LI>
<LI>moderate: <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>,</LI>
<LI>moderate to high: <LINK REF="STD-GISOT-1987" TYPE="STUDY">GISOT 1987</LINK>,</LI>
<LI>high: <LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>.</LI>
</UL>
<P>Overall, the reasons for higher grades of risk of bias were due to inadequate reporting of the methods used for random allocation, unbalanced risk factors for the outcome of interest and small sample sizes. For outcome assessor-related outcomes, inadequate reporting of the methods used for blinding were an additional reason for assuming higher risk of bias.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-12-18 10:39:08 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Survival</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Overall survival (OS)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Purified thymus extracts (pTE)</HEADING>
<P>Fifteen trials with pTE reported OS data with observation periods ranging from three to over 60 months. Data for meta-analysis of OS at one year could be obtained from eight trials. The analysis included a total of 705 patients and 355 events and the RR did not show a difference in the risk of survival between the thymic peptides regimen and no treatment or placebo (RR 1.00, 95% CI 0.79 to 1.25) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Heterogeneity was moderate (I² = 44%).</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis</HEADING>
<P>The thymostimulin group included five trials with 469 patients and the thymosin fraction 5 group had three trials including 236 patients. In the thymostimulin group, the pooled RR was above 1 (RR 1.07, 95% CI 0.85 to 1.35), whereas in the thymosin fraction 5 group the RR was 0.84 (95% CI 0.49 to 1.45).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Synthetic thymic peptides (sTP)</HEADING>
<P>Five trials with sTP reported OS data with observation periods from three months to two years. Data for meta-analysis of OS at one year could be obtained from four trials (<LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>; <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>; <LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>; <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>). All four trials used thymosin &#945;<SUB>1</SUB>. The analysis included 496 patients and 200 events. The RR for OS was 1.21 (95% CI 0.94 to 1.56, P = 0.14) without statistical heterogeneity (I² = 0%).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Disease-free survival (DFS)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Purified thymus extracts (pTE)</HEADING>
<P>Twelve trials with pTE reported DFS data with observation periods ranging from three to over 60 months. Data for meta-analysis of DFS at one year could be obtained from six trials (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>; <LINK REF="STD-Mantovani-1988" TYPE="STUDY">Mantovani 1988</LINK>; <LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK>; <LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>; <LINK REF="STD-Wara-1981" TYPE="STUDY">Wara 1981</LINK>). The DFS analysis included a total of 511 patients and 308 events. The RR did not show a difference in the risk of DFS between the thymic peptides regimen and no treatment or placebo (RR 0.97, 95% CI 0.82 to 1.16) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Heterogeneity was moderate (I² = 30%).</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis</HEADING>
<P>The thymostimulin group included three trials with 385 patients and the thymosin fraction 5 group had three trials including 126 patients. The subgroup analysis showed no difference between the two subgroups (thymostimulin: RR 0.93, 95% CI 0.73 to 1.19; thymosin fraction 5: RR 1.06, 95% CI 0.71 to 1.60).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Synthetic thymic peptides (sTP)</HEADING>
<P>Data were obtained for meta-analysis of DFS at one year from three trials. All trials used thymosin &#945;<SUB>1</SUB>. A total of 471 patients with 30 events were included in analysis. The RR was 3.37 (95% CI 0.66 to 17.30, P = 0.15) with moderate heterogeneity (I² = 37%) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tumour response</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Purified thymus extracts (pTE)</HEADING>
<P>Data could be obtained for response analysis from 11 trials with pTE. A total of 825 patients with 423 events were included in the analysis. There was no difference in the overall chance of achieving a complete or partial response between the intervention and the control groups (RR 1.07, 95% CI 0.92 to 1.25) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Heterogeneity among the trials was rather high (I² = 53%).</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis</HEADING>
<P>The thymostimulin group included eight trials with 553 patients and 258 events; the thymosin fraction 5 group had three trials including 225 patients with 131 events.</P>
<P>The pooled RR of trials using thymostimulin was 1.25 (95% CI 0.96 to 1.62, P = 0.09), whereas in the thymosin fraction 5 group the RR was below 1 (RR 0.73, 95% CI 0.24 to 2.19, P = 0.57).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Synthetic thymic peptides (sTP)</HEADING>
<P>Only two trials with thymosin &#945;<SUB>1</SUB> reported data on tumour response (<LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>; <LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>). Therefore we did not pool data. Both trials showed no significant difference between the intervention and the control groups (RR 0.79, 95% CI 0.13 to 4.72; RR 1.91, 95% CI 0.68 to 5.39 respectively) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>Sensitivity analyses were performed using data from treatment arms with higher doses of thymic peptides (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>) or maintenance regime instead of the loading dose (<LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>). Overall, no significant changes were found in risks for survival and tumour response and in statistical heterogeneity. Details are shown in <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Toxicity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Purified thymus extracts (pTE)</HEADING>
<P>
<I>Infectious complications</I>
<BR/>Data could be obtained from four studies for pooled analysis of severe infections (at least CTC grade 3 or 4). Three investigated thymostimulin and one thymosin fraction 5. A total of 214 patients were included and 73 experienced a severe infectious complication at any site. The RR indicated a lower risk of severe infectious complications (RR 0.54, 95% CI 0.38 to 0.78, P = 0.0008) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Heterogeneity among the trials was low (I² = 0%).</P>
<P>
<I>Neutropenia</I>
<BR/>Data for analysis of severe neutropenia (at least CTC grade 3 or 4) could be obtained from three trials, which all used thymostimulin. Overall, 72 of 149 patients experienced severe neutropenia. The RR was 0.55 (95% CI 0.25 to 1.23, P = 0.15) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) with high heterogeneity among the trials (I² = 63%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Synthetic thymic peptides (sTP)</HEADING>
<P>Only two trials with sTP reported data on infectious complications or neutropenia (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Therefore pooling of data was not feasible. <LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994 </LINK>found a non-significant reduction in the number of patients experiencing neutropenia during chemotherapy by treatment with thymopentin. <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK> reported a non-significant reduction in the rate of patients with severe bacterial infections by treatment with thymosin &#945;<SUB>1</SUB>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety</HEADING>
<P>Ten out of 20 studies with pTE and three out of six trials with sTP reported on adverse effects of the interventional treatments. Seven authors reported that the interventional treatments were well tolerated. Adverse events reported by the other authors were mild, transient local reactions at the injection site with systemic reactions in few patients. Details are shown in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> and <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-12-18 11:11:25 +0000" MODIFIED_BY="[Empty name]">
<P>This review included data from 26 trials (2736 patients) investigating the treatment of various malignancies with pTE or sTP while receiving basic oncologic treatment consisting of chemotherapy alone or in combination with radiotherapy or immunotherapy, chemotherapy applied as transcatheter arterial embolization, or radiotherapy alone. These 26 studies included both published and unpublished trials and represented all RCTs matching the inclusion criteria at the time of the literature search. The last trial was identified in March 2010. Twenty studies used one of two pTE, thymostimulin or thymosin fraction 5, and six one of two sTP, thymopentin or thymosin &#945;<SUB>1</SUB>, as investigational treatments.</P>
<P>We did not find evidence that the addition of pTE or sTP to antineoplastic treatment reduces the risk of death or disease progression, nor that it improves the rate of tumour response to antineoplastic treatment. However, there was preliminary evidence that pTE lowered the risk of severe infectious complications in patients undergoing chemotherapy or radiotherapy. There was no evidence of significant side effects either with pTE or sTP.</P>
<P>The pTE was used to treat 1436 patients, and 372 breast cancer patients from three studies was the largest group. There were 1300 participants treated with sTP, 488 patients with metastasised melanoma were from one study. There were sufficient numbers to assess treatment impact of both pTE and sTP on survival outcomes, and of pTE on tumour response. There were only a few trials with small numbers of patients that assessed the effects of pTE and sTP on adverse effects of chemotherapy or radiotherapy scored according to standardized criteria (CTC), therefore the trials in this review have low power to assess the impact of the intervention on this outcome. We had planned to perform subgroup analyses with respect to different types of cancer. After appraisal of the included studies, however, subgroup analysis was only possible for the different investigational drugs applied.</P>
<P>Other major problems for this review were the poor methodological quality of many of the included trials, variability in entry criteria, the nature and timing of outcomes, and poor reporting of both outcomes and methodology. In particular, there is a possibility of bias due to different treatment schedules and doses of both the investigational and the basic oncologic treatments across the trials, as well as a general failure to report data suitable for comparison of survival over time. Only four trials reported adequate methods of allocation concealment, which could have introduced bias. None of the trials with pTE and only one with sTP reported blinding of outcome assessors, which could have introduced bias in the assessment of DFS, tumour response and toxicity outcomes. Another limitation of this systematic review was the small sample size of many of the trials. In particular, two thirds of trials had a sample size of less than 60 participants and may have yielded inconclusive results because they were small and therefore did not have adequate statistical power. Only six trials included more than 100 participants.</P>
<P>The included trials were published over a 31-year period, up to 2010, and mainly involved participants from Italy, Spain and the USA. Studies with pTE were conducted from 1979 until the late 1990s. Thereafter this treatment concept was seemingly abandoned and clinical investigations became orientated towards the application of sTP. All studies (n = 3) which were conducted after 1997 used the sTP thymosin &#945;<SUB>1</SUB>.</P>
<P>Pooling of data was possible for a number of clinical outcomes of interest. For thymosin &#945;<SUB>1</SUB> there was a slight trend toward an overall reduction in the risk of dying (RR 1.21, 95% CI 0.94 to 1.56, P = 0.14) and improved DFS (RR 3.37, 95% CI 0.66 to 17.30, P = 0.15). Data from one large trial with low risk of bias on patients with metastatic melanoma mainly contributed to these results. Two trials with thymosin &#945;<SUB>1 </SUB>compared either different doses (<LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>) or different regimes of application (<LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>). Results from these individual studies indicated a possible dose-dependent effect. A further finding from Maio's trial that was not included in our analysis but which could be of interest was that thymosin &#945;<SUB>1 </SUB>added to chemotherapy seemed to be as effective as interferon &#945; but better tolerated.</P>
<P>The different RR for tumour response of thymostimulin (above 1) and thymosin fraction 5 (below 1) might be regarded as a possible indication of differential effects of the two different pTE. However, such an interpretation should be made with caution because the suggested negative effect of thymosin fraction 5 is mainly caused by one study at high risk of selection bias that involved patients with advanced non-small cell lung cancer (<LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>). Nevertheless, true opposite effects of different pTE, for instance caused by differences in the peptide composition, could not be ruled out based on our data. Thymostimulin and thymosin fraction 5 have dissimilar manufacturing processes and while there were little to no efforts to analyse the components of thymostimulin, those of thymosin fraction 5 came under scrutiny. One oligopeptide identified from the thymosin fraction 5 is thymosin ß<SUB>4</SUB>, which was recently discussed due to its possible stimulating effects on tumour metastasis by activating cell migration and angiogenesis (<LINK REF="REF-Cha-2003" TYPE="REFERENCE">Cha 2003</LINK>). The heterogeneity within the two groups might also be attributable to different reactions of the various cancer entities to pTE. Lack of sufficient studies with the same disease conditions hampers further evaluation of this aspect.</P>
<P>Pooled estimates of trials of pTE suggest an advantage on the risk of experiencing serious infectious complications or, as a trend, severe neutropenia during basic oncological treatment. Two trials with sTP reported similar findings on these outcomes but were not included in the meta-analysis (<LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>; <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>). Two of the four arms in <LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK> compared thymopentin with G-CSF. Although there was some evidence that thymopentin might reduce the risk of infections, G-CSF was significantly more effective (<LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>). Given the safety profile of sTP, they could still be of investigational interest for this indication.</P>
<P>All of these findings are subject to a potential publication bias. While we have made every effort to locate further unpublished data, it remains possible that this review is subject to a positive publication bias, with generally favourable trials more likely to achieve reporting. For instance Schulof referred, in a systematic review from 1985, to one trial of thymosin fraction 5 with negative effects on tumour response where the information was obtained by personal communication (<LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>). We could not trace a publication.</P>
<P>Only one systematic review on thymic peptides in cancer patients has been published so far (<LINK REF="REF-Ernst-1997" TYPE="REFERENCE">Ernst 1997</LINK>). The author addressed the question of clinical effectiveness of 'thymus therapy' in cancer patients and included 13 of 21 RCTs published between 1979 and 1996. Inclusion criteria were similar to those used in our review but additionally included oral thymus preparations as interventional treatments and immunologic parameters as outcomes. There was no tool for assessment of methodological quality and study results were interpreted narratively. The author criticised the trials because of low methodological quality, small sample sizes, heterogeneous study populations and statistical shortcomings. The overall conclusion saw no 'compelling' evidence for the efficacy of thymus extracts but regarded some results as 'promising' and deserving of further investigation. This overall conclusion is in accordance with the results of our review pertaining to the set of trials included in Ernst&#8217;s review.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-12-18 11:18:29 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-12-18 11:14:05 +0000" MODIFIED_BY="[Empty name]">
<P>Data provided by four small RCTs suggest that purified thymus extracts (pTE) might reduce the risk of infectious complications in patients undergoing chemotherapy or radiotherapy, or both. The effect of synthetic thymic petides on the same outcome is only supported by weak evidence. Findings that thymosin &#945;<SUB>1</SUB> might have beneficial effects on survival were mainly supported by one larger study with low risk of bias of patients with metastatic melanoma. Given the limited treatment options for this condition and the safety profile of thymosin &#945;<SUB>1</SUB>, treatment with thymosin &#945;<SUB>1</SUB> could be considered assuming that the decision about its use was based on expert clinical judgement. This should be discussed with patients before they give their consent and, where possible, patients should be offered entry into well-designed clinical trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-12-18 11:18:29 +0000" MODIFIED_BY="[Empty name]">
<P>There is a case for well-designed randomised trials to assess the possible value of the application of thymosin &#945;<SUB>1</SUB>, suggested by one large trial in patients with metastasised melanoma. Future trials must employ up-to-date antineoplastic and supportive treatment regimens in both arms; should take into account a possible dose-dependent effect of thymosin &#945;<SUB>1</SUB>, evaluate appropriate sample sizes with power to detect expected differences and apply effective and explicit blinding of treatment allocation. Examined outcome measures should include QoL measured with validated instruments and careful elucidation of any adverse effects.</P>
<P>Clinical trials with purified thymus extracts should not be advocated in the management of cancer until the exact compositions of the extracts are scrutinized and components are identified that might confer possible effects on host immunity and tumour biology.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-12-20 11:58:44 +0000" MODIFIED_BY="Clare Jess">
<P>Erik Ritter and Gerd Büschel initially contributed to the development of the protocol and the first literature search but subsequently left the review team. Gerd Büschel kindly commented on the final draft of the manuscript. We would also like to thank Prof Dr Ewald Hannappel (Institut für Biochemie, Friedrich-Alexander-Universität, Erlangen-Nürnberg) for his interest and his valuable suggestions.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-12-17 22:04:34 +0000" MODIFIED_BY="[Empty name]">
<P>None known. <BR/>It is certified that there are no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (for example employment, consultancy, stock ownership, honoraria).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-12-17 21:59:41 +0000" MODIFIED_BY="[Empty name]">
<P>MH and EW had full access to all data in the review and takes responsibility for the integrity of the data and the accuracy of the analysis.<BR/>Study concept and design: KB, MH, SM, EW.<BR/>Inclusion and exclusion of studies: KB, MH, SM, EW.<BR/>Acquisition of data: KB, MH, SM, EW.<BR/>Data entry and plausibility check: EW, MH.<BR/>Analysis and interpretation of data: MH, SM, EW.<BR/>Drafting of the manuscript: MH, EW with contributions from all other review authors.<BR/>Statistical analysis: MH, SM, EW, MZ.<BR/>Study supervision: MH.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2017-05-15 12:52:26 +0100" MODIFIED_BY="Clare Jess">
<P>Intervention is no longer clinically important.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-05-15 13:00:47 +0100" MODIFIED_BY="Clare Jess">
<STUDIES MODIFIED="2010-12-18 23:25:49 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-12-18 11:53:43 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Airoldi-1987" MODIFIED="2010-12-18 11:42:23 +0000" MODIFIED_BY="[Empty name]" NAME="Airoldi 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-12-18 11:42:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Airoldi M, Gabriele P, Penani F, Brando V, Melano A</AU>
<TI>Chemioterapia versus chemioimmunoterapia con Timostimulina nei carcinomi avanzati del cavo orale: risultati clinici di uno studio randomizzato</TI>
<SO>Recenti Progressi in Medicina</SO>
<YR>1987</YR>
<VL>78 Suppl 6</VL>
<PG>67-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323646"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323645"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bedikian-1984" MODIFIED="2010-02-11 13:52:02 +0000" MODIFIED_BY="[Empty name]" NAME="Bedikian 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-02-11 13:52:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bedikian AY, Patt YZ, Murphy WK, Umsawasadi T, Carr DT, Hersh EM, et al</AU>
<TI>Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1984</YR>
<VL>7</VL>
<NO>5</NO>
<PG>399-404</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323648"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323647"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canovas-1988" MODIFIED="2010-06-16 12:25:05 +0100" MODIFIED_BY="Clare Jess" NAME="Canovas 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-16 12:25:05 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canovas Fernandez A, Gonzalez de Zarate P, Alonso Alonso J, Aguirre Errasti C</AU>
<TI>[Thymostimulin as an adjuvant to antineoplastic chemotherapy. Experience with patients with myeloma and lymphoma]</TI>
<SO>Revista Clinica Espanola</SO>
<YR>1988</YR>
<VL>183</VL>
<NO>7</NO>
<PG>340-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323650"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323649"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canovas-1991" MODIFIED="2010-06-16 12:25:39 +0100" MODIFIED_BY="Clare Jess" NAME="Canovas 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-06-16 12:25:39 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canovas Fernandez A, Alonso Alonso J, Gonzalez de Zarate P, Garcia Masdevall MD, Rinon Martinez-Gallo M, Aguirre Errasti C</AU>
<TI>[The use of thymostimulin in lymphoma and myeloma patients]</TI>
<SO>Anales de Medicina Interna</SO>
<YR>1991</YR>
<VL>8</VL>
<NO>2</NO>
<PG>69-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323652"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323651"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2004" MODIFIED="2010-01-10 17:49:39 +0000" MODIFIED_BY="[Empty name]" NAME="Cheng 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-10 17:48:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng S, Mengchao W, Han C, Feng S, Jiahe Y, Wenming C, et al</AU>
<TI>Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma</TI>
<SO>Hepatogastroenterology</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>59</NO>
<PG>1445-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323654"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323653"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1979" MODIFIED="2010-02-11 14:01:11 +0000" MODIFIED_BY="[Empty name]" NAME="Cohen 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-02-11 14:00:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chretien PB, Lipson SD, Makuch R, Kenady DE, Cohen MH, Minna JD</AU>
<TI>Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1978</YR>
<VL>62</VL>
<NO>11</NO>
<PG>1787-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323656"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-11 14:01:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohen MH, Chretien PB, Ihde DC, Fossieck BE, Makuch R, Bunn PA, et al</AU>
<TI>Thymosin fraction V and intensive combination chemotherapy</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1979</YR>
<VL>241</VL>
<PG>1813-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323657"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-14 09:44:16 +0100" MODIFIED_BY="Elke Wolf" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipson SD, Chretien PB, Makuch R, Kenady DE, Cohen MH</AU>
<TI>Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course</TI>
<SO>Cancer</SO>
<YR>1979</YR>
<VL>43</VL>
<NO>3</NO>
<PG>863-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323658"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323655"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Giacco-1988" MODIFIED="2010-06-16 12:26:49 +0100" MODIFIED_BY="Clare Jess" NAME="Del Giacco 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-16 12:26:49 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Giacco GS, Mantovani G, Cengiarotti L, Puxeddu G, Pischedda A, Di Tucci A, et al</AU>
<TI>Secondary immunodeficiency in advanced lung cancer: effects of chemotherapy plus thymostimulin in immunodepressed patients: updating results</TI>
<SO>International Journal of Tissue Reactions</SO>
<YR>1984</YR>
<VL>6</VL>
<NO>6</NO>
<PG>499-504</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323660"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-14 12:19:59 +0100" MODIFIED_BY="Elke Wolf" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Del Giacco GS, Mantovani G, Pilidi G, et al</AU>
<TI>Thymic factors in lung cancer</TI>
<SO>Thymic hormones in oncology</SO>
<YR>1988</YR>
<PG>149-56</PG>
<ED>Nagel G, Schioppacassi G, Schuff-Werner P</ED>
<PB>Ares Serono Symposia</PB>
<CY>Roma</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323661"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323659"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Serdio-1997" MODIFIED="2010-02-11 14:02:20 +0000" MODIFIED_BY="[Empty name]" NAME="De Serdio 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-02-11 14:02:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Serdio JL, Villar A, Alvarez IE, Gil-Cubelo JA, Suner M, Hernandez R, et al</AU>
<TI>[The effects of thymostimulin in a protocol of concurrent hyperfractionated carboplatin and irradiation]</TI>
<SO>Acta Otorrinolaringologica Espanola</SO>
<YR>1997</YR>
<VL>48</VL>
<NO>6</NO>
<PG>487-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323663"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323662"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Federico-1995" MODIFIED="2010-02-11 14:04:20 +0000" MODIFIED_BY="[Empty name]" NAME="Federico 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-02-11 14:04:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Federico M, Gobbi PG, Mretti G, Avanzini P, di Renzo N, Cavanna L, et al</AU>
<TI>Effects of thymostimulin with combination chemotherapy in patients with aggressive Non-Hodgkin lymphoma. A report from the Italian Lymphoma Study Group (GISL)</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>1</NO>
<PG>8-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323665"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323664"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gebbia-1994" MODIFIED="2010-06-16 12:27:20 +0100" MODIFIED_BY="Clare Jess" NAME="Gebbia 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-16 12:27:20 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gebbia V, Valenza R, Testa A, Cannata G, Borsellino N, Gebbia N</AU>
<TI>A prospective randomized trial of thymopentin versus granulocyte-colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy</TI>
<SO>Anticancer Research</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>2B</NO>
<PG>731-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323667"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323666"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gish-2009" MODIFIED="2010-12-18 11:44:46 +0000" MODIFIED_BY="[Empty name]" NAME="Gish 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-12-18 11:44:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I</AU>
<TI>A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma</TI>
<SO>Hepatology International</SO>
<YR>2009</YR>
<VL>3</VL>
<PG>480-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323669"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323668"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GISOT-1987" MODIFIED="2010-06-16 12:28:42 +0100" MODIFIED_BY="Clare Jess" NAME="GISOT 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-06-16 12:28:42 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>GISOT (Gruppo Italiano di Studio Sugli Ormoni Timici)</AU>
<TI>[Efficacy and tolerability of thymopoietin in patients at risk of infection]</TI>
<SO>Recenti Progressi in Medicina</SO>
<YR>1987</YR>
<VL>78</VL>
<NO>7-8</NO>
<PG>358-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323671"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323670"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonnelli-1995" MODIFIED="2010-12-18 11:45:45 +0000" MODIFIED_BY="[Empty name]" NAME="Gonnelli 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-12-18 11:45:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonnelli S, Petrioli R, Cepollaro C, Palmieri R, Aquino A, Gennari C</AU>
<TI>Thymostimulin in association with chemotherapy in breast cancer patients with bone metastases</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>2</NO>
<PG>79-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323673"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323672"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guzman-1988" MODIFIED="2010-06-16 12:30:23 +0100" MODIFIED_BY="Clare Jess" NAME="Guzman 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-16 12:30:23 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Guzman Machado CA, Verruno L, Ribas MC</AU>
<TI>Adjuvant therapy with thymic factors in solid tumours</TI>
<SO>Thymic Hormones in Oncology</SO>
<YR>1988</YR>
<PG>121-32</PG>
<ED>Nagel G, Schioppacassi G, Schuff-Werner P</ED>
<PB>Ares serono Symposia</PB>
<CY>Roma</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323675"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323674"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iaffaioli-1994" MODIFIED="2010-12-18 11:46:21 +0000" MODIFIED_BY="[Empty name]" NAME="Iaffaioli 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-12-18 11:46:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iaffaioli RV, Caponigro F, Facchini G, Tortoriello A, Panelli G, Muto P, et al</AU>
<TI>Immunological and clinical effects of thymostimulin in patients with locally advanced non-small-cell lung cancer treated with combined chemoradiotherapy</TI>
<SO>Drug Investigation</SO>
<YR>1994</YR>
<VL>7</VL>
<PG>209-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323677"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323676"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luzi-1984" MODIFIED="2009-07-14 09:26:41 +0100" MODIFIED_BY="Elke Wolf" NAME="Luzi 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-07-14 09:26:41 +0100" MODIFIED_BY="Elke Wolf" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luzi G, Tropea F, Siminara R, et al</AU>
<TI>Clinical and immunological evaluation in non-resectable lung cancer patients treated with thymostimulin</TI>
<SO>Serono Symposia Publications</SO>
<YR>1984</YR>
<VL>16</VL>
<PG>309-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323679"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323678"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macchiarini-1989" MODIFIED="2010-12-18 11:47:39 +0000" MODIFIED_BY="[Empty name]" NAME="Macchiarini 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-12-18 11:47:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macchiarini P, Danesi R, Del Tacca M, Angeletti CA</AU>
<TI>Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients</TI>
<SO>Anticancer Research</SO>
<YR>1989</YR>
<VL>9</VL>
<PG>193-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323681"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323680"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Maio-2010" MODIFIED="2010-12-18 11:50:27 +0000" MODIFIED_BY="[Empty name]" NAME="Maio 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-12-18 11:48:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Camerini R, Mackiewicz A, Testori A, Trefzer U, Jassem J, Ferraresi V, et al</AU>
<TI>A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>18S</NO>
<PG>8535</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323683"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-18 11:48:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Camerini R, Mackiewicz A, Testori A, Trefzer U, Jassem J, Ferraresi V, et al</AU>
<TI>A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results</TI>
<SO>Powerpoint presentation ASCO Annual Meeting</SO>
<YR>June 1-5, 2007, Chicago</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323684"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-18 11:50:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, et al</AU>
<TI>Large randomized study of thymosin {alpha} 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>[Epub ahead of print]</VL>
<PG>1780-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323685"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323682"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mantovani-1988" MODIFIED="2010-02-11 14:08:54 +0000" MODIFIED_BY="[Empty name]" NAME="Mantovani 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-02-11 14:08:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Coiana A, Zucca MV, Sanna GP, Floris C, Sulis E, et al</AU>
<TI>[Results of a controlled clinical protocol in the treatment of patients with operable breast carcinoma with positive axillary lymph nodes. Comparison of a chemotherapeutic regimen with a chemo-immunotherapeutic regimen]</TI>
<SO>Recenti Progressi in Medicina</SO>
<YR>1988</YR>
<VL>79</VL>
<NO>12</NO>
<PG>513-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323687"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323686"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mustacchi-1994" MODIFIED="2010-12-18 11:50:49 +0000" MODIFIED_BY="[Empty name]" NAME="Mustacchi 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-12-18 11:50:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mustacchi G, Pavesi L, Milani S, Iaffaioli V, Caraco A, Comella G, et al</AU>
<TI>High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: results of a randomized multicenter clinical trial</TI>
<SO>Anticancer Research</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>617-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323689"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323688"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavesi-1993" MODIFIED="2010-12-18 11:52:23 +0000" MODIFIED_BY="[Empty name]" NAME="Pavesi 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-12-18 11:52:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pavesi L</AU>
<TI>Fluorouracil (F), with and without high-dose folinic acid (HDFA) plus epirubicin (E) and cyclophosphamide (C): FEC versus HDFA-FEC plus or minus thymostimulin (TS) in metastatic breast cancer: results of a multicenter study</TI>
<SO>European Journal of Cancer</SO>
<YR>1993</YR>
<VL>29 A Suppl</VL>
<PG>77</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323691"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323690"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salvati-1984" MODIFIED="2010-06-16 12:36:13 +0100" MODIFIED_BY="Clare Jess" NAME="Salvati 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-06-16 12:36:13 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salvati F, Pallotta G, Antilli A, Nunziati F, De Marinis F, Lucchesi M</AU>
<TI>[MACC plus Thymostimulin (TP-1 Serono) therapy of small cell bronchogenic carcinoma. Clinico-immunologic evaluation of the results of a randomized trial]</TI>
<SO>Giornale Italiano di Chemiotherapia</SO>
<YR>1984</YR>
<VL>31</VL>
<PG>185-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323693"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323692"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchiz-1996" MODIFIED="2010-02-11 14:11:44 +0000" MODIFIED_BY="[Empty name]" NAME="Sanchiz 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-02-11 14:11:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchiz F, Milla A</AU>
<TI>A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of heamatological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy</TI>
<SO>European Journal of Cancer</SO>
<YR>1996</YR>
<VL>32 A</VL>
<PG>52-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323695"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323694"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scher-1988" MODIFIED="2010-12-18 11:52:53 +0000" MODIFIED_BY="[Empty name]" NAME="Scher 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-12-18 11:52:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scher HI, Shank B, Geller N, Pinsky C, Gralla R, Kelsen D, et al</AU>
<TI>Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer</TI>
<SO>Cancer Research</SO>
<YR>1988</YR>
<VL>48</VL>
<NO>6</NO>
<PG>1663-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323697"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323696"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulof-1985" MODIFIED="2010-12-18 11:53:43 +0000" MODIFIED_BY="[Empty name]" NAME="Schulof 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-12-18 11:53:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulof RS, Lloyd MJ, Cleary PA, Palaszynski SR, Mai DA, Cox JW, et al</AU>
<TI>A randomized trail to evaluate the immunorestorative properties of synthetic thymosin-a in patients with lung cancer</TI>
<SO>Journal of Biological Response Modifiers</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>2</NO>
<PG>147-58</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323699"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323698"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wara-1981" MODIFIED="2009-07-14 09:26:41 +0100" MODIFIED_BY="Elke Wolf" NAME="Wara 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-07-14 09:26:41 +0100" MODIFIED_BY="Elke Wolf" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Wara WM, Neely MH, Amman AJ, Wara DW</AU>
<TI>Biologic modifications of immunologic parameters in head and neck cancer patients with thymosin fraction V</TI>
<SO>Lymphokines and Thymic Hormones: their potential utilization in cancer therapeutics</SO>
<YR>1981</YR>
<PG>257-62</PG>
<ED>Goldstein AL, Chirigos MA</ED>
<PB>Raven Press, New York</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323701"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323700"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-12-18 23:25:49 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Azizi-1984" MODIFIED="2010-12-18 11:55:38 +0000" MODIFIED_BY="[Empty name]" NAME="Azizi 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-12-18 11:55:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azizi E, Brenner HJ, Shoham J</AU>
<TI>Postoperative adjuvante behandlung von patienten mit malignem melanom durch die thymusfaktor thymostimulin</TI>
<SO>Arzneimittelforschung</SO>
<YR>1984</YR>
<VL>34</VL>
<NO>II</NO>
<PG>1043-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323703"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323702"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernengo-1983" MODIFIED="2010-02-12 12:03:29 +0000" MODIFIED_BY="[Empty name]" NAME="Bernengo 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-02-12 12:03:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernengo MG, Fra P, Lisa F, Meregalli M, Zina G</AU>
<TI>Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course</TI>
<SO>Clinical Immunology and Immunopathology</SO>
<YR>1983</YR>
<VL>28</VL>
<NO>3</NO>
<PG>311-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323705"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-12 12:03:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernengo MG, Lisa F, Meregalli M, De Matteis A, Zina G</AU>
<TI>The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up</TI>
<SO>Cancer</SO>
<YR>1983</YR>
<VL>52</VL>
<NO>10</NO>
<PG>1841-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323706"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323704"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cartia-1990" MODIFIED="2010-02-12 12:03:40 +0000" MODIFIED_BY="[Empty name]" NAME="Cartia 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-02-12 12:03:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cartia GL</AU>
<TI>[Evaluation of the effects of thymopentin on the incidence of leucopenia in patients treated with chemotherapy for breast carcinoma] Valutazione degli effetti di Timopentina sull`incidenza di leucopenia in pazienti trattate con chemioterapia per carcinom mammario</TI>
<SO>Minerva Medica</SO>
<YR>1990</YR>
<VL>81</VL>
<NO>11</NO>
<PG>815-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323708"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323707"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2000" MODIFIED="2010-12-18 11:59:46 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-12-18 11:59:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Chen J, Huang F, Zheng X, Chen L, Qin S, Li G, et al</AU>
<TI>Thymosin alpha 1 positively alters quality of life in chemotherapy treated patients</TI>
<SO>Proceedings American Society of Clinical Oncology</SO>
<YR>2000</YR>
<VL>1</VL>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323710"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323709"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Maria-1993" MODIFIED="2010-12-18 12:00:06 +0000" MODIFIED_BY="[Empty name]" NAME="De Maria 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-12-18 12:00:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Maria D, Falchi AM, Armaroli L, Balli M, Bortolus R, Busutti L, et al</AU>
<TI>T-lymphocyte subsets in cancer patients undergoing radiotherapy and their recovery after thymostimulin treatment. A cooperative study</TI>
<SO>RAYS</SO>
<YR>1993</YR>
<VL>18</VL>
<PG>438-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323712"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323711"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denaro-1994" MODIFIED="2010-06-16 12:50:19 +0100" MODIFIED_BY="Clare Jess" NAME="Denaro 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-06-16 12:50:19 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denaro A, Stivala F, Mazzarino MC</AU>
<TI>[Immunologic study on patients with head and neck cancer treated with thymopentin associated with surgery, chemotherapy and radiotherapy]</TI>
<SO>Acta Otorhinolaryngologica Italica</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>611-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323714"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323713"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holowiecki-1984" MODIFIED="2010-12-18 12:00:30 +0000" MODIFIED_BY="[Empty name]" NAME="Holowiecki 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-12-18 12:00:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holowiecki J, Duraj M, Rudzka E, Jarczok K, Krawczyk M, Holowiecka B, et al</AU>
<TI>Cooperative randomized studies on the treatment of adult acute leukemia in Poland. A comparison of two remission induction regimes and two maintenance regimes for AML</TI>
<SO>Folia Haematologica</SO>
<YR>1984</YR>
<VL>111</VL>
<NO>2</NO>
<PG>201-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323716"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323715"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iaffaioli-1988" MODIFIED="2010-12-18 11:57:00 +0000" MODIFIED_BY="[Empty name]" NAME="Iaffaioli 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-12-18 11:57:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iaffaioli RV, Frasci G, Tortora G, Ciardiello F, Nuzzo F, Scala S, et al</AU>
<TI>Effect of thymic extract "thymostimulin" on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer</TI>
<SO>Thymus</SO>
<YR>1988</YR>
<VL>12</VL>
<PG>69-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323718"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323717"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreuser-1998" MODIFIED="2010-06-17 14:29:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kreuser 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-17 14:29:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Kreuser ED</AU>
<TI>[Randomised, double-blind trial to compare low-molecular thymic peptides, 5-fluorouracil and folic acid with placebo, 5-fluorouracil and folic acid in patients with metastasised colorectal cancer]</TI>
<TO>Randomisierter, doppelblinder Therapievergleich von niedermolekularen Thymus- Peptiden, 5-Fluorouracil und Folinsäure versus Placebo, 5-Fluorouracil und Folinsäure bei Patienten mit metastasiertem kolorektalen Karzinom im Stadium UICC IV (pT1-4, N0-2, M1)</TO>
<SO>Internet ("This trial was identified via internet databases. In this multicenter study patients were randomised to receive thymuvocal or placebo. The pharmaceutical company (DR Schmidt) supposed to be in charge of did not provide information about this study".)</SO>
<YR>1998</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323720"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323719"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liberati-1998" MODIFIED="2010-12-18 11:58:07 +0000" MODIFIED_BY="[Empty name]" NAME="Liberati 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-12-18 11:58:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liberati AM, Ballatori E, Fizzotti M, Schippa M, Cini L, Cinieri S, et al</AU>
<TI>A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin`s disease in complete remission</TI>
<SO>Cancer Immunology, Immunotherapy</SO>
<YR>1998</YR>
<VL>26</VL>
<PG>87-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323722"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323721"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mantovani-1995" MODIFIED="2010-12-18 12:01:22 +0000" MODIFIED_BY="[Empty name]" NAME="Mantovani 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-12-18 12:01:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Ghiani M, Bianchi A, Curreli L, Contini L, Maccio A, et al</AU>
<TI>[The immunological assessment of a combined therapeutic approach (chemo- + radiotherapy +/- surgery) including immunotherapy in neoplasms of the head and neck area at an advanced stage]</TI>
<TO>Valutazione immunologica di un approccio terapeutico combinato (chemio + radioterapia +/- chirurgia) includente l'immunoterapia nelle neoplasie del distretto cervico-facciale in stadio avanzato.</TO>
<SO>Recenti Progressi in Medicina</SO>
<YR>1995</YR>
<VL>86</VL>
<PG>8-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323724"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323723"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Migeod-1985" MODIFIED="2010-06-17 14:25:59 +0100" MODIFIED_BY="[Empty name]" NAME="Migeod 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-06-17 14:25:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Migeod F</AU>
<TI>[Results of a prospective randomised study on the immunologic effects of the xenogenic organ lysates Ney Tumorin-Sol and Neythymun compared to placebo]</TI>
<TO>Ergebnisse einer prospektiv randomisierten Studie über immunologische Wirkungen der xenogenen Organlysate Ney Tumorin-Sol und Neythymun in Vergleich zu einem Placebo</TO>
<SO>Therapiewoche</SO>
<YR>1985</YR>
<VL>35, 26A</VL>
<PG>115-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323726"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323725"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munno-1995" MODIFIED="2010-12-18 23:25:49 +0000" MODIFIED_BY="[Empty name]" NAME="Munno 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-12-18 23:25:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munno I, Marinaro M, Gesario A, Cannuscio B, Michel Y, Paulling E</AU>
<TI>Immunomodulatory effects of alpha interferon and thymostimulin in patients with neoplasias</TI>
<SO>Clinical and Diagnostic Laboratory Immunology</SO>
<YR>1995</YR>
<VL>2</VL>
<PG>503-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323728"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323727"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quang_x002d_Xing-2001" MODIFIED="2010-12-18 12:02:18 +0000" MODIFIED_BY="[Empty name]" NAME="Quang-Xing 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-12-18 12:02:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Quang-Xing Ni, Fu DI, Yu XJ, Xu J, Hua JM, Chen W, et al</AU>
<TI>Efficacy of thymalfasin on cellular immune function and chemotherapy induced toxicity in pancreatic cancer</TI>
<SO>Proceedings American Society of Clinical Oncology</SO>
<YR>2001</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323730"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323729"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoham-1988" MODIFIED="2010-06-16 12:56:48 +0100" MODIFIED_BY="Clare Jess" NAME="Shoham 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-16 12:56:48 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Shoham J</AU>
<TI>The effect of the thymic factor thymostimulin on survival rate, immune function and resistance to infection in experimental and clinical cancer</TI>
<SO>Thymic Hormones in Oncology</SO>
<YR>1988</YR>
<PG>45-57</PG>
<PB>Ares Serono Symposia</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323732"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323731"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Surico-1992" MODIFIED="2010-06-16 12:57:13 +0100" MODIFIED_BY="Clare Jess" NAME="Surico 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-16 12:57:13 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Surico N, Tavassoli K</AU>
<TI>Effect of immunostimulating therapy on the immunocompetent system in breast carcinoma</TI>
<SO>Panminerva Medica</SO>
<YR>1992</YR>
<VL>34</VL>
<PG>172-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323734"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323733"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tetti-1987" MODIFIED="2010-12-18 12:03:02 +0000" MODIFIED_BY="[Empty name]" NAME="Tetti 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-12-18 12:03:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tetti M, Tomassone W, Milani R, Paste M, Vaudano G, Rolfo A, et al</AU>
<TI>Uso di un farmaco immunomodulatore nella prevenzione della comparsadi episodi infettivi a carico delle vie urinarie in pazienti affette da neoplasie ginecologiche e sottoposte a ciclo TCT</TI>
<SO>Recenti Progressi in Medicina</SO>
<YR>1987</YR>
<VL>78 Suppl 6</VL>
<PG>51-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323736"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323735"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-11-17 15:14:18 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Dollinger-2010" MODIFIED="2010-11-17 15:14:18 +0000" MODIFIED_BY="[Empty name]" NAME="Dollinger 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-11-17 15:14:18 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;matthias.dollinger@medizin.uni-halle.de&lt;/p&gt;" NOTES_MODIFIED="2010-11-17 15:14:18 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, et al</AU>
<TI>Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial</TI>
<SO>BMC Cancer</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>457</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3323738"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3323737"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-07-13 14:26:58 +0100" MODIFIED_BY="Elke Wolf"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-06-20 15:51:01 +0100" MODIFIED_BY="Elke Wolf">
<ADDITIONAL_REFERENCES MODIFIED="2011-06-20 15:51:01 +0100" MODIFIED_BY="Elke Wolf">
<REFERENCE ID="REF-Billich-2002" MODIFIED="2010-12-18 12:04:49 +0000" MODIFIED_BY="[Empty name]" NAME="Billich 2002" TYPE="JOURNAL_ARTICLE">
<AU>Billich A</AU>
<TI>Thymosin alpha1. SciClone Pharmaceuticals</TI>
<SO>Current Opinion in Investigational Drugs</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>5</NO>
<PG>698-707</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bodey-2000" MODIFIED="2009-07-13 13:26:01 +0100" MODIFIED_BY="Elke Wolf" NAME="Bodey 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bodey B, Bodey BJr, Siegel SE, Kaiser HE</AU>
<TI>Review of thymic hormones in cancer diagnosis and treatment</TI>
<SO>International Journal of Immunopharmacology</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>4</NO>
<PG>261-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cha-2003" MODIFIED="2010-05-17 14:26:33 +0100" MODIFIED_BY="Elke Wolf" NAME="Cha 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cha HJ, Jeong MJ, Kleinman HK</AU>
<TI>Role of thymosin beta4 in tumor metastasis and angiogenesis</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2003</YR>
<VL>95</VL>
<NO>22</NO>
<PG>1674-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chretien-1978" NAME="Chretien 1978" TYPE="JOURNAL_ARTICLE">
<AU>Chretien PB, Lipson SD, Makuch R, Kenady DE, Cohen MH, Minna JD</AU>
<TI>Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1978</YR>
<VL>62</VL>
<NO>11</NO>
<PG>1787-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costanzi-1977" MODIFIED="2010-12-18 12:05:38 +0000" MODIFIED_BY="[Empty name]" NAME="Costanzi 1977" TYPE="JOURNAL_ARTICLE">
<AU>Costanzi JJ, Gagliano RG, Delaney F, Harris N, Thurman GB, Sakai H, et al</AU>
<TI>The effect of thymosin on patients with disseminated malignancies. A phase I study</TI>
<SO>Cancer</SO>
<YR>1977</YR>
<VL>40</VL>
<NO>1</NO>
<PG>14-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CTC-2009" MODIFIED="2010-06-17 13:49:20 +0100" MODIFIED_BY="[Empty name]" NAME="CTC 2009" TYPE="OTHER">
<AU>National Cancer Institute</AU>
<TI>Common Terminology Criteria for Adverse Events (CTCAE) - Version 4.0</TI>
<SO>http://evs.nci.nih.gov/ftp1/CTCAE/About.html</SO>
<YR>May 28, 2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunn-2002" MODIFIED="2010-06-17 13:49:29 +0100" MODIFIED_BY="[Empty name]" NAME="Dunn 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD</AU>
<TI>Cancer immunoediting: from immunosurveillance to tumor escape</TI>
<SO>Nature Immunology</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>11</NO>
<PG>991-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ernst-1997" NAME="Ernst 1997" TYPE="JOURNAL_ARTICLE">
<AU>Ernst E</AU>
<TI>Thymus therapy for cancer? A criteria-based, systematic review [see comments]</TI>
<SO>European Journal of Cancer</SO>
<YR>1997</YR>
<VL>33</VL>
<NO>4</NO>
<PG>531-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falchetti-1977" MODIFIED="2010-06-16 13:03:04 +0100" MODIFIED_BY="Clare Jess" NAME="Falchetti 1977" TYPE="JOURNAL_ARTICLE">
<AU>Falchetti R, Bergesi G, Eshkol A, Cafiero G, Adorini L, Caprino L</AU>
<TI>Pharmacological and biological properties of a calf thymus extract (TP-1)</TI>
<SO>Drugs Under Experimental and Clinical Research</SO>
<YR>1977</YR>
<VL>3</VL>
<PG>39-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1966" MODIFIED="2010-06-16 13:03:47 +0100" MODIFIED_BY="Clare Jess" NAME="Goldstein 1966" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein AL, Slater FD, White A</AU>
<TI>Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin)</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1966</YR>
<VL>56</VL>
<NO>3</NO>
<PG>1010-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1977" MODIFIED="2010-12-18 12:06:26 +0000" MODIFIED_BY="[Empty name]" NAME="Goldstein 1977" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio J, et al</AU>
<TI>Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1977</YR>
<VL>74</VL>
<NO>2</NO>
<PG>725-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1979" MODIFIED="2010-03-24 15:50:57 +0000" MODIFIED_BY="[Empty name]" NAME="Goldstein 1979" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein G, Scheid MP, Boyse EA, Schlesinger DH, Van Wauwe J</AU>
<TI>A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin</TI>
<SO>Science</SO>
<YR>1979</YR>
<VL>204</VL>
<NO>4399</NO>
<PG>1309-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-2009" MODIFIED="2010-06-16 13:47:36 +0100" MODIFIED_BY="Clare Jess" NAME="Goldstein 2009" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein AL, Goldstein AL</AU>
<TI>From lab to bedside: emerging clinical applications of thymosin à1</TI>
<SO>Expert Opinion on Biological Therapy</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>5</NO>
<PG>593-608</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grothey-1998" MODIFIED="2010-12-18 12:07:41 +0000" MODIFIED_BY="[Empty name]" NAME="Grothey 1998" TYPE="JOURNAL_ARTICLE">
<AU>Grothey A, Düppe J, Hasenburg A, Voigtmann R</AU>
<TI>Anwendung alternativmedizinischer methoden durch onkologische patienten</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1998</YR>
<VL>123</VL>
<PG>923-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hannappel-2003" MODIFIED="2010-06-16 13:48:14 +0100" MODIFIED_BY="Clare Jess" NAME="Hannappel 2003" TYPE="BOOK_SECTION">
<AU>Hannappel E, Huff T</AU>
<TI>The thymosins prothymosin à, parathymosin, and á-thymosins: structure and function</TI>
<SO>Vitamins and Hormones</SO>
<YR>2003</YR>
<PG>2-296</PG>
<PB>Academic press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hardell-1998" MODIFIED="2010-05-18 20:37:05 +0100" MODIFIED_BY="[Empty name]" NAME="Hardell 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hardell L, Nordenstam M, Moqvist I, Lindberg L</AU>
<TI>A new study of patients with cancer in Umea alternative medicine is no alternative</TI>
<TO>Ny studie av cancerpatienter i Umea: alternativmedicin inget alternativ.</TO>
<SO>Lakartidningen</SO>
<YR>1998</YR>
<VL>95</VL>
<NO>18</NO>
<PG>2092-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-12-18 12:08:30 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</SO>
<YR>2009</YR>
<VL>available from www.cochrane-handbook.org</VL>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirkwood-2003" MODIFIED="2010-05-19 14:08:07 +0100" MODIFIED_BY="Elke Wolf" NAME="Kirkwood 2003" TYPE="BOOK_SECTION">
<AU>Kirkwood BR, Sterne JAC</AU>
<TI>Essential medical statistics</TI>
<SO>Essential medical statistics</SO>
<YR>2003</YR>
<PG>Chapter 22</PG>
<PB>Blackwell Science Ltd</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2010-03-29 12:36:26 +0100" MODIFIED_BY="Elke Wolf"/>
</REFERENCE>
<REFERENCE ID="REF-Kullmer-1999" MODIFIED="2010-12-18 12:09:17 +0000" MODIFIED_BY="[Empty name]" NAME="Kullmer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kullmer U, Stenger K, Milch W, Zygmunt M, Sachsse S, Münstedt K</AU>
<TI>Self-concept, body image, and use of unconventional therapies in patients with gynaecological malignancies in the state of complete remission and recurrence</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>1</NO>
<PG>101-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1981" MODIFIED="2010-06-17 13:40:48 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 1981" TYPE="JOURNAL_ARTICLE">
<AU>Miller AB, Hoogstraten B, Staquet M, Winkler A</AU>
<TI>Reporting Results of Cancer Treatment</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>47</VL>
<NO>1</NO>
<PG>207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moschen-2001" MODIFIED="2010-12-18 12:12:23 +0000" MODIFIED_BY="[Empty name]" NAME="Moschen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moschen R, Kemmler G, Schweigkofler H, Holzner B, Dnser M, Richter R, et al</AU>
<TI>Use of alternative / complementary therapy in breast cancer patients - a psychological perspective</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2001</YR>
<VL>9</VL>
<PG>267-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rost-1999" MODIFIED="2010-06-16 13:59:15 +0100" MODIFIED_BY="Clare Jess" NAME="Rost 1999" TYPE="JOURNAL_ARTICLE">
<AU>Rost KL, Wierich W, Masayuki F, Tuthill CW, Horwitz DL, Herrmann WM</AU>
<TI>Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>1999</YR>
<VL>37</VL>
<NO>1</NO>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schlesinger-1975" MODIFIED="2010-03-24 15:50:57 +0000" MODIFIED_BY="[Empty name]" NAME="Schlesinger 1975" TYPE="JOURNAL_ARTICLE">
<AU>Schlesinger DH, Goldstein G, Scheid MP, Boyse EA</AU>
<TI>Chemical synthesis of a peptide fragment of thymopoietin II that induces selective T cell differentiation</TI>
<SO>Cell</SO>
<YR>1975</YR>
<VL>5</VL>
<NO>4</NO>
<PG>367-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulof-1985a" MODIFIED="2010-06-16 14:00:50 +0100" MODIFIED_BY="Clare Jess" NAME="Schulof 1985a" TYPE="JOURNAL_ARTICLE">
<AU>Schulof RS</AU>
<TI>Thymic peptide hormones: basic properties and clinical applications in cancer</TI>
<SO>Critical Reviews in Oncology/Hematology</SO>
<YR>1985</YR>
<VL>3</VL>
<NO>4</NO>
<PG>309-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sehouli-2000" MODIFIED="2010-05-18 20:36:02 +0100" MODIFIED_BY="[Empty name]" NAME="Sehouli 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sehouli J</AU>
<TI>How frequently do female patients with gynecological cancers use unconventional cancer therapies?</TI>
<SO>Gynecologic Oncology</SO>
<YR>2000</YR>
<VL>79</VL>
<NO>2</NO>
<PG>336-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seybold-1950" MODIFIED="2010-12-18 12:10:37 +0000" MODIFIED_BY="[Empty name]" NAME="Seybold 1950" TYPE="JOURNAL_ARTICLE">
<AU>Seybold WD, McDonald JR, Clagett OR, Good CA</AU>
<TI>Tumors of the thymus</TI>
<SO>Journal of Thoracic Surgery</SO>
<YR>1950</YR>
<VL>20</VL>
<NO>2</NO>
<PG>195-215</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singh-1998" MODIFIED="2010-06-17 13:49:35 +0100" MODIFIED_BY="[Empty name]" NAME="Singh 1998" TYPE="JOURNAL_ARTICLE">
<AU>Singh VK, Biswas S, Mathur KB, Haq W, Garg SK, Agarwal SS</AU>
<TI>Thymopentin and splenopentin as immunomodulators. Current status</TI>
<SO>Immunologic Research</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>3</NO>
<PG>345-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soellner-1997" MODIFIED="2010-06-16 14:01:38 +0100" MODIFIED_BY="Clare Jess" NAME="Soellner 1997" TYPE="JOURNAL_ARTICLE">
<AU>Soellner W, Zingg-Schir M, Rumpold G, Fritsch P</AU>
<TI>Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma</TI>
<SO>Archives of Dermatology</SO>
<YR>1997</YR>
<VL>133</VL>
<NO>3</NO>
<PG>316-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Therasse-2000" MODIFIED="2010-06-17 13:37:26 +0100" MODIFIED_BY="[Empty name]" NAME="Therasse 2000" TYPE="JOURNAL_ARTICLE">
<AU>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al</AU>
<TI>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>3</NO>
<PG>205-16</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2010-11-17 15:14:18 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-12-18 11:36:12 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-12-18 11:33:03 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-12-18 11:19:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Airoldi-1987">
<CHAR_METHODS MODIFIED="2010-12-18 11:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>2-arm parallel trial with a no-treatment control group; stratification by type of pretreatment, location and grading of tumour, disease status (non-responsive or recurrent)<BR/>
<B>No of centres:</B> 1<BR/>
<B>Recruitment and setting: </B>Medical Clinic and Department of Radiotherapy, University of Turin, Italy<BR/>
<B>Recruitment period:</B> 01/84-08/85<BR/>
<B>Observation period:</B> median: 14 months, minimum: 11 months<BR/>
<B>Ethical approval:</B> unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-18 11:19:18 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No of patients: </B>48 randomised, 48 evaluated<BR/>
<B>Condition: </B>squamous cell cancer of the oral cavity non-responsive or recurrent after conventional therapy with surgery and/or irradiation<B>
<BR/>Demographics</B>: men: 39, women: 9; mean age (range): 58 (37-71) years<B>
<BR/>Informed consent: </B>unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:09:00 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymostimulin, dose/schedule: 1 mg/kg/day i.m. starting 7 days before chemotherapy treatment, thereafter 2x/week for 4 weeks and 1x/week until tumour progression<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>vincristine 1.2 mg/m² i.v. (d1), bleomycin 18 mg/m² i.m. (d1), methotrexate 30 mg/m² i.v. (d2); every week for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-15 12:29:32 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-15 12:31:26 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcomes:</B> side effects of chemotherapy were not scored using standardized criteria <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-18 11:19:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bedikian-1984">
<CHAR_METHODS MODIFIED="2010-12-17 22:09:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>2-arm parallel trial with a no-treatment control group; stratification by histological type of disease and performance status<BR/>
<B>No of centers:</B> 1<BR/>
<B>Recruitment and setting: </B>M.D. Anderson Cancer Center, University of Texas, USA<BR/>
<B>Recruitment period:</B> 01/79-05/80<BR/>
<B>Observation period: </B>max. 104 weeks<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-18 11:19:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 105 randomised, 99 evaluated<BR/>
<B>Condition:</B> advanced stage non-small cell lung cancer (NSCLC)<BR/>
<B>Demographics:</B> men: 70, women: 29; median age (range): IG: 55 (37-77), CG: 57 (35-80) years<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:11:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymosin fraction 5; dose/schedule: 60 mg/m² s.c. every chemotherapy cycle (d1,4,8,12,16)<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>vindesine 3 mg/m² (d1), doxorubicin 50 mg/m² (d1), cisplatin 60 mg/m² (d1) every 3-4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-15 14:00:55 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), chemotherapy dose/schedule modifications, other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-17 22:11:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants</B>: first 13 patients were not randomised because of unavailability of thymosin fraction 5 and allocated to the no-treatment arm, thereafter to equalise the two arms a randomisation scheme favouring the thymosin arm was used<BR/>
<B>Outcomes: </B>side effects of chemotherapy were not scored using standardized criteria<BR/>
<B>Funding:</B> sponsored by the National Cancer Institute (NCI)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:12:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canovas-1988">
<CHAR_METHODS MODIFIED="2010-12-17 22:12:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> 2-arm parallel trial with a no-treatment control group<BR/>
<B>No of centres: </B>1<BR/>
<B>Recruitment and setting: </B>outpatients department, Hospital de Cruces, Bilbao, Spain<BR/>
<B>Recruitment period:</B> unclear<BR/>
<B>Observation period: </B>4 chemotherapy cycles<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-15 14:03:24 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>No. of patients:</B> 46 randomised, 41 evaluated <I>
<BR/>
</I>
<B>Condition:</B> multiple myeloma (28 patients), non-Hodgkin lymphoma (NHL) (11 patients), Hodgkin lymphoma (2 patients)<BR/>
<B>Demographics:</B> unclear<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-16 15:10:15 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 25 mg i.m., 6x within 2 weeks at beginning of the study, thereafter 4x within 2 weeks before each chemotherapy cycle<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>multiple myeloma: VCAP/VMCP, MP or M-2; NHL: Promace MOPP, CVP or CHOP; Hodgkin lymphoma: MOPP/ABVD</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-24 16:42:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Outcome measures: </B>survival, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides/extracts), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-15 14:12:03 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcomes: </B>side effects of chemotherapy were not scored using standardized criteria; pre/post analysis of performance status (ECOG)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:13:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canovas-1991">
<CHAR_METHODS MODIFIED="2010-12-17 22:13:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> 2-arm parallel trial with a no-treatment control group; patients stratified by diagnosis<BR/>
<B>No of centres:</B> 1<BR/>
<B>Recruitment and setting:</B> Hospital de Cruces, Bilbao, Spain<BR/>
<B>Recruitment period:</B> unclear<BR/>
<B>Observation period: </B>approximately 4-6 months (6 cycles of chemotherapy)<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-15 14:55:28 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>No. of patients:</B> 40 randomised, 32 evaluated<BR/>
<B>Condition:</B> multiple myeloma (13 patients), NHL (11 patients), Hodgkin lymphoma (8 patients)<BR/>
<B>Demographics:</B> unclear<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-16 15:10:10 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 1 mg/kg body weight i.m., daily for one week; thereafter 2x/week for 6 chemotherapy cycles<B>
<BR/>Control treatment: </B>no treatment <B>
<BR/>Basic treatment: </B>multiple myeloma: VCAP/VMCP, MP or M-2; NHL: Promace MOPP, CVP, LSA2Ls, C-MOPP or IMVP-16; Hodgkin lymphoma: MOPP MOPP/ABVD</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-15 14:59:40 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-15 15:06:31 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcomes: </B>side effects of chemotherapy were not scored using standardized criteria; pre/post analysis of performance status (ECOG)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:15:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2004">
<CHAR_METHODS MODIFIED="2010-12-17 22:14:20 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>3-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres: </B>1<BR/>
<B>Recruitment and setting: </B>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China<BR/>
<B>Recruitment period: </B>01/00-12/02<BR/>
<B>Observation period: </B>6-32 months<BR/>
<B>Ethical approval: </B>yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:14:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 57 for the whole trial, 41 randomised, 41 evaluated in the two relevant arms<BR/>
<B>Condition:</B> hepatocellular carcinoma after hepatectomy; Edmondson´s stage II-IV<BR/>
<B>Demographics:</B> men: 34, women: 7; median age (range): 48 (30-66) years for whole study population<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:15:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymosin &#945;<SUB>1 </SUB>(thymalfasin; Zadaxin) dose/schedule: 1.6 mg/day s.c., 2x/week from the first week after hepatectomy for 6 months <BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>transcatheter hepatic arterial chemoembolisation (TACE) with carboplatin: 100 mg, epidoxorubicin 10 mg and mitomycin C 10 mg, starting 1.5 months after hepatectomy. In patients with recurrence, treatment was repeated max. four times</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-15 15:18:34 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 15:07:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: 2 arms were relevant for this review, the third arm compares transcatheter hepatic arterial chemoembolisation with no treatment<BR/>
<B>Participants:</B> imbalance in stage of disease, with a higher proportion of patients with stage IV in the intervention group; distribution of patients with radical and palliative resection unclear<BR/>
<B>Funding:</B> supported by Shanghai Science and Technology Committee and Shanghai Hospital New Star Plan</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-18 11:21:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-1979">
<CHAR_METHODS MODIFIED="2010-12-17 22:16:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> 3-arm parallel with placebo control<BR/>
<B>No of centres:</B> unclear<BR/>
<B>Recruitment and setting: </B>NCI-VA Medical Oncology Branch, Veterans Administration Hospital, Washington, D.C.; Surgery Branch, National Cancer Institute, Bethesda, USA<B>
<BR/>Recruitment period:</B> 07/75-01/77<BR/>
<B>Observation period: </B>approximately 2 years for survival, 12 weeks for response<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-18 11:21:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 55 randomised, 46 evaluated<BR/>
<B>Condition:</B> small cell lung cancer (SCLC), limited (15) or extensive (31) disease<BR/>
<B>Demographics:</B> men: 34, women: 12; median age (range): IG1: 58 (49-69), IG2: 61 (47-69), CG: 53 (41-67) years<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-15 15:59:08 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymosin fraction 5; dose/schedule: IG1: 60 mg/m² s.c., IG2: 20 mg/m² s.c., 2x/week during induction chemotherapy<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment:</B> induction therapy: cyclophosphamide 1500 mg/m² (d1), lomustine 100 mg/m² (d1), cyclophosphamide 1000 mg/m² (d22), methotrexate 15 mg/m² 2x/week for 10 doses; maintenance therapy: cyclically alternating two or three drug chemotherapy regimes for 2 years; starting on week 6</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-15 15:54:40 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-17 22:17:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Participants: </B>as stated by study authors patients in the IG2 tended to have a lower performance status<BR/>
<B>Outcomes: </B>side effects of chemotherapy were not scored using standardized criteria<BR/>
<B>ITT analysis:</B> was performed<BR/>
<B>Funding: </B>thymosin fraction 5 was provided by Hoffmann-La Roche <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:18:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Serdio-1997">
<CHAR_METHODS MODIFIED="2010-12-17 22:17:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> 2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres:</B> 1<BR/>
<B>Recruitment and setting:</B> Hospital Nuestra Se&#328;ora de la Cruz, Santa Cruz de Tenerife, Spain<BR/>
<B>Recruitment period:</B> 03/93-09/95<BR/>
<B>Observation period:</B> mean 18 months, max. 30 months<I>
<BR/>
</I>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:18:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 36 randomised, 36 evaluated<BR/>
<B>Condition:</B> locally advanced head and neck cancer, stage III or IV<BR/>
<B>Demographics:</B> men: 35, women: 1; age (range): 30-66 years (no median given)<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-16 15:09:44 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 1.5 mg/kg/day i.m. for 7 days before radiochemotherapy, 1.5 mg/kg/day i.m. 2x/week during treatment, 1 mg/kg/day i.m. 2x/week for 2 years or until recurrence <B>
<BR/>Control treatment: </B>no treatment<BR/>
<B>Basic treatment : </B>radiochemotherapy with 1.15 Gy per fraction up to 80.5 Gy (cumultative dose), carboplatin 5 mg/m² per fraction up to 700 mg (cumulative dose); 2x/day, 5 days/week </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 10:21:41 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-18 11:22:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Del-Giacco-1988">
<CHAR_METHODS MODIFIED="2010-03-16 13:33:03 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Design:</B> 2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres:</B> 1<BR/>
<B>Recruitment and setting: </B>Institute of Internal Medicine, University of Cagliari, Italy<B>
<BR/>Recruitment period:</B> starting 01/81; duration unclear<BR/>
<B>Observation period: </B>12-33 months<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-18 11:22:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 48 randomised, 48 evaluated (22 evaluated for tumour response)<BR/>
<B>Condition:</B> NSCLC or SCLC after incomplete resection or unresectable, classified as immunodepressed by various immunologic tests<BR/>
<B>Demographics</B> (only reported in the preliminary publication for 22 patients): men: all patients; mean age (SD): IG: 58 (±8), CG: 57 (±11) years<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:20:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 1.5 mg/kg  i.m. daily between cycles for 2 months; on alternate days for 4 months; thereafter 2x/week<BR/>
<B>Control treatment: </B>no treatment<B>
<BR/>Basic treatment: </B>doxorubicin 50 mg/m² (d1), vincristine 1,2 mg/m² (d1), cyclophosphamide 400 mg/m² (d1), lomustine 30 mg/m² (d1); every 4 weeks; until demonstrable response for max 6 cycles;<BR/>maintenance chemotherapy: NSCLC: cyclophosphamide 400 mg/m² (d1,d8), methotrexate 15 mg/m² (d1,d8), procarbazine 100 mg/m² (d1-10); every 4 weeks; SCLC: cyclophosphamide 1000-1500 mg/m²; every 3 weeks, methotrexate 10 mg/m² every 2 weeks, lomustine 50 mg/m² d1; thereafter VP16+adriamycin and methotrexate (no exact description given by authors)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-15 16:03:29 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 10:14:45 +0000" MODIFIED_BY="Elke Wolf">
<P>Various inconsistencies regarding inclusion criteria and dose of thymostimulin<BR/>
<B>Participants:</B> in an earlier publication (1984) preliminary results were published on 22 patients 1 year after terminating an enrolment phase of 21 months; patients with SCLC were not included at the beginning of the trial and inclusion criteria were later changed<BR/>
<B>Interventions: </B>there are differing doses stated in the two publications, the preliminary publication refers a dose of 1 mg/kg i.m.<BR/>
<B>Outcomes: </B>side effects of chemotherapy were not scored using standardized criteria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:22:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Federico-1995">
<CHAR_METHODS MODIFIED="2010-03-16 13:33:13 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Design:</B> 2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres:</B> 6<BR/>
<B>Recruitment and setting:</B> 2 university hospitals (Modena and Pavia) and 4 other hospitals in Italy<BR/>
<B>Recruitment period:</B> 11/88-12/90<BR/>
<B>Observation period: </B>4 years, median follow up 38 months<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:22:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 150 randomised, 134 evaluated <I>
<BR/>
</I>
<B>Condition:</B> intermediate- or high-grade NHL, stage II-IV and stage I with bulky disease<BR/>
<B>Demographics:</B> men: 73, women: 65 (mistake in publication); median age: IG: 52, CG: 51 years<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-16 15:09:18 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 1 mg/kg i.m.; for pats. treated with MACOP-B: (d22-29, 50-57, 77-85), for pats. treated with ProMACE-CytaBOM (d22-28) of each chemotherapy cycle<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>comparative study of 2 chemotherapy regimes:<BR/>MACOP-B and ProMACE-CytaBOM: in both regimes doxorubicin was replaced by a 20% higher dose of epidoxorubicin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 10:48:58 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-08 17:40:56 +0000" MODIFIED_BY="[Empty name]">
<P>The study was designed by the Italian Lymphoma Study Group<BR/>
<B>Participants:</B> performance status significantly better in IG (P = 0.04)<BR/>
<B>Funding: </B>supported by public funding (MURST), the Associacione Italiana per la Ricerca sul Cancro (AIRC) and Serono, Italy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:23:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gebbia-1994">
<CHAR_METHODS MODIFIED="2010-12-17 22:22:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> 4-arm parallel trial with placebo control<BR/>
<B>No. of centres:</B> 1<BR/>
<B>Recruitment and setting: </B>University of Palermo, Italy<B>
<BR/>Recruitment period:</B> unclear<BR/>
<B>Observation period:</B> unclear<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:22:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 100 randomised, 96 evaluated (51 relevant to this review)<I>
<BR/>
</I>
<B>Condition:</B> advanced breast cancer (26), advanced head and neck cancer (12), advanced gastric cancer (2), inoperable ovarian cancer (4), recurrent or metastatic endometrium cancer (4), SCLC (6)<BR/>
<B>Demographics:</B> women: 64, men: 36; mean age (range): 58.6 (40-75) years<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:23:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymopentin; dose/schedule: 50 mg i.m. every other day starting two days after application of chemotherapy until the beginning of the next cycle<BR/>
<B>Control treatment:</B> placebo (sodium chloride solution)<BR/>
<B>Basic treatment: </B>breast cancer: 5-FU 400 mg/m² (d1-3), FA 100 mg/m² (d1-3), mitoxantrone 24 mg/m² (d3) or 5-FU 400 mg/m² (d1-3), FA 100 mg/m² (d1-3), cyclophosphamide 500 mg/m² (d1), epidoxorubicin 120 mg/m² (d1); SCLC, head and neck cancer, endometrium cancer: cisplatin 80 mg/m²(d1), vinorelbine 25-30 mg/m² (d1, d8); gastric cancer: according to EAP regime; ovarian cancer: carboplatin 300 mg/m² (d1), cyclophosphamide 500 mg/m² (d1), epidoxorubicin 90 mg/m² (d1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 10:59:57 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 15:50:32 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-18 11:26:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gish-2009">
<CHAR_METHODS MODIFIED="2010-12-17 22:23:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> 2-arm open-label trial with a no-treatment control group<BR/>
<B>No. of centres: </B>4<BR/>
<B>Recruitment and setting: </B>California Pacific Medical Center, San Francisco; Henry Ford Health System, Detroit; University of Florida College of Medicine, Gainesville; Metropolitan Liver and Gastroenterology Center Fairfax<BR/>
<B>Recruitment period: </B>unclear<BR/>
<B>Observation period: </B>72 weeks (24 weeks treatment and 48 weeks post-treatment monitoring); 30 months for survival<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-16 11:37:08 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>No. of patients:</B> 28 randomised, 25 evaluated<BR/>
<B>Condition:</B> unresectable HCC, stage I-III (Okuda),<BR/>
<B>Demographics: </B>women: 6, men: 22; mean age (SD): IG: 59 (±9.1), CG: 60 (±6.7)<BR/>
<B>Informed consent: </B>unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-17 14:06:22 +0100" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymosin &#945;<SUB>1</SUB>; dose/schedule: 1.6 mg s.c., 5x/week for 24 weeks<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>TACE with doxorubicin or cisplatin (according to participating site´s guidelines)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 11:22:41 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-18 11:26:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Method:</B> small pilot study, sample size calculation was performed based on tumour response, accordingly 18 patients would have been required in each arm<BR/>
<B>Outcomes: </B>side effects of chemotherapy were not scored using standardized criteria<BR/>
<B>Funding:</B> supported by SciClone Pharmaceuticals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:24:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GISOT-1987">
<CHAR_METHODS MODIFIED="2010-03-16 13:33:25 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Design:</B> 2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres:</B> 153<BR/>
<B>Recruitment and setting: </B>inpatients of 153 hospitals, Italy<BR/>
<B>Recruitment period:</B> unclear<BR/>
<B>Observation period: </B>3 months<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:24:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 650 randomised, 609 evaluated<I>
<BR/>
</I>
<B>Condition:</B> solid tumors<BR/>
<B>Demographics:</B> unclear<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:24:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymopentin; dose/schedule: 50 mg s.c. 3x/week; for 4 weeks<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>chemotherapy or radiotherapy (not further specified by the author)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 13:28:55 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, toxicity (AEs of chemo-/radiotherapy)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-31 11:55:26 +0100" MODIFIED_BY="Elke Wolf">
<P>
<B>Participants:</B> the trial included in total three groups of patients at risk of infections: elderly people (&gt; 65 years) affected by chronic bronchitis (n=519), patients with solid tumours undergoing chemo- or radiotherapy (n=650), patients with HIV infection and lymphoadenopathy syndrome (LAS) (n=250)<BR/>
<B>Outcomes: </B>side effects of chemotherapy were not scored using standardized criteria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-18 11:27:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonnelli-1995">
<CHAR_METHODS MODIFIED="2010-12-17 22:24:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> 2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres:</B> 1<BR/>
<B>Recruitment and setting: </B>Institute of Internal Medicine and Division of Medical Oncology, University of Siena, Italy<B>
<BR/>Recruitment period:</B> unclear<BR/>
<B>Observation period</B>: 6 months<BR/>
<B>Ethical approval: </B>yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 40 randomised, 36 evaluated<BR/>
<B>Condition:</B> breast cancer, patients with bone metastasis and at least one measurable osteolytic lesion<BR/>
<B>Demographics:</B> median age (range): IG: 59 (47-71), CG: 61 (43-70) years<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-18 11:27:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 50 mg i.m. daily for 6 months<I>
<BR/>
</I>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>5-fluoruracil 500 mg/m² (d1), epirubicin 50 mg/m² (d1), cyclophosphamide 500 mg/m² (d1), or: 5-fluoruracil 400 mg/m² (d1-5), folinic acid 200 mg/m² (d1-5); mitomycin C 5 mg/m² (d3-5); every 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 14:42:34 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>response, toxicity (AEs of chemo-/radiotherapy), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 14:47:33 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Method:</B> according to a sample size calculation 60 patients would have been required, but accrual was finished earlier due to loss of funding<BR/>
<B>Funding:</B> thymostimulin was supplied by Serono, Italy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:26:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guzman-1988">
<CHAR_METHODS MODIFIED="2010-12-17 22:26:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> 2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres:</B> unclear<BR/>
<B>Recruitment and setting: </B>Medical Institute Oncology Service and Guernes Center, Buenos Aires, Argentina<BR/>
<B>Recruitment period:</B> 12/83-12/85<BR/>
<B>Observation period: </B>up to 42 months<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:26:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 32 randomised, 32 evaluated <I>
<BR/>
</I>
<B>Condition:</B> colorectal cancer, Dukes B2, C1, C2 after surgery; colon cancer (29), rectal cancer (4)<BR/>
<B>Demographics:</B> women: 15, men: 17; mean age: women: 58.8, men: 61.8 years<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:26:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 25 mg/m² i.m. every chemotherapy cycle (d9-13,17,19, 24, 26)<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment : </B>5-fluoruracil 600 mg/m² i.v. (d1,d8), lomustine 60 mg/m² p.o. (d1); every 3 weeks; for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 14:03:06 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, toxicity (AEs of chemo-/radiotherapy), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 15:00:48 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Participants:</B> no reporting of distribution of risk factors between groups<BR/>
<B>Outcomes: </B>side effects of chemotherapy were not scored using standardized criteria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-16 15:38:33 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Iaffaioli-1994">
<CHAR_METHODS MODIFIED="2010-03-16 13:33:37 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Design:</B> 2-arm parallel with placebo control<BR/>
<B>No. of centers:</B> unclear<BR/>
<B>Recruitment and setting: </B>unclear<BR/>
<B>Recruitment period:</B> 04/89-02/92<BR/>
<B>Observation period: </B>approximately 5 months<BR/>
<B>Ethical approval: </B>yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-16 15:06:41 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>No. of patients:</B> 69 randomised, 69 evaluated<BR/>
<B>Condition:</B> NSCLC, stage IIIA and B<BR/>
<B>Demographics:</B> men: 51, women: 18; age: patients under or 65 years: 39, patients over 65 years: 30<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-16 15:38:33 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 1 mg/kg; daily; after 2nd cycle: 3x/week, until end of treatment<BR/>
<B>Control treatment: </B>placebo (not further described)<BR/>
<B>Basic treatment: </B>radiochemotherapy: 24 fractions of 1.60 Gy 2x/day up to 38.4 G, followed within 14 days by one cycle of chemotherapy: carboplatin 250 mg/m² (d1), etoposide 100 mg/m² (d1), mitomycin C 8 mg/m² (d1-3), followed within 14 days by radiotherapy: 12 fractions of 1.6 Gy 2x/day up to 19.2 Gy, thereafter 5 cycles of chemotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 15:18:16 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>toxicity (AEs of chemo-/radiotherapy), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 15:28:41 +0000" MODIFIED_BY="Elke Wolf"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-18 11:28:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luzi-1984">
<CHAR_METHODS MODIFIED="2010-12-18 11:28:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres: </B>1<BR/>
<B>Recruitment and setting: </B>unclear<BR/>
<B>Recruitment period: </B>unclear<BR/>
<B>Observation period: </B>2 years<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:28:42 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 50 randomised, 47 evaluated<BR/>
<B>Condition:</B> unresectable NSCLC, stage II or III<BR/>
<B>Demographics:</B> men: 45, women: 5; mean age (range): 59 (35-70) years<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:28:53 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 0.5 mg/kg/day i.m. daily (starting 5 days before radiotherapy); thereafter 1x/week for 6 months<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>3 Gy on alternate days for 5 weeks; bleomycin 8 mg/m² 2x/week during radiotherapy, after 18 days: doxorubicin 40 mg/m² (d1, 28), vincristine 1.4 mg/m² (d1, 28), lomustine 65 mg/m² (d2, 57)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 15:26:47 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival; response, other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 15:32:29 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Funding: </B>the trial was supported by a grant of the national research institute (Consiglio Nazionale delle Ricerche); thymostimulin was supplied by Serono, Rome</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:29:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macchiarini-1989">
<CHAR_METHODS MODIFIED="2010-03-16 15:34:31 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Design: </B>2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres: </B>unclear<BR/>
<B>Recruitment and setting: </B>unclear<BR/>
<B>Recruitment period: </B>01/86-05/87<BR/>
<B>Observation period: </B>up to 32 months; median 26.5 months<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:29:16 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 28 randomised, 26 evaluated<BR/>
<B>Condition:</B> SCLC limited (20) or extensive (6) disease<BR/>
<B>Demographics:</B> men: 25, women: 1, median age: 61 years<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-16 15:36:46 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 1 mg/kg/day i.m.; every chemotherapy cycle (d7-14); thereafter in pats. with complete remission, 2x/week<B>
<BR/>Control treatment: </B>no treatment<BR/>
<B>Basic treatment : </B>cyclophosphamide 1 g/m² (d1), epidoxorubicin 60 mg/m² (d1), etoposide 120 mg/m² (d1-4), or: cisplatin 60 mg/m² (d1), etoposide 120 mg/m² (d1-4); every 3-4 weeks, alternating the two regimes; for 6 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 15:41:36 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:29:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maio-2010">
<CHAR_METHODS MODIFIED="2010-03-18 13:24:27 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Design:</B> open label 5-arm parallel, patients stratified by site of distant metastasis (M1a,b,c) and lactate dehydrogenase (LDH) level<BR/>
<B>No of centres:</B> 64<BR/>
<B>Recruitment and setting: </B>multi-centre study across 8 European countries<B>
<BR/>Recruitment period:</B> 08/02-01/06<BR/>
<B>Observation period:</B> 14.9-56.5 months<BR/>
<B>Ethical approval: </B>yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-18 13:41:39 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>No. of patients:</B> 488 patients evaluated (389 relevant to this review)<BR/>
<B>Condition:</B> melanoma, stage IV without brain metastasis<I>
<BR/>
</I>
<B>Demographics:</B> men: 250, women: 238<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:29:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymosin &#945;<SUB>1</SUB>; dose/schedule: IG1: 1.6 mg s.c.; IG2: 3.2 mg s.c. or IG3: 6.4 mg s.c. (d8-11 and d15-18) of every chemotherapy cycle<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>dacarbazine 800 mg/m² i.v. every 4 weeks for a maximum of six cycles; interferon &#945; (IFN&#945;) 3 MIU s.c. (d11,18) of every chemotherapy cycle</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-15 14:01:34 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-25 13:48:40 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Method:</B> sample size calculation was performed, accordingly 95 patients would be required in each arm; the original study design scheduled a four arm trial, but after preliminary analysis, which suggested a dose-response relation the protocol was extended to integrate a fifth arm with a dose of thymosin &#945;<SUB>1 </SUB>dose of 6.4 mg; sample size calculation was performed, accordingly 95 patients would be required in each arm<BR/>
<B>Participants:</B> only 4 of the 5 arms had a control group in accordance with the selection criteria of the review (the other arm was controlled by IFN&#945;)<BR/>
<B>Outcomes: </B>AEs of thymic peptides not reported differentially; side effects of chemotherapy were not scored using standardized criteria<BR/>
<B>Funding: </B>supported by sigma-tau and SciClone Pharmaceuticals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:30:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mantovani-1988">
<CHAR_METHODS MODIFIED="2010-12-17 22:30:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres: </B>2<BR/>
<B>Recruitment and setting: </B>university hospital and regional hospital, Cagliari, Italy<BR/>
<B>Recruitment period: </B>unclear<BR/>
<B>Observation period: </B>1 (20 patients) or 2 years (16 patients)<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:30:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 37 randomised, 37 evaluated<I>
<BR/>
</I>
<B>Condition:</B> breast cancer, patients with positive axillary lymph nodes, after radical or modified radical mastectomy<BR/>
<B>Demographics:</B> mean/median age (range): IG: 47.8/47.5 (31-60), CG: 45.8/47 (32-57) years<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-17 22:30:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 60 mg/m²/day i.m or s.c. starting within 1 month after termination of chemotherapy: 7x/week (d1-15), 2x/week (d16-30), 1x/week (d31-60), repetition until d180 with a pause of 30 days in-between<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment : </B>CMF regime; for 6 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 14:08:17 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, toxicity (AEs of chemo-/radiotherapy), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 15:46:56 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Funding:</B> supported by the National Research Council C.N.R.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-18 11:30:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mustacchi-1994">
<CHAR_METHODS MODIFIED="2010-12-17 22:30:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres: </B>multicentre<BR/>
<B>Recruitment and setting: </B>various hospitals in Italy (Trieste, Pavia, Cagliari, Napoli, Sassari, Vigevano, Pinerolo, Savona, Rome, Turin)<BR/>
<B>Recruitment period: </B>02/90-12/92<BR/>
<B>Observation period: </B>unclear<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:31:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 235 randomised, 211 evaluated <I>
<BR/>
</I>
<B>Condition:</B> colorectal cancer stage IV<BR/>
<B>Demographics:</B> men: 107, women: 128; median age: IG: 61, CG: 60 years<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-18 11:30:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 1 mg/kg i.m.; daily during chemotherapy treatment, 3x/week between cycles<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>5-fluoruracil 375 mg/m² i.v. (60 min. infusion) (d1-5), folinic acid 200 mg/m² i.v. (60 min. infusion) (d1-5); every 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 15:49:42 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, safety (AEs of thymic peptides), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 16:38:22 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Method:</B> sample size calculation was performed for incidence of side effects and tumour response and resulted in the requirement of 130 patients per group<BR/>
<B>Outcomes: </B>side effects of chemotherapy were not scored using standardized criteria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-18 11:31:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavesi-1993">
<CHAR_METHODS MODIFIED="2010-03-16 15:54:48 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Design: </B>4-arm parallel (2 chemotherapy regimes) with no treatment control<BR/>
<B>No. of centres: </B>13<BR/>
<B>Recruitment and setting: </B>13 centres all over Italy<BR/>
<B>Recruitment period: </B>01/90-12/92<BR/>
<B>Observation period: </B>unclear<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-16 15:54:54 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>No. of patients:</B> 296 randomised, 245 evaluated<I>
<BR/>
</I>
<B>Condition:</B> metastatic breast cancer (presumably stage IV)<BR/>
<B>Demographics:</B> unclear<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-18 11:31:26 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: IG1/IG2: 1 mg/kg i.m. daily (during chemotherapy treatment), thereafter 3x/week (until progression or withdrawal)<I>
<BR/>
</I>
<B>Control treatment: </B>no additional treatment<BR/>
<B>Basic treatment: </B>5-fluoruracil 500 mg/m² i.v. (d1), epidoxorubicin 75 mg/m² i.v. (d1), cyclophosphamide 500 mg/m² i.v. (d1); every three weeks or: folinic acid 200 mg/m² (d1-5), 5-fluoruracil 370 mg/m² (d1-5), epidoxorubicin 75 mg/m² (d1), cyclophosphamide 500 mg/m² (d1); every three weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 15:57:18 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival; response, other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 16:06:07 +0000" MODIFIED_BY="Elke Wolf">
<P>This study has not been published in full text (February 2010) and was performed by the Italian Cooperative Trials Group<BR/>
<B>Participants:</B> unclear how many patients were allocated to which arm</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:31:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salvati-1984">
<CHAR_METHODS MODIFIED="2010-12-17 22:31:34 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres: </B>1 or 2<BR/>
<B>Recruitment and setting: </B>Hospital C. Forlanini and Clinic of Respiratory Diseases, University of Rome, Italy<BR/>
<B>Recruitment period: </B>unclear<BR/>
<B>Observation period: </B>6 months<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:31:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 46 randomised, 40 evaluated<BR/>
<B>Condition:</B> SCLC, limited (34) or extensive (12) disease<BR/>
<B>Demographics:</B> men: 42, women: 4; median age (range): 57 (46-71) years<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-16 16:12:50 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymostimulin; dose/schedule: 1 mg/kg/day; 1st cycle (d4-10), 2nd-4th cycle (d4-6), 5th-9th cycle (d4, 5)<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>methotrexate 40 mg/m² i.v. (d1), doxorubicin 40 mg/m² i.v. (d1), cyclophosphamide 400 mg/m² i.v. (d1), nitrosourea 30 mg/m² i.v., (d1); every 3 weeks; for 6 months or until progression</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 14:13:53 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 16:19:26 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Participants:</B> distribution of risk factors between groups not reported<BR/>
<B>Funding:</B> thymostimulin supplied by Serono, Rome</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:32:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchiz-1996">
<CHAR_METHODS MODIFIED="2010-12-17 22:31:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>2-arm parallel trial with a no-treatment control group<BR/>
<B>No. of centres: </B>1<BR/>
<B>Recruitment and setting: </B>Department of Radiotherapy and Oncology, Clinica Platon, Barcelona, Spain<BR/>
<B>Recruitment period: </B>06/92-12/93<BR/>
<B>Observation period: </B>one cycle of chemotherapy<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:32:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 54 randomised, 54 evaluated<BR/>
<B>Condition:</B> metastatic breast cancer<BR/>
<B>Demographics:</B> median age (range): IG: 46 (38-54), CG: 46 (32-54) years<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-21 15:17:30 +0100" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment:</B> thymostimulin; dose/schedule: 50 mg/day i.m.; every cycle (d2-16)<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>mitoxantrone 28 mg/m² i.v., supportive treatment: G-CSF 5 µg/kg s.c. (d2-16)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 16:22:38 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>response, toxicity (AEs of chemo-/radiotherapy)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-18 11:33:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scher-1988">
<CHAR_METHODS MODIFIED="2010-12-17 22:32:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>2-arm parallel trial with a no-treatment control group; patients stratified by performance status and disease extent<BR/>
<B>No. of centres: </B>2<BR/>
<B>Recruitment and setting: </B>Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, USA<BR/>
<B>Recruitment period: </B>05/79- 05/82<BR/>
<B>Observation period: </B>approximately 25 to 60 months<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:32:15 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 91 randomised, 80 evaluated <I>
<BR/>
</I>
<B>Condition:</B> SCLC limited (32) or and extensive disease (48)<BR/>
<B>Demographics:</B> men: 59, women: 32; median age (range): IG: 59 (35-73), CG: 53 (32-72) years<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-18 11:33:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Interventional treatment: </B>thymosin fraction 5; dose/schedule: 60 mg/m² s.c.; 2x/week from the start of induction therapy through the completion of radiotherapy<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>induction therapy: 1st and 3rd cycle: cyclophosphamide 1200 mg/m² (d1), doxorubicin 50 mg/m² (d1), vincristine 1.2 mg/m² (d1, 8); 2nd and 4th cycle: cisplatin 60 mg/m² (d1) and etoposide 120 mg/m² (d4, 6, 8); consolidation therapy: cyclophosphamide 500 mg/m² (d1,14), vincristine 1,4 mg/m² (d1,14) along with radiation therapy in patients with limited disease; maintenance therapy was started 10 weeks after completion of radiotherapy in patients who had achieved complete remission, others started after hematologic recovery: 1st cycle: lomustine 60 mg/m² p.o. (d1), methotrexate 30 mg/week for 4 weeks, procarbazine 100 mg/m² p.o. (d1-14); 2nd cycle cyclophosphamide 1000 mg/m² (d42) and doxorubicin 30 mg/m²(d42); 3rd cycle: vincristine 1,2 mg/m² d63, cisplatin 50 mg/m² d63 and etoposide 120 mg/m² (d67, 69, 71); radiotherapy with 2.5 Gy/day up to 45 Gy to primary site and anterior mediastinum (patients with LD); 3 Gy/day up to 30 Gy whole brain radiation (all patients)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 16:34:54 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, response, toxicity (AEs of chemo-/radiotherapy), safety (AEs of thymic peptides), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 16:47:51 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Method:</B> sample size calculation was performed, accordingly 80 patients would be required in order to detect a 25% increase in complete remission rate<BR/>
<B>Funding:</B> supported in part by the American Cancer Society and the National Institutes of Health (NIH); thymosin fraction 5 was supplied by Hoffmann-La Roche</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-17 22:32:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulof-1985">
<CHAR_METHODS MODIFIED="2010-03-16 16:51:11 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Design: </B>double blind 3-arm parallel with placebo control<BR/>
<B>No. of centres: </B>1<BR/>
<B>Recruitment and setting: </B>Washington University Medical Center, Washington D.C., USA<BR/>
<B>Recruitment period: </B>11/80-01/83<BR/>
<B>Observation period: </B>1 year for relapse; all patients were followed up until death; median 40 weeks (8-108)<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-17 22:32:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>No. of patients:</B> 42 randomised, 41 evaluated <I>
<BR/>
</I>
<B>Condition:</B> locally advanced NSCLC, patients who had received radiotherapy because of either an unresectable tumour or incomplete resection (R1 or R2); patients with progression under radiotherapy were not included<BR/>
<B>Demographics:</B> men: 26, women: 15; mean age (SD): IG1: 57.3 (± 9.2), IG2: 52.8 (± 8.5), CG: 55.6 (± 10.5) years<BR/>
<B>Informed consent:</B> yes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-17 14:06:45 +0100" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymosin &#945;<SUB>1</SUB>; dose/schedule: IG1: placebo daily for 14 days; thereafter 900 µg/m²/day s.c., 2x/week as maintenance therapy; IG2: 900µg/m²/day, for 14 days as loading dose, thereafter placebo 2x/week as maintenance therapy; administration was initiated one week after completion of radiotherapy for a period of up to 1 year or until relapse<B>
<BR/>Control treatment: </B>placebo (mannitol powder reconstituted in bicarbonate diluent, provided in same coded vials as thymosin &#945;<SUB>1</SUB>): daily for 14 days; maintenance therapy: 2x/week<BR/>
<B>Basic treatment: </B>radiotherapy: 2 Gy/day 5x/week for 6-8 weeks to mediastinum and primary lesion, patients with prior resection of tumour received irradiation only to mediastinum</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 16:50:44 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, safety (AEs of thymic peptides), other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 17:01:56 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Participants:</B> imbalance in gender distribution and proportion of patients with resection of primary (IGs 11/28, CG 1/13) which was also discussed by the authors<BR/>
<B>Funding:</B> supported by the National Cancer Institute (NCI) and Hoffmann-La Roche</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-16 17:07:48 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Wara-1981">
<CHAR_METHODS MODIFIED="2010-03-16 17:07:48 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Design: </B>open label 2-arm parallel<BR/>
<B>No. of centres: </B>1<BR/>
<B>Recruitment and setting: </B>Department of Radiation Oncology and Pediatrics, University of California, San Francisco, USA<BR/>
<B>Recruitment period: </B>4 years before publication<BR/>
<B>Observation period: </B>min. 8 months, median 2 years.<BR/>
<B>Ethical approval: </B>unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-16 14:17:17 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>No. of patients:</B> 76 randomised, 75 evaluated<I>
<BR/>
</I>
<B>Condition:</B> squamous cell cancer of head and neck, stage II-IV<BR/>
<B>Demographics:</B> unclear<BR/>
<B>Informed consent:</B> unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-16 17:03:14 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventional treatment: </B>thymosin fraction 5; dose/schedule: 60 mg/m²: daily for 10 days; thereafter 2x/week for 50 weeks<BR/>
<B>Control treatment: </B>no treatment<BR/>
<B>Basic treatment: </B>radiotherapy with 50-60 Gy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-16 14:16:49 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Outcome measures: </B>survival, other</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-16 17:06:53 +0000" MODIFIED_BY="Elke Wolf">
<P>
<B>Interventions: </B>thymosin fraction 5 was supplied by Hoffmann-La Roche</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Outcomes which were not relevant to this review are indicated as 'other'. This includes immunologic parameters, dose modifications of chemotherapy or radiotherapy</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-12-18 11:35:28 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-12-17 22:32:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Azizi-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-17 22:32:55 +0000" MODIFIED_BY="[Empty name]">
<P>Patients received neither chemotherapy nor radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-13 16:26:48 +0100" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Bernengo-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-13 16:26:48 +0100" MODIFIED_BY="Elke Wolf">
<P>No sufficient outcome data reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:21:27 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Cartia-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:21:27 +0000" MODIFIED_BY="Elke Wolf">
<P>No sufficient outcome data reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:22:28 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Chen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:22:28 +0000" MODIFIED_BY="Elke Wolf">
<P>Outcome assessment not according to eligibility criteria of the review </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-02 19:14:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Maria-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-02 19:14:30 +0000" MODIFIED_BY="[Empty name]">
<P>Only immune parameters reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:20:00 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Denaro-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:20:00 +0000" MODIFIED_BY="Elke Wolf">
<P>Only immune parameters reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-01 12:14:35 +0100" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Holowiecki-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-01 12:14:35 +0100" MODIFIED_BY="Elke Wolf">
<P>Not randomised for purified thymic extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:24:03 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Iaffaioli-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:24:03 +0000" MODIFIED_BY="Elke Wolf">
<P>Outcome assessment not according to eligibility criteria of the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:27:05 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Kreuser-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:27:05 +0000" MODIFIED_BY="Elke Wolf">
<P>Registered randomised controlled trial, yet unpublished; manufacturer contacted, but no data provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:25:43 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Liberati-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:25:43 +0000" MODIFIED_BY="Elke Wolf">
<P>Only immune parameters reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:25:44 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Mantovani-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:25:44 +0000" MODIFIED_BY="Elke Wolf">
<P>Only immune parameters reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:25:46 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Migeod-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:25:46 +0000" MODIFIED_BY="Elke Wolf">
<P>Only immune parameters reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:25:48 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Munno-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:25:48 +0000" MODIFIED_BY="Elke Wolf">
<P>Only immune parameters reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:24:11 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Quang_x002d_Xing-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:24:11 +0000" MODIFIED_BY="Elke Wolf">
<P>Outcome assessment not according to eligibility criteria of the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-18 11:35:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shoham-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-18 11:35:28 +0000" MODIFIED_BY="[Empty name]">
<P>No concomitant chemotherapy or radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:24:41 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Surico-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:24:41 +0000" MODIFIED_BY="Elke Wolf">
<P>Outcome assessment not according to eligibility criteria of the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:24:45 +0000" MODIFIED_BY="Elke Wolf" STUDY_ID="STD-Tetti-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:24:45 +0000" MODIFIED_BY="Elke Wolf">
<P>Outcome assessment not according to eligibility criteria of the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-12-18 11:36:12 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-12-18 11:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dollinger-2010">
<CHAR_METHODS MODIFIED="2010-12-18 11:35:51 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective randomised, placebo-controlled, double blind, multicentre clinical phase III trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 08:21:40 +0000" MODIFIED_BY="[Empty name]">
<P>135 patients with locally advanced or metastasised HCC (Karnofsky &gt;=60% - Child-Pugh &lt;=12)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 08:22:01 +0000" MODIFIED_BY="[Empty name]">
<P>Thymostimulin 75mg s.c. 5x per week or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-18 11:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Primary endpoint was 12-month survival, secondary endpoints overall survival (OS), time to progression (TTP), tumour response, safety and quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-29 08:22:41 +0000" MODIFIED_BY="[Empty name]">
<P>Current Controlled Trials ISRCTN64487365</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-07-13 14:26:58 +0100" MODIFIED_BY="Elke Wolf" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-03-24 16:41:23 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-03-24 16:41:23 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-03-24 16:40:14 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-03-24 16:40:14 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Observer assessed outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Mortality</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-03-24 16:40:14 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-03-24 16:40:14 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-11-24 11:27:39 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-05-10 15:38:43 +0100" MODIFIED_BY="Elke Wolf"/>
<ADDITIONAL_TABLES MODIFIED="2010-12-18 11:41:24 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-06-15 14:24:38 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE MODIFIED="2010-03-28 12:36:27 +0100" MODIFIED_BY="[Empty name]">Type of interventional treatment</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TD>
<P>
<B>Type</B>
</P>
</TD>
<TD>
<P>
<B>Name</B>
</P>
</TD>
<TD>
<P>
<B>Ingredients</B>
</P>
</TD>
<TD>
<P>
<B>Provider</B>
</P>
</TD>
<TD>
<P>
<B>Applied in study</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Purified thymus extracts</P>
</TD>
<TD>
<P>Thymosin fraction 5</P>
</TD>
<TD>
<P>Peptide mixture, range 1-15 kDa</P>
</TD>
<TD>
<P>Hoffmann-La Roche</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>; <LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>; <LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>; <LINK REF="STD-Wara-1981" TYPE="STUDY">Wara 1981</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Thymostimulin</P>
</TD>
<TD>
<P>Peptide mixture, range 1-12 kDa</P>
</TD>
<TD>
<P>Serono S.A.</P>
</TD>
<TD>
<P>
<LINK REF="STD-Airoldi-1987" TYPE="STUDY">Airoldi 1987</LINK>; <LINK REF="STD-Canovas-1988" TYPE="STUDY">Canovas 1988</LINK>; <LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>; <LINK REF="STD-De-Serdio-1997" TYPE="STUDY">De Serdio 1997</LINK>; <LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988</LINK>; <LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>; <LINK REF="STD-Gonnelli-1995" TYPE="STUDY">Gonnelli 1995</LINK>; <LINK REF="STD-Guzman-1988" TYPE="STUDY">Guzman 1988</LINK>; <LINK REF="STD-Iaffaioli-1994" TYPE="STUDY">Iaffaioli 1994</LINK>; <LINK REF="STD-Luzi-1984" TYPE="STUDY">Luzi 1984</LINK>; <LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>; <LINK REF="STD-Mantovani-1988" TYPE="STUDY">Mantovani 1988</LINK>; <LINK REF="STD-Mustacchi-1994" TYPE="STUDY">Mustacchi 1994</LINK>; <LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK>; <LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>; <LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Synthetic thymic peptides</P>
</TD>
<TD>
<P>Thymosin &#945;<SUB>1 </SUB>
</P>
</TD>
<TD>
<P>Polypeptide (28 amino acids)</P>
</TD>
<TD>
<P>SciClone Pharmaceuticals</P>
</TD>
<TD>
<P>
<LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>; <LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>; <LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>; <LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Thymopentin</P>
</TD>
<TD>
<P>Oligopeptide (5 amino acids)</P>
</TD>
<TD>
<P>Italfarmaco</P>
</TD>
<TD>
<P>
<LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>; <LINK REF="STD-GISOT-1987" TYPE="STUDY">GISOT 1987</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-12-18 11:37:25 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-12-18 11:37:25 +0000" MODIFIED_BY="[Empty name]">Purified thymus extracts: survival, response, toxicity</TITLE>
<TABLE COLS="7" ROWS="24">
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Survival rates</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Tumour response</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Toxicity (no. of patients)</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Overall survival (OS)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Disease-/progression-free survival (DFS/PFS)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Complete remission</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Partial remission</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Grade 3/4 neutropenia</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Grade 3/4 infection</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Airoldi-1987" TYPE="STUDY">Airoldi 1987</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of survival in IG of 7.9 months§:</I>
<BR/>IG: 12/24 (50%)<BR/>CG: 10/24 (42%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of DFS in IG of 3.8 months§:</I>
<BR/>IG: 7/14 (50%)<BR/>CG: 2/6 (33%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 8 cycles of chemotherapy:</I>
<BR/>IG: 3/24 (12.5%)<BR/>CG: 1/24 (4%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 11/24 (46%)<BR/>CG: 5/24 (21%)<BR/>(p&lt; 0.05 chi² test) </P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year</I>#<I>:</I>
<BR/>IG: 8/46 (17%)<BR/>CG: 16/53 (30%)<BR/>(P = 0.14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 0/46<BR/>CG: 2/53 (4%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 10/46 (22%)<BR/>CG: 22/53 (42%)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Canovas-1988" TYPE="STUDY">Canovas 1988</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 4 cycles of chemotherapy (approximately 3 to 4 months):</I>
<BR/>IG: 23/23<BR/>CG: 20/23 (87%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 6 cycles of chemotherapy (approximately 4 to 6 months):</I>
<BR/>IG: 19/20 (95%)<BR/>CG:17/20 (85%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r. </P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r. </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>("life threatening infections")<BR/>IG: 2/20 (10%)<BR/>CG: 4/20 (5%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#:</I>
<BR/>IG1 (60 mg/m²): 10/18 (56%)<BR/>IG2 (20 mg/m²): 2/12 (17%)<BR/>CG: 3/16 (19%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year (complete responders):</I>
<BR/>IG1: 6/9 (67%)<BR/>IG2: 1/2 (50%)<BR/>CG: 2/8 (25%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 3 months of chemotherapy:</I>
<BR/>IG1: 9/18 (50%)<BR/>IG2: 2/12 (17%)<BR/>CG: 8/16 (50%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r. </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-De-Serdio-1997" TYPE="STUDY">De Serdio 1997</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a mean time of observation of 18 months:</I>
<BR/>IG: 15/18 (83%)<BR/>CG: 14/18 (78%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After approximately 2 months of radiochemotherapy:</I>
<BR/>IG: 17/18 (94%)<BR/>CG: 17/18 (94%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 12 to 33 months observation time:</I>
<BR/>IG: 8/25 (32%)<BR/>CG: 8/23 (35%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After induction chemotherapy (only reported in preliminary publication):</I>
<BR/>IG: 0/10<BR/>CG: 0/12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 0/10<BR/>CG: 0/12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(lethal infections)<BR/>IG: 0/25<BR/>CG: 2/23 (9%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#:</I>
<BR/>IG: 51/66 (72%)<BR/>CG: 48/68 (71%)<BR/>(P = 0.62)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Pats. with CR</I>
<BR/>IG: 35/39 (90%)<BR/>CG: 24/29 (83%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After completion of chemotherapy (approximately 3 to 6 months):</I>
<BR/>IG: 39/66 (59%)<BR/>CG: 29/68 (43%) (P = 0.05 log-rank)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 14/66 (21%)<BR/>CG: 22/68 (32%)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Gonnelli-1995" TYPE="STUDY">Gonnelli 1995</LINK>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>At 3 months of chemotherapy (40 patients evaluated):</I>
<BR/>IG: 0/20<BR/>CG: 0/20<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 1/20 (5%)<BR/>CG: 0/20<BR/>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="2" VALIGN="TOP">
<P>n.r. </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>At 6 months of chemotherapy (36 patients evaluated):</I>
<BR/>IG: 0/19<BR/>CG: 0/17</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 6/19 (32%)<BR/>CG: 4/17 (24%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Guzman-1988" TYPE="STUDY">Guzman 1988</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 18 to 42 months observation time:</I>
<BR/>IG: 14/16 (87.5%)<BR/>CG: 11/16 (69%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 11/16 (69%)<BR/>CG: 10/16 (62.5%)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Iaffaioli-1994" TYPE="STUDY">Iaffaioli 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P> n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(grade 3/4)<BR/>IG: 7/37 (19%)<BR/>CG: 12/32 (37.5%)<BR/>(P = 0.074)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Luzi-1984" TYPE="STUDY">Luzi 1984</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#:</I>
<BR/>IG: 8/25 (32%)<BR/>CG: 6/25 (24%)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<I>At 40 days (response was defined as CR, PR or radiologic improvement of atelectasis):</I>
<BR/>IG: 13/23 (57%)<BR/>CG: 21/24 (88%)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#:</I>
<BR/>IG: 10/15 (67%)<BR/>CG: 2/11 (18%)<BR/>(log rank p&lt;0,0032)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of DFS/PFS in IG of 6 months</I>§:<BR/>IG: 7/15 (47%)<BR/>CG: 3/11 (27%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After approximately 6 months of chemotherapy:</I>
<BR/>IG: 7/15 (47%)<BR/>CG: 1/11 (9%) (P = 0.45, Fisher exact)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 4/15 (27%)<BR/>CG: 3/11 (27%)<BR/>(n.s.)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(grade 3)<BR/>IG: 0/15<BR/>CG: 3/11 (27%)<BR/>(grade 4)<BR/>IG: 0/15<BR/>CG: 1/11 (9%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mantovani-1988" TYPE="STUDY">Mantovani 1988</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 or 2 years:</I>
<BR/>IG: 18/20 (90%)<BR/>CG: 16/17 (94%)<BR/>(n.s.)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year: </I>
<BR/>IG: 6/11 (55%)<BR/>CG: 3/10 (30%)<BR/>
<I>After 2 years:</I>
<BR/>IG: 2/9 (22%)<BR/>CG: 4/7 (57%)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mustacchi-1994" TYPE="STUDY">Mustacchi 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of survival in IG of 10 months§:</I>
<BR/>IG: 53/106 (50%)<BR/>CG: 60/105 (57%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of DFS/PFS in IG of 6.5 months</I>§:<BR/>IG: 62/106 (58%)<BR/>CG: 62/105 (59%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 6/106 (6%)<BR/>CG: 3/105 (3%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 26/106 (25%)<BR/>CG:16/105 (15%) (P = 0.02, chi²)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of survival in IG of approximately 16 to 17months§:</I>
<BR/>IG: 74/148<BR/>CG: 85/148</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of survival in IG of 15 months§:</I>
<BR/>IG: 74/148<BR/>CG: 86/148</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>"Overall response" (not further described):<BR/>IG: 77/148 (52%)<BR/>CG: 88/148 (60%)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r. </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of survival in IG of 6 for extensive and 18 months for limited disease§:</I>
<BR/>IG: 12/23 (52%)<BR/>CG: 7/23 (30%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of survival in IG of 2.1 for extensive and 2.8 months for limited disease§:</I>
<BR/>IG: 11/23 (48%)<BR/>CG: 3/23 (13%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 6/20 (32%)<BR/>CG: 3/20 (16%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 6/20 (30%)<BR/>CG: 9/20 (45%)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 cycle of chemotherapy: </I>
<BR/>IG: 0/27<BR/>CG: 0/27</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG: 1/27 (3%)<BR/>CG: 0/27</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(grade 4)<BR/>IG: 20/27 (74%)<BR/>CG: 27/27 (p&lt;0.01)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(ANC &lt;500/mm² and fever &gt; 38°C)<BR/>IG: 6/27 (22%)<BR/>CG: 16/27 (59%) (P = 0.0119)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#: Limited disease: </I>
<BR/>IG: 11/17 (65%)<BR/>CG: 16/18 (89%) (P = 0.38, log rank)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#: Limited disease: </I>
<BR/>IG: 10/17 (59%)<BR/>CG: 11/15 (73%)<BR/>(P = 0.32, log rank)<BR/>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<I>After induction and consolidation radiochemotherapy (at approximately 6 months):</I>
<BR/>IG:18/41 (44%)<BR/>CG:17/39 (44%)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>IG:23/41 (56%)<BR/>CG: 20/39 (51%)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>(Admission for neutropenia and sepsis</I>)<BR/>
<I>Limited disease:</I>
<BR/>IG: 5/17 (29%) CG: 11/15 (73%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#: Extensive disease: </I>
<BR/>IG: 12/28 (43%)<BR/>CG: 15/28 (54%) (P = 0.49, log rank)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#:Extensive disease: approximately 28 to 60 months observation time</I>#<I>:</I>
<BR/>IG: 8/23 (35%)<BR/>CG: 10/24 (42%)<BR/>(P = 0.49, log rank)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Extensive disease:</I>
<BR/>IG: 12/24 (50%)<BR/>CG: 15/24 (63%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wara-1981" TYPE="STUDY">Wara 1981</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#:</I>
<BR/>IG: 22/33 (67%)<BR/>CG: 25/42 (60%) (p&lt;0.08)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r. </P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r. </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: # survival rates extracted from Kaplan-Meier curves, § survival rates estimated from median survival times, CR: complete remission, PR: partial remission, SD: stable disease, NC: no change, PD: progressive disease, n.r.: not reported</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-12-18 11:38:14 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-12-18 11:38:14 +0000" MODIFIED_BY="[Empty name]">Synthetic thymic peptides: survival, response, toxicity</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Survival rates</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Tumour response</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Toxicity (no. of patients)</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>OS </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>DFS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>CR</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PR</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Grade 3/4 neutropenia</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Grade 3/4 infection</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>At 1 year:</I>
<BR/>IG1 (IFN &#593;+1.6 mg thymosin &#945;<SUB>1</SUB>): 39/97 (40%)<BR/>IG2 (IFN &#593;+3.2 mg thymosin &#945;<SUB>1</SUB>): 36/97 (37%)<BR/>IG3 (IFN &#593;+6.4 mg thymosin &#945;<SUB>1</SUB>): 45/98 (46%)<BR/>IG4 (3.2 mg thymosin &#945;<SUB>1</SUB>)*: 38/99 (39%)</P>
<P>
<BR/>total IG (IG1-3): 120/292 (41%)<BR/>CG (IFN &#593;): 33/97 (34%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>At 1 year#:</I>
<BR/>IG1: 4/97 (4%)<BR/>IG2: 10/97 (10%)<BR/>IG3: 3/98 (3%)<BR/>IG4*: 10/99 (10%)<BR/>total IG (IG1-3): 17/292 (5%)<BR/>CG: 0/97</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>Best response within 12 months (measured at various time points):</I>
<BR/>IG1: 2/97 (2%)<BR/>IG2: 3/97 (3%)<BR/>IG3: 2/98 (3%)<BR/>IG4*: 2/99 (2%)</P>
<P>total IG (IG1-3): 7/292 (2%)<BR/>CG: 0/97</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>IG1: 5/97 (5%)<BR/>IG2: 7/97 (7%)<BR/>IG3: 4/98 (4%)<BR/>IG4*: 10/99 (10%)<BR/>total IG (IG1-3): 16/292 (5%)<BR/>CG: 4/97 (4%)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After a median time of survival in IG of 10 months§:</I>
<BR/>IG: 9/18 (50%)<BR/>CG: 9/23 (39%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>At 1 year:</I>
<BR/>IG: 3/18 (17%)<BR/>CG: 3/23 (13%)(n.s.)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r. </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(ANC&lt;1,000/mm² and fever&gt;38°C)<BR/>IG1 (thymopentin): 12/23 (52%) IG2 (thymopentin+G-CSF): 4/22 (18%)<BR/>IG1+IG2: 16/45 (36%)<BR/>CG1 (placebo): 18/28 (64%)<BR/>CG2 (G-CSF): 5/23 (22%)<BR/>CG1+CG2: 23/51 (45%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>At 6 months</I>
<BR/>IG: 12/14 (86%)<BR/>CG: 7/11 (64%)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<I>Best response within 18 months (measured at various time points):</I>
<BR/>IG: 0/14<BR/>CG: 0/11</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>IG: 2/14 (14%)<BR/>CG: 2/11 (18%)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>n.r. </P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>(severe bacterial infections)<BR/>IG: 0/14<BR/>CG: 4/11 (36%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>At 12 months</I>
<BR/>IG: 9/14 (64%)<BR/>CG: 7/11 (64%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>At 2 years</I>
<BR/>IG: 8/14 (57%)<BR/>CG: 5/11 (45%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-GISOT-1987" TYPE="STUDY">GISOT 1987</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 3 months mean observation time:</I>
<BR/>IG: 432/447 (97%)<BR/>CG:197/203 (97%)<BR/>(P = 0,068, chi²)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r. </P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year</I>#:<BR/>IG1 (maintenance therapy): 8/15 (53%)<BR/>IG2 (loading dose): 4/13 (31%)<BR/>CG: 1/13 (8%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<I>After 1 year#:</I>
<BR/>IG1: 3/15 (20%)<BR/>IG2: 4/13 (31%)<BR/>CG: 0/13</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>n.r.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: # survival rates extracted from Kaplan-Meier curves, § survival rates estimated from median survival times, * not included in metaanalysis; CR: complete remission, PR: partial remission, SD: stable disease, NC: no change, PD: progressive disease</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2010-12-18 11:38:50 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-12-18 11:38:50 +0000" MODIFIED_BY="[Empty name]">Purified thymus extract: safety</TITLE>
<TABLE COLS="3" ROWS="12">
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2" VALIGN="TOP">
<P>
<B>Adverse effects of purified thymus extracts </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>local</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>systemic</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Erythema and induration of site of injection<BR/>
</P>
</TD>
<TD>
<P>Generalized skin rash, febrile reaction</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Canovas-1988" TYPE="STUDY">Canovas 1988</LINK>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Authors stated that thymostimulin was well tolerated, but 2 patients were excluded because of allergic reaction to TP-1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Authors stated that thymostimulin was well tolerated and no adverse reactions were observed</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>"Toxic effects of thymosin were confined to local irritation at the injection site manifested by greater or lesser degrees of pain and swelling. All reactions subsided within 12-72 hours of injection."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988</LINK>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>"No side effects were observed with thymostimulin,[...]."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Luzi-1984" TYPE="STUDY">Luzi 1984</LINK>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>"(...) no allergic reactions or toxic effects were noted during TS treatment."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>"No local or systemic thymostimulin-related clinical toxicities were noted."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Authors stated that no toxic effects attributable to thymostimulin treatment were observed.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>"(...) GCS-F and TS were well tolerated without adverse events related to these drugs."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Dose reduction because of local reactions (pain and inflammation at injection site): 9/45 patients</P>
</TD>
<TD VALIGN="TOP">
<P>chills and fever within 24 h of injection in 5/45 patients</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2010-12-18 11:39:09 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-12-18 11:39:09 +0000" MODIFIED_BY="[Empty name]">Synthetic thymic peptides: safety</TITLE>
<TABLE COLS="3" ROWS="5">
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2" VALIGN="TOP">
<P>
<B>Adverse effects of synthetic thymic peptides</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>local</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>systemic</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>"Thymopentin treatment did not cause any significant side effects."</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>
</P>
</TD>
<TD COLSPAN="2">
<P>"Of the 23 adverse events the author judged possibly or probably related to thymalfasin, most were mild and resolved without sequelae. Only three of these events occurred in more than one patient: nausea (n=2), fatigue (n=2), and nipple pain (n=2).(...) Overall, thymalfasin was well tolerated."</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>mild burning at the injection site in 3 patients.</P>
</TD>
<TD VALIGN="TOP">
<P>mild transient loss of muscle mass in1 patient.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2010-12-18 11:39:29 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2010-12-18 11:39:29 +0000" MODIFIED_BY="[Empty name]">Purified thymus extracts: risk of bias</TITLE>
<TABLE COLS="8" ROWS="22">
<TR>
<TD ROWSPAN="2">
<P>
<B>Study</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Sequence</B> <B>generation</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Allocation concealment</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Blinding</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Attrition</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Selective reporting</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Risk of Bias</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>OS</P>
</TD>
<TD>
<P>DFS/Tox</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Airoldi-1987" TYPE="STUDY">Airoldi 1987</LINK>
</P>
</TD>
<TD>
<P>Quote: "i pazienti sono stati stratificati (...) prima di essere randomizzati al trattamento (...)" Comment: sequence generation not reported; no earlier reports from the same investigators found that clearly describe the use of random sequences</P>
</TD>
<TD>
<P>Not reported; prognostic factors similarly distributed</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>No dropouts or withdrawals</P>
</TD>
<TD>
<P>Comprehensive report of outcomes</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bedikian-1984" TYPE="STUDY">Bedikian 1984</LINK>
</P>
</TD>
<TD>
<P>Quote: "Patients (...) were randomized (...)." Comment: sequence generation not reported</P>
</TD>
<TD>
<P>Probably not done: no concealment reported, dissimilarities in baseline prognostic factors</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Quote: Three of 49 thymosin patients have been excluded from the subsequent evaluation of response and survival of the thymosin group (...) Comment: differential loss in comparison groups, but extent of possible bias unclear</P>
</TD>
<TD>
<P>No indication for selective reporting</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Canovas-1988" TYPE="STUDY">Canovas 1988</LINK>
</P>
</TD>
<TD>
<P>Quote: "La asignación de los pacientes.....se realizó mediante el sistema de numeros aleatorios." Comment: probably done, table of random numbers used</P>
</TD>
<TD>
<P>Not reported. Equal distribution of characteristics/prognostic factors stated in text, but no detailed data provided</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>All patients analysed</P>
</TD>
<TD>
<P>All intended outcomes were reported</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Canovas-1991" TYPE="STUDY">Canovas 1991</LINK>
</P>
</TD>
<TD>
<P>Quote: " (...) se realizó mediante la aplicación de la tabla de numeros aleatorios (...)." Comment: probably done, table of random numbers used</P>
</TD>
<TD>
<P>Not reported. Equal distribution of characteristics/prognostic factors stated in text, but no detailed data provided</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>All patients analysed</P>
</TD>
<TD>
<P>All intended outcomes were reported</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) randomly received (...)" Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported. Dissimilarities in baseline characteristics; small sample size</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Quote:"Statistical analysis was also (...) of 55 patients. All results (..) in the 46 protocol-eligible patients were also significant for (...) 55 patients." Comment: number of withdrawals/drop-outs balanced, reasons for exclusions described, PP and ITT performed</P>
</TD>
<TD>
<P>Comprehensive report of outcomes</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-De-Serdio-1997" TYPE="STUDY">De Serdio 1997</LINK>
</P>
</TD>
<TD>
<P>Quote: "Las tablas de azar nos suministratron (...) siguiente esquema de randomización (...)" Comment: adequate sequence generation</P>
</TD>
<TD>
<P>No concealment reported. Detailed list of disease localisation and stage given; other patient related characteristics not reported</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>All patients analysed</P>
</TD>
<TD>
<P>All intended outcomes were reported</P>
</TD>
<TD>
<P>Outcomes not assessed</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Del-Giacco-1988" TYPE="STUDY">Del Giacco 1988</LINK>
</P>
</TD>
<TD>
<P>Quote:" (...) patients were randomised between (...)" Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported.</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Quote: "31 could be randomised (...) but only 22 are completely evaluable (the other 9 having an incomplete follow-up (..)" Comment: 9 patients lost to follow-up, reasons not commented, distribution between intervention and control group unclear</P>
</TD>
<TD>
<P>Discrepancy between intended and reported outcome measures, results on quality of life were not reported, tumour response only reported in the preliminary publication</P>
</TD>
<TD>
<P>high</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Federico-1995" TYPE="STUDY">Federico 1995</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) patients were randomised (...)." Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported. Dissimilarities in baseline prognostic factors, which were discussed by study authors as possibly having influenced the outcomes</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Equal numbers of drop-outs/exclusions in both groups</P>
</TD>
<TD>
<P>Comprehensive report of outcomes</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gonnelli-1995" TYPE="STUDY">Gonnelli 1995</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) were randomly selected (...)" Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported.</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>4 patients inevaluable, 1 in IG, 3 in CG, reasons not stated, ITT for tumour response and rate of infection</P>
</TD>
<TD>
<P>Intended outcomes not stated</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guzman-1988" TYPE="STUDY">Guzman 1988</LINK>
</P>
</TD>
<TD>
<P>Quote: &#8220;(...) were randomised.&#8221; Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported. No data on distribution of risk factors</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>All patients analysed</P>
</TD>
<TD>
<P>All intended outcomes were reported</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Iaffaioli-1994" TYPE="STUDY">Iaffaioli 1994</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) and randomised (...)" Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported; prognostic factors similarly distributed</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>All patients analysed</P>
</TD>
<TD>
<P>Intended outcomes were not comprehensively reported</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Luzi-1984" TYPE="STUDY">Luzi 1984</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) in a randomized controlled study; (...)" Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported. Slight imbalances in patient-related factors. Small sample size. (direction of possible risk unclear)</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Three patients with adenocarcinoma were excluded afterwards for unknown reasons, (two in IG and on in CG)</P>
</TD>
<TD>
<P>Intended outcomes were not comprehensively reported</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Macchiarini-1989" TYPE="STUDY">Macchiarini 1989</LINK>
</P>
</TD>
<TD>
<P>Quote: "The randomization was performed by assigning a prerandomized sequential number to each patient (...)" Comment: probably done, table of random numbers used</P>
</TD>
<TD>
<P>No concealment reported. Dissimilarities in disease stage. Small sample size.(possible risk of bias in favor of the intervention group)</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Two patients from the control group excluded because of death within the first 2 weeks of treatment; no ITT; (possible risk of bias concerning mortality outcomes in favor of the control group)</P>
</TD>
<TD>
<P>All intended outcomes were reported</P>
</TD>
<TD>
<P>high</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mantovani-1988" TYPE="STUDY">Mantovani 1988</LINK>
</P>
</TD>
<TD>
<P>Quote:"(...) enrolled for study and randomized (...)" Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported. Dissimilarities in disease characteristics. Small sample size.(possible risk of bias in favour of the control group)</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>All patients analysed</P>
</TD>
<TD>
<P>All intended outcomes were reported</P>
</TD>
<TD>
<P>high</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mustacchi-1994" TYPE="STUDY">Mustacchi 1994</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) entering this prospective randomized multicenter trial (...)"Comment: sequence generation not reported</P>
</TD>
<TD>
<P>Quote: "(...) were randomly allocated over the phone by the Central Office (...)"Comment: probably done (central allocation)</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Quote: "(...) 25 out of 235 patients were lost due to cancellation, ineligibility or protocol violations (..)"Comment: distribution between groups similar, outcome measure not likely to be influenced</P>
</TD>
<TD>
<P>All intended outcomes reported</P>
</TD>
<TD>
<P>low - moderate</P>
</TD>
<TD>
<P>moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pavesi-1993" TYPE="STUDY">Pavesi 1993</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) and randomly allocated (...)"Comment: sequence generation not reported</P>
</TD>
<TD>
<P>Quote: "(...) and randomly allocated over the phone (...)"Comment: probably done (central allocation)</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Quote: "(...) in 245 fully evaluable patients (..)"Comment: 51 randomised patients not included in analysis, reasons not reported, distribution between groups unclear</P>
</TD>
<TD>
<P>Intended outcomes were reported (only abstract publication available)</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Salvati-1984" TYPE="STUDY">Salvati 1984</LINK>
</P>
</TD>
<TD>
<P>&#8220;(?) hanno ricevuto a random (?)&#8221;Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported. Distribution of possible risk factors/disease characteristics unclear. Small sample size</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Quote: "I pazienti valutabili sono stati 40 (..)"Comment: six patients not included in analysis, reasons not reported, distribution between groups unclear</P>
</TD>
<TD>
<P>Intended outcomes were reported (but report was not very detailed)</P>
</TD>
<TD>
<P>high</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sanchiz-1996" TYPE="STUDY">Sanchiz 1996</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) were randomly assigned (by means of tables of random numbers) (...)"Comment: probably done, table of random numbers used</P>
</TD>
<TD>
<P>No concealment reported. Slight imbalances in possible risk factors/disease characteristics. Small sample size</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>No dropouts/withdrawals reported but unclear whether all patients were included in the analyses</P>
</TD>
<TD>
<P>All intended outcomes were reported</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Scher-1988" TYPE="STUDY">Scher 1988</LINK>
</P>
</TD>
<TD>
<P>Quote: "Randomization was by the method of random permuted blocks (...)"Comment: probably done</P>
</TD>
<TD>
<P>No concealment reported. Dissimilarities in prognostic factors between groups</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>All randomised patients were included in the survival analysis and the reasons for the exclusion of three patients from the response analysis were reported and unlikely to introduce bias</P>
</TD>
<TD>
<P>Outcomes comprehensively reported</P>
</TD>
<TD>
<P>low - moderate</P>
</TD>
<TD>
<P>moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Wara-1981" TYPE="STUDY">Wara 1981</LINK>
</P>
</TD>
<TD>
<P>Quote: &#8220;(?) were randomly assigned (?)"Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported. Dissimilarities in prognostic factors.</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>All but one randomised patients included in the analyses, reason for exclusion not reported</P>
</TD>
<TD>
<P>All intended outcomes reported</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2010-12-18 11:40:10 +0000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2010-12-18 11:39:59 +0000" MODIFIED_BY="[Empty name]">Synthetic thymic peptides: risk of bias</TITLE>
<TABLE COLS="8" ROWS="8">
<TR>
<TD ROWSPAN="2">
<P>
<B>Study</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Sequence generation</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Allocation</B> <B>concealment</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Blinding</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Attrition</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>Selective</B> <B>reporting</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Risk of Bias</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>OS</P>
</TD>
<TD>
<P>DFS/Tox</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cheng-2004" TYPE="STUDY">Cheng 2004</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) were randomly divided (...) based on the date of admission." Comment: Quasi-randomisation</P>
</TD>
<TD>
<P>Probably not done; study authors did not use adequate sequence generation and baseline prognostic factors dissimilarly distributed.</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>All patients analysed.</P>
</TD>
<TD>
<P>All intended outcomes were reported.</P>
</TD>
<TD>
<P>high</P>
</TD>
<TD>
<P>high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gebbia-1994" TYPE="STUDY">Gebbia 1994</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) were randomised (...)" Comment: sequence generation not reported</P>
</TD>
<TD>
<P>Not reported. Similar distribution of age, gender, performance status, but no data on site of primary tumour for the placebo group</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Quote: "(...) 4 patients were excluded from final analysis due to major protocol violation." Comment: unclear distribution of drop-outs between groups</P>
</TD>
<TD>
<P>Incomplete reporting of hematological and infectious outcomes</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gish-2009" TYPE="STUDY">Gish 2009</LINK>
</P>
</TD>
<TD>
<P>Quote: "Randomization was carried out centrally using a randomization table (...)" Comment: probably done, table of random numbers used</P>
</TD>
<TD>
<P>Quote: "Randomization was carried out centrally using a randomization table (...)" Comment: probably done (central allocation)</P>
</TD>
<TD>
<P>Quote: "tumour measurements and interpretation (...) performed centrally by radiologists blinded to treatment assignment</P>
</TD>
<TD>
<P>28 randomised, 25 treated and evaluated, 3 withdrawals in CG before beginning of treatment</P>
</TD>
<TD>
<P>All intended outcomes reported</P>
</TD>
<TD>
<P>low - moderate</P>
</TD>
<TD>
<P>low - moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-GISOT-1987" TYPE="STUDY">GISOT 1987</LINK>
</P>
</TD>
<TD>
<P>Quote:"(...) per mezzo di una lista di randomizzazione;" Comment: probably done, table of random numbers used</P>
</TD>
<TD>
<P>Not reported. No data on characteristics/ risk factors</P>
</TD>
<TD>
<P>No blinding reported</P>
</TD>
<TD>
<P>Inconsistent numbers of drop-outs/withdrawals</P>
</TD>
<TD>
<P>All intended outcomes were reported</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>moderate - high</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>
</P>
</TD>
<TD>
<P>Quote: "The randomization list was produced by the Internal QualityControl Unit of Biostatistics and Data Management (...)"<BR/>Comment: adequate sequence generation</P>
</TD>
<TD>
<P>Quote: "Randomization was blinded and centralized (...).<BR/>Comment: probably done (central allocation)</P>
</TD>
<TD>
<P>Quote: "tumour response was evaluated (...) utilizing a central review." Comment: although central review performed, unclear whether assessor was blinded</P>
</TD>
<TD>
<P>For tumour response all patients were analyzed, authors assumed that this was the case for the outcomes OS and PFS as well</P>
</TD>
<TD>
<P>Comprehensive report of outcomes</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>low - moderate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>
</P>
</TD>
<TD>
<P>Quote: "(...) was performed using a randomized, double-blind design (...)"Comment: sequence generation not reported</P>
</TD>
<TD>
<P>No concealment reported. Dissimilarities in prognostic factors between groups (possibly in favour of intervention group). Small sample size</P>
</TD>
<TD>
<P>Quote: "The code did not have to be broken because of toxicity in any patient (...)"Comment: Successful blinding of patients and care provider likely</P>
<P>Quote: "(...) and administered (...) for a period of up to 1 year or until relapse."Comment: Outcome was assessed during the blinded study phase in the majority of patients</P>
</TD>
<TD>
<P>All but one randomised patients included in the analyses, reason for exclusion reported</P>
</TD>
<TD>
<P>All intended outcomes reported</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>moderate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2010-12-18 11:41:24 +0000" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2010-10-25 13:38:14 +0100" MODIFIED_BY="Elke Wolf">Sensitivity analyses</TITLE>
<TABLE COLS="3" ROWS="17">
<TR>
<TD COLSPAN="3">
<P>
<B>Purified thymus extracts - overall survival</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Outcome</B>
</P>
</TD>
<TD>
<P>
<B>Random effects model</B>
</P>
</TD>
<TD>
<P>
<B>Single intervention groups in studies with more doses/regimes tested </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>pTE</P>
</TD>
<TD>
<P>RR 1.00, 95% CI 0.79 to 1.25, P = 0.98, I²=44%</P>
</TD>
<TD>
<P>60 mg thymosin fraction 5 (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>)<BR/>RR 1.02, 95% CI 0.80 to 1.31, P = 0.87, I²=52%</P>
</TD>
</TR>
<TR>
<TD>
<P>Thymostimulin (subgroup)</P>
</TD>
<TD>
<P>RR 1.07, 95% CI 0.85 to 1.35, P = 0.57, I²=35%</P>
</TD>
<TD>
<P>not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Thymosin fraction 5 (subgroup)</P>
</TD>
<TD>
<P>RR 0.84, 95% CI 0.49 to 1.45, P = 0.53, I²= 48%</P>
</TD>
<TD>
<P>60 mg thymosin fraction 5 (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>)<BR/>RR 0.95, 95% CI 0.46 to 1.95, P = 0.89, I²=69%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Purified thymus extracts - disease-free survival</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>pTE</P>
</TD>
<TD>
<P>RR 0.97, 95% CI 0.82 to 1.16, P = 0.77, I²= 30%</P>
</TD>
<TD>
<P>60 mg thymosin fraction 5 (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>)<BR/>RR 0.97, 95% CI 0.82 to 1.16, P = 0.78, I²=32%</P>
</TD>
</TR>
<TR>
<TD>
<P>Thymostimulin (subgroup)</P>
</TD>
<TD>
<P>RR 0.93, 95% CI 0.73 to 1.19, P = 0.59, I²= 54%</P>
</TD>
<TD>
<P>not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Thymosin fraction 5 (subgroup)</P>
</TD>
<TD>
<P>RR 1.06, 95% CI 0.71 to 1.60, P = 0.76, I²= 38%</P>
</TD>
<TD>
<P>60 mg thymosin fraction 5 (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>)<BR/>RR 1.07, 95% CI 0.70 to 1.64, P = 0.48, I²=41%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Purified thymus extracts - tumour response</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>pTE</P>
</TD>
<TD>
<P>RR 1.07, 95% CI 0.92 to 1.25, P = 0.37, I²= 53%</P>
</TD>
<TD>
<P>60 mg thymosin fraction 5 (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>)<BR/>RR 1.04, 95% CI 0.89 to 1.21, P = 0.64, I²=56%</P>
</TD>
</TR>
<TR>
<TD>
<P>Thymostimulin (subgroup)</P>
</TD>
<TD>
<P>RR 1.25, 95% CI 0.96 to 1.62, P = 0.09, I²=66%</P>
</TD>
<TD>
<P>not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Thymosin fraction 5 (subgroup)</P>
</TD>
<TD>
<P>RR 0.73, 95% CI 0.24 to 2.19, P = 0.57, I²=94%</P>
</TD>
<TD>
<P>60 mg thymosin fraction 5 (<LINK REF="STD-Cohen-1979" TYPE="STUDY">Cohen 1979</LINK>)<BR/>RR 0.81, 95% CI 0.32 to 2.07, P = 0.65, I²=92%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Synthetic thymic peptides - overall survival</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>sTP</P>
</TD>
<TD>
<P>RR 1.21, 95% CI 0.94 to 1.56, P = 0.14, I²=0%</P>
</TD>
<TD>
<P>6.4 mg thymosin &#945;<SUB>1</SUB>(<LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>) and maintenance regime (<LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>)<BR/>RR 1.30, 95% CI 0.92 to 1.85, P = 0.14, I²=23%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Synthetic thymic peptides - disease-free survival</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>sTP</P>
</TD>
<TD>
<P>RR 3.37, 95% CI 0.66 to 17.30, P = 0.15, I²= 37%</P>
</TD>
<TD>
<P>6.4 mg thymosin &#945;<SUB>1 </SUB>(<LINK REF="STD-Maio-2010" TYPE="STUDY">Maio 2010</LINK>) and maintenance regime (<LINK REF="STD-Schulof-1985" TYPE="STUDY">Schulof 1985</LINK>)<BR/>RR 2.22, 95% CI 0.67 to 7.37, P = 0.19, I²=0%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-06-20 15:44:38 +0100" MODIFIED_BY="Elke Wolf">
<COMPARISON ID="CMP-001" MODIFIED="2011-06-20 15:44:38 +0100" MODIFIED_BY="Elke Wolf" NO="1">
<NAME>Purified thymus extracts versus no treatment or placebo</NAME>
<DICH_OUTCOME CHI2="12.600604538866722" CI_END="1.2493880674698605" CI_START="0.7948850810240908" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9965540302669557" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="176" I2="44.44710983184646" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.09669735381366741" LOG_CI_START="-0.09969565409152316" LOG_EFFECT_SIZE="-0.0014991501389278695" METHOD="MH" MODIFIED="2011-06-20 15:44:38 +0100" MODIFIED_BY="Elke Wolf" NO="1" P_CHI2="0.08245864560810956" P_Q="0.4233893783037199" P_Z="0.9761288989146556" Q="0.6408888082136994" RANDOM="YES" SCALE="2.45" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03765394051257466" TOTALS="YES" TOTAL_1="357" TOTAL_2="348" WEIGHT="100.00000000000001" Z="0.02992245305530707">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.179567535248651" CI_END="1.3514912411813331" CI_START="0.8481792039140219" DF="4" EFFECT_SIZE="1.070657165035548" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="126" I2="35.270551261334354" ID="CMP-001.01.01" LOG_CI_END="0.13081323544433263" LOG_CI_START="-0.07151237999715987" LOG_EFFECT_SIZE="0.029650427723586444" MODIFIED="2010-11-15 10:37:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18613358118677603" P_Z="0.565658008705826" STUDIES="5" TAU2="0.022262216944677407" TOTAL_1="236" TOTAL_2="233" WEIGHT="69.9077502623446" Z="0.574457864246481">
<NAME>Thymostimulin</NAME>
<DICH_DATA CI_END="2.2302564728344407" CI_START="0.6456656521525073" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.34835480848854367" LOG_CI_START="-0.18999231639329411" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-10-26 15:35:51 +0100" MODIFIED_BY="Elke Wolf" ORDER="119" O_E="0.0" SE="0.316227766016838" STUDY_ID="STD-Airoldi-1987" TOTAL_1="24" TOTAL_2="24" VAR="0.10000000000000003" WEIGHT="9.66804357975564"/>
<DICH_DATA CI_END="1.3392553758926498" CI_START="0.8947968229472203" EFFECT_SIZE="1.0946969696969697" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="48" LOG_CI_END="0.12686339834586932" LOG_CI_START="-0.048275566572435695" LOG_EFFECT_SIZE="0.0392939158867168" MODIFIED="2010-10-25 12:47:47 +0100" MODIFIED_BY="Elke Wolf" ORDER="121" O_E="0.0" SE="0.10287749494487072" STUDY_ID="STD-Federico-1995" TOTAL_1="66" TOTAL_2="68" VAR="0.010583778966131902" WEIGHT="27.589287184028947"/>
<DICH_DATA CI_END="3.2851342560759567" CI_START="0.5411583330239009" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5165531229008231" LOG_CI_START="-0.2666756496842232" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2010-11-15 10:37:44 +0000" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.4600724580614087" STUDY_ID="STD-Luzi-1984" TOTAL_1="25" TOTAL_2="25" VAR="0.21166666666666664" WEIGHT="5.337883261466201"/>
<DICH_DATA CI_END="13.503550026545355" CI_START="0.9956229597413481" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.1304479576995088" LOG_CI_START="-0.001905096822383558" LOG_EFFECT_SIZE="0.5642714304385625" MODIFIED="2010-11-15 10:37:51 +0000" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.6651497894641796" STUDY_ID="STD-Macchiarini-1989" TOTAL_1="15" TOTAL_2="11" VAR="0.4424242424242424" WEIGHT="2.7721407535318354"/>
<DICH_DATA CI_END="1.1261626017595074" CI_START="0.6798529793155922" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="60" LOG_CI_END="0.05160110094926267" LOG_CI_START="-0.16758499490463624" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2010-11-15 10:37:48 +0000" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.12875099769325318" STUDY_ID="STD-Mustacchi-1994" TOTAL_1="106" TOTAL_2="105" VAR="0.016576819407008087" WEIGHT="24.540395483561976"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8583458973519837" CI_END="1.4499848969204565" CI_START="0.48693435327503537" DF="2" EFFECT_SIZE="0.8402663018594351" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="50" I2="48.16431566250663" ID="CMP-001.01.02" LOG_CI_END="0.16136347863617098" LOG_CI_START="-0.3125295848472321" LOG_EFFECT_SIZE="-0.07558305310553057" MODIFIED="2010-11-15 10:37:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14526843163206016" P_Z="0.5318367858663119" STUDIES="3" TAU2="0.11531415342163802" TOTAL_1="121" TOTAL_2="115" WEIGHT="30.09224973765541" Z="0.6252046013904418">
<NAME>Thymosin fraction 5</NAME>
<DICH_DATA CI_END="1.2210256416458947" CI_START="0.27180115646639824" EFFECT_SIZE="0.5760869565217391" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.08672478426297371" LOG_CI_START="-0.5657486997525062" LOG_EFFECT_SIZE="-0.23951195774476622" MODIFIED="2010-11-15 10:37:40 +0000" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.3832661543065283" STUDY_ID="STD-Bedikian-1984" TOTAL_1="46" TOTAL_2="53" VAR="0.14689294503691552" WEIGHT="7.211415634775197"/>
<DICH_DATA CI_END="6.474371079829836" CI_START="0.7029425800584057" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.8111975874520897" LOG_CI_START="-0.15308014892364027" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2010-10-28 13:32:59 +0100" MODIFIED_BY="Elke Wolf" ORDER="122" O_E="0.0" SE="0.5664215155988809" STUDY_ID="STD-Cohen-1979" TOTAL_1="30" TOTAL_2="16" VAR="0.3208333333333333" WEIGHT="3.712389233579075"/>
<DICH_DATA CI_END="1.0755799454988175" CI_START="0.5347862396578383" EFFECT_SIZE="0.7584229390681003" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="0.03164269607971649" LOG_CI_START="-0.2718197759006154" LOG_EFFECT_SIZE="-0.12008853991044943" MODIFIED="2010-10-25 12:47:29 +0100" MODIFIED_BY="Elke Wolf" ORDER="124" O_E="0.0" SE="0.17825535820470984" STUDY_ID="STD-Scher-1988" TOTAL_1="45" TOTAL_2="46" VAR="0.03177497272868941" WEIGHT="19.16844486930114"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.153865637302101" CI_END="1.1590654066791042" CI_START="0.8186125922088462" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9740767614008569" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="155" I2="30.107717232922152" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.0641079441243582" LOG_CI_START="-0.0869215791572095" LOG_EFFECT_SIZE="-0.011406817516425683" METHOD="MH" MODIFIED="2010-10-28 13:24:40 +0100" MODIFIED_BY="Elke Wolf" NO="2" P_CHI2="0.20944644492073206" P_Q="0.5922984000002509" P_Z="0.7671837435070986" Q="0.2867692793898332" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.013106579401066916" TOTALS="YES" TOTAL_1="259" TOTAL_2="252" WEIGHT="100.0" Z="0.29606067773562883">
<NAME>Disease free survival</NAME>
<GROUP_LABEL_1>intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.346948074440431" CI_END="1.1930005583730066" CI_START="0.7325100201521024" DF="2" EFFECT_SIZE="0.93481809089003" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="117" I2="53.99070875127825" ID="CMP-001.02.01" LOG_CI_END="0.07664064693795197" LOG_CI_START="-0.1351864301315295" LOG_EFFECT_SIZE="-0.029272891596788798" MODIFIED="2010-10-26 15:35:56 +0100" MODIFIED_BY="Elke Wolf" NO="1" P_CHI2="0.11378172781858298" P_Z="0.588022268424595" STUDIES="3" TAU2="0.02311471995518869" TOTAL_1="198" TOTAL_2="187" WEIGHT="70.48186109454937" Z="0.5417042433553667">
<NAME>Thymostimulin</NAME>
<DICH_DATA CI_END="1.3206735310338371" CI_START="0.8903995118557583" EFFECT_SIZE="1.0844017094017093" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="24" LOG_CI_END="0.1207954737890519" LOG_CI_START="-0.05041508676679898" LOG_EFFECT_SIZE="0.03519019351112646" MODIFIED="2010-10-25 15:39:19 +0100" MODIFIED_BY="Elke Wolf" ORDER="144" O_E="0.0" SE="0.10056993077644999" STUDY_ID="STD-Federico-1995" TOTAL_1="39" TOTAL_2="29" VAR="0.010114310976379944" WEIGHT="33.89378255596834"/>
<DICH_DATA CI_END="1.3940617815473835" CI_START="0.30246598206291775" EFFECT_SIZE="0.6493506493506493" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.14428202110098007" LOG_CI_START="-0.5193234627739061" LOG_EFFECT_SIZE="-0.18752072083646307" MODIFIED="2010-10-25 15:39:20 +0100" MODIFIED_BY="Elke Wolf" ORDER="145" O_E="0.0" SE="0.38980514612823153" STUDY_ID="STD-Mantovani-1988" TOTAL_1="11" TOTAL_2="10" VAR="0.15194805194805192" WEIGHT="4.768383672581892"/>
<DICH_DATA CI_END="1.0629692259817591" CI_START="0.6965396534874457" EFFECT_SIZE="0.8604651162790697" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="86" LOG_CI_END="0.026520691447312783" LOG_CI_START="-0.15705415447249593" LOG_EFFECT_SIZE="-0.06526673151259155" MODIFIED="2010-10-26 15:35:56 +0100" MODIFIED_BY="Elke Wolf" ORDER="144" O_E="0.0" SE="0.10783277320343841" STUDY_ID="STD-Pavesi-1993" TOTAL_1="148" TOTAL_2="148" VAR="0.011627906976744186" WEIGHT="31.819694865999136"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2215582059770176" CI_END="1.603436545525041" CI_START="0.7071065356234092" DF="2" EFFECT_SIZE="1.064800667166479" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" I2="37.91824104592112" ID="CMP-001.02.02" LOG_CI_END="0.20505177781381445" LOG_CI_START="-0.15051514865324883" LOG_EFFECT_SIZE="0.027268314580282806" MODIFIED="2010-10-28 13:24:40 +0100" MODIFIED_BY="Elke Wolf" NO="2" P_CHI2="0.19973208669700038" P_Z="0.7637057814890431" STUDIES="3" TAU2="0.05057149533498985" TOTAL_1="61" TOTAL_2="65" WEIGHT="29.51813890545063" Z="0.3006180300709907">
<NAME>Thymosin fraction 5</NAME>
<DICH_DATA CI_END="9.161174945136615" CI_START="0.7072606823663911" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9619511766663315" LOG_CI_START="-0.15042048429834307" LOG_EFFECT_SIZE="0.4057653461839942" MODIFIED="2010-10-28 13:24:40 +0100" MODIFIED_BY="Elke Wolf" ORDER="150" O_E="0.0" SE="0.6534126199791765" STUDY_ID="STD-Cohen-1979" TOTAL_1="11" TOTAL_2="8" VAR="0.42694805194805185" WEIGHT="1.7885138642814504"/>
<DICH_DATA CI_END="1.3242271044652585" CI_START="0.4858887370637331" EFFECT_SIZE="0.8021390374331551" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.121962472836363" LOG_CI_START="-0.31346316779799843" LOG_EFFECT_SIZE="-0.09575034748081773" MODIFIED="2010-10-25 12:50:32 +0100" MODIFIED_BY="Elke Wolf" ORDER="149" O_E="0.0" SE="0.25577117670030675" STUDY_ID="STD-Scher-1988" TOTAL_1="17" TOTAL_2="15" VAR="0.06541889483065953" WEIGHT="10.02278326758801">
<FOOTNOTE>data from Kaplan-Meier curve differ: 3/17 vs 6/18</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5845718287702655" CI_START="0.7916334098741987" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.19991193057682435" LOG_CI_START="-0.10147588523646105" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2010-10-25 12:50:34 +0100" MODIFIED_BY="Elke Wolf" ORDER="148" O_E="0.0" SE="0.1770366949024731" STUDY_ID="STD-Wara-1981" TOTAL_1="33" TOTAL_2="42" VAR="0.03134199134199134" WEIGHT="17.706841773581168"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.072023923150955" CI_END="1.2466304175369443" CI_START="0.9211240586678608" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0715881997579295" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="182" I2="52.810461877225464" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.09573771938518237" LOG_CI_START="-0.03568187429117709" LOG_EFFECT_SIZE="0.030027922547002664" METHOD="MH" MODIFIED="2010-11-11 12:42:39 +0000" MODIFIED_BY="Elke Wolf" NO="3" P_CHI2="0.024587424168199035" P_Q="0.35047093526028406" P_Z="0.37043430784667786" Q="0.8717516301071774" RANDOM="YES" SCALE="2.81" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02055276802995121" TOTALS="YES" TOTAL_1="395" TOTAL_2="383" WEIGHT="99.99999999999999" Z="0.8956601535022151">
<NAME>Tumour response</NAME>
<GROUP_LABEL_1>intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.618594045626395" CI_END="1.61821079540149" CI_START="0.9645477561125896" DF="6" EFFECT_SIZE="1.2493364605348216" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="113" I2="65.94506925772873" ID="CMP-001.03.01" LOG_CI_END="0.20903509410983753" LOG_CI_START="-0.01567626495868898" LOG_EFFECT_SIZE="0.09667941457557427" MODIFIED="2010-11-10 13:56:02 +0000" MODIFIED_BY="Elke Wolf" NO="1" P_CHI2="0.00725951971851313" P_Z="0.09169899198028371" STUDIES="8" TAU2="0.05936878005785603" TOTAL_1="278" TOTAL_2="275" WEIGHT="64.3837564963343" Z="1.6865028221092935">
<NAME>Thymostimulin</NAME>
<DICH_DATA CI_END="5.044727147522061" CI_START="1.079234671218784" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7028376816670672" LOG_CI_START="0.03311588892212165" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2010-10-25 12:52:42 +0100" MODIFIED_BY="Elke Wolf" ORDER="78" O_E="0.0" SE="0.3933978962347216" STUDY_ID="STD-Airoldi-1987" TOTAL_1="24" TOTAL_2="24" VAR="0.15476190476190477" WEIGHT="3.3992036057528265"/>
<DICH_DATA CI_END="1.171697669476647" CI_START="0.8534624810226534" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.0688155661051688" LOG_CI_START="-0.06881556610516876" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-25 12:52:44 +0100" MODIFIED_BY="Elke Wolf" ORDER="152" O_E="0.0" SE="0.08084520834544436" STUDY_ID="STD-De-Serdio-1997" TOTAL_1="18" TOTAL_2="18" VAR="0.006535947712418305" WEIGHT="21.99920710760599"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-26 14:28:28 +0100" MODIFIED_BY="Elke Wolf" ORDER="79" O_E="0.0" SE="0.0" STUDY_ID="STD-Del-Giacco-1988" TOTAL_1="10" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2843758084610366" CI_START="0.8925842605489204" EFFECT_SIZE="1.0707070707070707" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="51" LOG_CI_END="0.10869211692652354" LOG_CI_START="-0.04935077559208288" LOG_EFFECT_SIZE="0.02967067066722033" MODIFIED="2010-10-26 14:28:29 +0100" MODIFIED_BY="Elke Wolf" ORDER="80" O_E="0.0" SE="0.09283517739036456" STUDY_ID="STD-Federico-1995" TOTAL_1="66" TOTAL_2="68" VAR="0.008618370161100456" WEIGHT="20.42876297772492"/>
<DICH_DATA CI_END="3.96315450714824" CI_START="0.4544981867719917" EFFECT_SIZE="1.3421052631578947" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.5980410040258046" LOG_CI_START="-0.34246784506355227" LOG_EFFECT_SIZE="0.1277865794811262" MODIFIED="2010-10-26 14:28:29 +0100" MODIFIED_BY="Elke Wolf" ORDER="81" O_E="0.0" SE="0.5524595535489757" STUDY_ID="STD-Gonnelli-1995" TOTAL_1="19" TOTAL_2="17" VAR="0.3052115583075335" WEIGHT="1.829329425340708"/>
<DICH_DATA CI_END="4.6676345559217545" CI_START="0.87130738186964" EFFECT_SIZE="2.0166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.6690968463965898" LOG_CI_START="-0.059828606530977026" LOG_EFFECT_SIZE="0.3046341199328064" MODIFIED="2010-10-26 14:28:31 +0100" MODIFIED_BY="Elke Wolf" ORDER="83" O_E="0.0" SE="0.4281744192888377" STUDY_ID="STD-Macchiarini-1989" TOTAL_1="15" TOTAL_2="11" VAR="0.18333333333333338" WEIGHT="2.9228587133245747"/>
<DICH_DATA CI_END="2.748952564508145" CI_START="1.0124938094614964" EFFECT_SIZE="1.6683217477656405" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="19" LOG_CI_END="0.4391672457910489" LOG_CI_START="0.005392376553440861" LOG_EFFECT_SIZE="0.22227981117224482" MODIFIED="2010-04-14 16:43:17 +0100" MODIFIED_BY="Elke Wolf" ORDER="84" O_E="0.0" SE="0.25480150541040364" STUDY_ID="STD-Mustacchi-1994" TOTAL_1="106" TOTAL_2="105" VAR="0.06492380715940796" WEIGHT="6.971854763428099"/>
<DICH_DATA CI_END="1.658743726765969" CI_START="0.6028658820911937" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.21977929340914595" LOG_CI_START="-0.21977929340914598" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-26 14:28:31 +0100" MODIFIED_BY="Elke Wolf" ORDER="86" O_E="0.0" SE="0.2581988897471611" STUDY_ID="STD-Salvati-1984" TOTAL_1="20" TOTAL_2="20" VAR="0.06666666666666665" WEIGHT="6.832539903157184"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="33.1371182151464" CI_END="2.1932587510891275" CI_START="0.2420384607355264" DF="2" EFFECT_SIZE="0.728596577063285" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="69" I2="93.96447214566221" ID="CMP-001.03.02" LOG_CI_END="0.34108987086640885" LOG_CI_START="-0.6161156176640551" LOG_EFFECT_SIZE="-0.13751287339882315" MODIFIED="2010-11-10 13:33:12 +0000" MODIFIED_BY="Elke Wolf" NO="2" P_CHI2="6.37341689424531E-8" P_Z="0.5733396580085204" STUDIES="3" TAU2="0.8769913142408028" TOTAL_1="117" TOTAL_2="108" WEIGHT="35.616243503665686" Z="0.5631398534625759">
<NAME>Thymosin fraction 5</NAME>
<DICH_DATA CI_END="0.8951641850952078" CI_START="0.25746066956854036" EFFECT_SIZE="0.48007246376811596" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="-0.0480973019563303" LOG_CI_START="-0.5892891056284518" LOG_EFFECT_SIZE="-0.318693203792391" MODIFIED="2010-10-26 14:28:26 +0100" MODIFIED_BY="Elke Wolf" ORDER="88" O_E="0.0" SE="0.3178987444196378" STUDY_ID="STD-Bedikian-1984" TOTAL_1="46" TOTAL_2="53" VAR="0.10105961170358217" WEIGHT="4.900243455487057"/>
<DICH_DATA CI_END="1.4463032147088746" CI_START="0.3718292072565341" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.1602593515133059" LOG_CI_START="-0.42965649930821836" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2010-11-08 11:55:53 +0000" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.3465194909031202" STUDY_ID="STD-Cohen-1979" TOTAL_1="30" TOTAL_2="16" VAR="0.12007575757575759" WEIGHT="4.237620108215528">
<FOOTNOTE>response includes only CR</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1493427575374189" CI_START="0.9665080961165966" EFFECT_SIZE="1.053968253968254" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="37" LOG_CI_END="0.06044956350875279" LOG_CI_START="-0.014794503679881246" LOG_EFFECT_SIZE="0.022827529914435797" MODIFIED="2010-11-10 13:33:12 +0000" MODIFIED_BY="Elke Wolf" ORDER="90" O_E="0.0" SE="0.04419873753074324" STUDY_ID="STD-Scher-1988" TOTAL_1="41" TOTAL_2="39" VAR="0.0019535283993115313" WEIGHT="26.4783799399631"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8976464105353625" CI_END="0.7753859533432653" CI_START="0.3774220240670657" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5409692560062785" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="48" I2="0.0" I2_Q="30.540174293051418" ID="CMP-001.04" LOG_CI_END="-0.11048207080464718" LOG_CI_START="-0.4231727606318333" LOG_EFFECT_SIZE="-0.26682741571824026" METHOD="MH" MODIFIED="2010-10-26 15:19:46 +0100" MODIFIED_BY="Elke Wolf" NO="4" P_CHI2="0.5939200845527224" P_Q="0.23019121826365163" P_Z="8.228836534336858E-4" Q="1.4396811247684467" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="105" WEIGHT="100.00000000000001" Z="3.3449804673409194">
<NAME>Toxicity (patients with grade 3/4 infectious complications)</NAME>
<GROUP_LABEL_1>intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.34870965584437663" CI_END="0.7486615711355253" CI_START="0.19482165366227322" DF="2" EFFECT_SIZE="0.38191031057306984" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.1257144586739046" LOG_CI_START="-0.7103627746473089" LOG_EFFECT_SIZE="-0.41803861666060677" MODIFIED="2010-10-25 15:55:06 +0100" MODIFIED_BY="Elke Wolf" NO="1" P_CHI2="0.8399988233579111" P_Z="0.005065329358097947" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="66" WEIGHT="28.604904028982585" Z="2.8028495436186525">
<NAME>Thymostimulin</NAME>
<DICH_DATA CI_END="2.3545282765375117" CI_START="0.10617838082099462" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3719039104383159" LOG_CI_START="-0.9739639017662782" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-03-15 15:05:05 +0000" MODIFIED_BY="Elke Wolf" ORDER="219" O_E="0.0" SE="0.7905694150420949" STUDY_ID="STD-Canovas-1991" TOTAL_1="16" TOTAL_2="16" VAR="0.625" WEIGHT="5.397903146806276">
<FOOTNOTE>we categorised "severe" infectious complications as ECOG grade  3/4;</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.6537903954807707" CI_START="0.009328077570854127" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5627436298536662" LOG_CI_START="-2.0302078510441275" LOG_EFFECT_SIZE="-0.7337321105952307" MODIFIED="2010-10-25 15:55:06 +0100" MODIFIED_BY="Elke Wolf" ORDER="153" O_E="0.0" SE="1.5231125351961998" STUDY_ID="STD-Del-Giacco-1988" TOTAL_1="25" TOTAL_2="23" VAR="2.319871794871795" WEIGHT="1.4542568577331083"/>
<DICH_DATA CI_END="0.8114275155414687" CI_START="0.17330568326384696" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.09075026943768937" LOG_CI_START="-0.7611871951068728" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2010-03-04 14:22:10 +0000" MODIFIED_BY="Elke Wolf" ORDER="218" O_E="0.0" SE="0.393817968854384" STUDY_ID="STD-Sanchiz-1996" TOTAL_1="27" TOTAL_2="27" VAR="0.1550925925925926" WEIGHT="21.7527440244432"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9523355449896501" CI_START="0.4061838513618755" DF="0" EFFECT_SIZE="0.6219512195121951" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-0.021210005752020318" LOG_CI_START="-0.3912773468195403" LOG_EFFECT_SIZE="-0.20624367628578033" MODIFIED="2010-09-14 13:35:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.028915958726566177" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="39" WEIGHT="71.39509597101743" Z="2.1846303777750222">
<NAME>Thymosin fraction 5</NAME>
<DICH_DATA CI_END="0.95233554498965" CI_START="0.4061838513618755" EFFECT_SIZE="0.6219512195121951" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="-0.02121000575202037" LOG_CI_START="-0.3912773468195403" LOG_EFFECT_SIZE="-0.20624367628578033" MODIFIED="2010-09-14 13:35:48 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.21737938800594342" STUDY_ID="STD-Scher-1988" TOTAL_1="41" TOTAL_2="39" VAR="0.047253798329838496" WEIGHT="71.39509597101743"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.3772433667850255" CI_END="1.2307249971264163" CI_START="0.2483837241583869" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5528942558944515" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="43" I2="62.806221262851814" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.09016102159666992" LOG_CI_START="-0.6048768655799378" LOG_EFFECT_SIZE="-0.257357921991634" METHOD="MH" MODIFIED="2010-11-04 12:40:20 +0000" MODIFIED_BY="Elke Wolf" NO="5" P_CHI2="0.06797473816659694" P_Q="1.0" P_Z="0.14664988108935575" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2837545973433048" TOTALS="SUB" TOTAL_1="79" TOTAL_2="70" WEIGHT="100.0" Z="1.4514669417193977">
<NAME>Toxicity (patients with grade 3/4 neutropenia)</NAME>
<GROUP_LABEL_1>intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.3772433667850255" CI_END="1.2307249971264163" CI_START="0.2483837241583869" DF="2" EFFECT_SIZE="0.5528942558944515" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="43" I2="62.806221262851814" ID="CMP-001.05.01" LOG_CI_END="0.09016102159666992" LOG_CI_START="-0.6048768655799378" LOG_EFFECT_SIZE="-0.257357921991634" MODIFIED="2010-11-04 12:40:20 +0000" MODIFIED_BY="Elke Wolf" NO="1" P_CHI2="0.06797473816659694" P_Z="0.14664988108935575" STUDIES="3" TAU2="0.2837545973433048" TOTAL_1="79" TOTAL_2="70" WEIGHT="100.0" Z="1.4514669417193977">
<NAME>Thymostimulin</NAME>
<DICH_DATA CI_END="1.1263256590159003" CI_START="0.2259779780633963" EFFECT_SIZE="0.5045045045045045" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.05166397796224655" LOG_CI_START="-0.6459338815231608" LOG_EFFECT_SIZE="-0.29713495178045707" MODIFIED="2010-11-04 12:40:10 +0000" MODIFIED_BY="Elke Wolf" ORDER="215" O_E="0.0" SE="0.40977243582682465" STUDY_ID="STD-Iaffaioli-1994" TOTAL_1="37" TOTAL_2="32" VAR="0.16791344916344914" WEIGHT="36.903945043170204"/>
<DICH_DATA CI_END="1.4040189591274042" CI_START="0.0049461187110752475" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.1473729723157383" LOG_CI_START="-2.3057354644109878" LOG_EFFECT_SIZE="-1.0791812460476249" MODIFIED="2010-11-04 12:40:18 +0000" MODIFIED_BY="Elke Wolf" ORDER="213" O_E="0.0" SE="1.4409680388158819" STUDY_ID="STD-Macchiarini-1989" TOTAL_1="15" TOTAL_2="11" VAR="2.076388888888889" WEIGHT="7.062423476909507"/>
<DICH_DATA CI_END="0.937795813410304" CI_START="0.5925623375498184" EFFECT_SIZE="0.7454545454545455" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="-0.02789171040806885" LOG_CI_START="-0.2272659551409478" LOG_EFFECT_SIZE="-0.12757883277450835" MODIFIED="2010-11-04 12:40:20 +0000" MODIFIED_BY="Elke Wolf" ORDER="214" O_E="0.0" SE="0.11711341827452133" STUDY_ID="STD-Sanchiz-1996" TOTAL_1="27" TOTAL_2="27" VAR="0.013715552739942988" WEIGHT="56.033631479920295"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-12-18 12:13:41 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Synthetic thymic peptides versus no treatment or placebo</NAME>
<DICH_OUTCOME CHI2="2.9877450457988646" CI_END="1.5571188861010994" CI_START="0.9395947179266543" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2095704529147646" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.1923217722383808" LOG_CI_START="-0.027059433339466903" LOG_EFFECT_SIZE="0.08263116944945698" METHOD="MH" MODIFIED="2010-11-15 11:45:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3935186990693672" P_Q="1.0" P_Z="0.13981964178756587" Q="0.0" RANDOM="YES" SCALE="2.45" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="352" TOTAL_2="144" WEIGHT="100.0" Z="1.476462996862258">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9877450457988646" CI_END="1.5571188861010994" CI_START="0.9395947179266543" DF="3" EFFECT_SIZE="1.2095704529147646" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="50" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.1923217722383808" LOG_CI_START="-0.027059433339466903" LOG_EFFECT_SIZE="0.08263116944945698" MODIFIED="2010-11-15 11:45:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3935186990693672" P_Z="0.13981964178756587" STUDIES="4" TAU2="0.0" TOTAL_1="352" TOTAL_2="144" WEIGHT="100.0" Z="1.476462996862258">
<NAME>Thymosin &#945;<SUB>1</SUB>
</NAME>
<DICH_DATA CI_END="2.5422122157427838" CI_START="0.6422422326790954" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.40521180124520173" LOG_CI_START="-0.1923011394166282" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2010-10-26 15:36:57 +0100" MODIFIED_BY="Elke Wolf" ORDER="442" O_E="0.0" SE="0.3509820590815169" STUDY_ID="STD-Cheng-2004" TOTAL_1="18" TOTAL_2="23" VAR="0.12318840579710144" WEIGHT="13.480444308763667"/>
<DICH_DATA CI_END="1.8284052858034636" CI_START="0.5581433692360083" EFFECT_SIZE="1.010204081632653" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.26207246813685037" LOG_CI_START="-0.2532542303267403" LOG_EFFECT_SIZE="0.004409118905055016" MODIFIED="2010-10-13 11:38:26 +0100" MODIFIED_BY="Elke Wolf" ORDER="440" O_E="0.0" SE="0.3027054535858111" STUDY_ID="STD-Gish-2009" TOTAL_1="14" TOTAL_2="11" VAR="0.09163059163059162" WEIGHT="18.12314440277813"/>
<DICH_DATA CI_END="1.6458114323335211" CI_START="0.8866093423648929" EFFECT_SIZE="1.207970112079701" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="33" LOG_CI_END="0.21638007474726847" LOG_CI_START="-0.0522676967721407" LOG_EFFECT_SIZE="0.0820561889875639" MODIFIED="2010-10-28 13:26:49 +0100" MODIFIED_BY="Elke Wolf" ORDER="439" O_E="0.0" SE="0.15780503081841718" STUDY_ID="STD-Maio-2010" TOTAL_1="292" TOTAL_2="97" VAR="0.024902427751601598" WEIGHT="66.68564448405644"/>
<DICH_DATA CI_END="38.424087299623146" CI_START="0.8078478503465989" EFFECT_SIZE="5.571428571428571" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.5846035603501836" LOG_CI_START="-0.09267042632569894" LOG_EFFECT_SIZE="0.7459665670122424" MODIFIED="2010-10-28 13:27:10 +0100" MODIFIED_BY="Elke Wolf" ORDER="441" O_E="0.0" SE="0.9852390424135508" STUDY_ID="STD-Schulof-1985" TOTAL_1="28" TOTAL_2="13" VAR="0.9706959706959706" WEIGHT="1.710766804401755"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1518091231481282" CI_END="17.297045991108767" CI_START="0.6562968879653365" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3692725409141335" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="36.54438064439842" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.237971940163298" LOG_CI_START="-0.1828996550797921" LOG_EFFECT_SIZE="0.527536142541753" METHOD="MH" MODIFIED="2010-11-10 15:35:31 +0000" MODIFIED_BY="Elke Wolf" NO="2" P_CHI2="0.2068205013927502" P_Q="1.0" P_Z="0.1455649513404175" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.8012852700250266" TOTALS="SUB" TOTAL_1="338" TOTAL_2="133" WEIGHT="100.0" Z="1.4553768875197062">
<NAME>Disease free survival</NAME>
<GROUP_LABEL_1>intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1518091231481282" CI_END="17.297045991108767" CI_START="0.6562968879653365" DF="2" EFFECT_SIZE="3.3692725409141335" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="3" I2="36.54438064439842" ID="CMP-002.02.01" LOG_CI_END="1.237971940163298" LOG_CI_START="-0.1828996550797921" LOG_EFFECT_SIZE="0.527536142541753" MODIFIED="2010-11-10 15:35:31 +0000" MODIFIED_BY="Elke Wolf" NO="1" P_CHI2="0.2068205013927502" P_Z="0.1455649513404175" STUDIES="3" TAU2="0.8012852700250266" TOTAL_1="338" TOTAL_2="133" WEIGHT="100.0" Z="1.4553768875197062">
<NAME>Thymosin &#945;<SUB>1</SUB>
</NAME>
<DICH_DATA CI_END="5.594517033350725" CI_START="0.29184218041514" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7477626004614804" LOG_CI_START="-0.5348519386329068" LOG_EFFECT_SIZE="0.10645533091428677" MODIFIED="2010-10-26 14:30:49 +0100" MODIFIED_BY="Elke Wolf" ORDER="472" O_E="0.0" SE="0.7534141293084076" STUDY_ID="STD-Cheng-2004" TOTAL_1="18" TOTAL_2="23" VAR="0.5676328502415459" WEIGHT="50.88706424150302"/>
<DICH_DATA CI_END="192.85710631501692" CI_START="0.7105871558658805" EFFECT_SIZE="11.706484641638225" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="2.285235646191626" LOG_CI_START="-0.1483826468143043" LOG_EFFECT_SIZE="1.068426499688661" MODIFIED="2010-11-10 15:35:14 +0000" MODIFIED_BY="Elke Wolf" ORDER="475" O_E="0.0" SE="1.4295194319165192" STUDY_ID="STD-Maio-2010" TOTAL_1="292" TOTAL_2="97" VAR="2.0435258062269277" WEIGHT="24.486766417944406"/>
<DICH_DATA CI_END="117.98491616964391" CI_START="0.44444303575969896" EFFECT_SIZE="7.241379310344827" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.071826488297497" LOG_CI_START="-0.35218389462757027" LOG_EFFECT_SIZE="0.8598212968349632" MODIFIED="2010-11-10 15:35:31 +0000" MODIFIED_BY="Elke Wolf" ORDER="473" O_E="0.0" SE="1.423875697975098" STUDY_ID="STD-Schulof-1985" TOTAL_1="28" TOTAL_2="13" VAR="2.027422003284072" WEIGHT="24.626169340552586"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.7520896658470524" CI_START="0.623265476055435" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5292311636200857" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.5742732084163243" LOG_CI_START="-0.20532692889794574" LOG_EFFECT_SIZE="0.18447313975918928" METHOD="MH" MODIFIED="2010-11-16 13:50:33 +0000" MODIFIED_BY="Elke Wolf" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.35363884994827144" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="306" TOTAL_2="108" WEIGHT="0.0" Z="0.927554249255561">
<NAME>Tumour response</NAME>
<GROUP_LABEL_1>intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intervention</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.724082322594292" CI_START="0.13068081727172062" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6743174570906988" LOG_CI_START="-0.8837881581307248" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2010-11-11 12:39:27 +0000" MODIFIED_BY="Elke Wolf" ORDER="40" O_E="0.0" SE="0.9152389511282492" STUDY_ID="STD-Gish-2009" TOTAL_1="14" TOTAL_2="11" VAR="0.8376623376623377" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.385977792523541" CI_START="0.6774057779022913" EFFECT_SIZE="1.9101027397260273" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" LOG_CI_END="0.7312645583951414" LOG_CI_START="-0.16915110338022743" LOG_EFFECT_SIZE="0.281056727507457" MODIFIED="2010-11-11 12:33:32 +0000" MODIFIED_BY="Elke Wolf" ORDER="41" O_E="0.0" SE="0.528908616856261" STUDY_ID="STD-Maio-2010" TOTAL_1="292" TOTAL_2="97" VAR="0.2797443249848031" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-06-16 12:23:54 +0100" MODIFIED_BY="Clare Jess"/>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-12-18 12:15:14 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-12-18 12:14:20 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-12-18 12:14:02 +0000" MODIFIED_BY="[Empty name]">Glossary of terms</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-18 12:14:20 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="10">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>EORTC</P>
</TD>
<TD>
<P>European Organization for Research and Treatment of Cancer</P>
</TD>
</TR>
<TR>
<TD>
<P>Breslow thickness</P>
</TD>
<TD>
<P>Measuring of the depth of penetration of a melanoma into the skin in mm</P>
</TD>
</TR>
<TR>
<TD>
<P>Dukes</P>
</TD>
<TD>
<P>Staging score for Colorectal cancer</P>
</TD>
</TR>
<TR>
<TD>
<P>WHO</P>
</TD>
<TD>
<P>World Health Organization</P>
</TD>
</TR>
<TR>
<TD>
<P>RECIST</P>
</TD>
<TD>
<P>Response Evaluation Criteria In Solid Tumors: a set of published rules that define when malignant tumours respond ("respond"), stay the same ("stable") or worsen ("progression") during treatments</P>
</TD>
</TR>
<TR>
<TD>
<P>OS</P>
</TD>
<TD>
<P>Overall survival: denotes the chances of staying alive for a group of individuals suffering from a cancer. It denotes the percentage of individuals in the group who are likely to be alive after a particular duration of time</P>
</TD>
</TR>
<TR>
<TD>
<P>DFS</P>
</TD>
<TD>
<P>Disease-free survival: denotes the chances of staying free of disease after a particular treatment for a group of individuals suffering from a cancer. It is the percentage of individuals in the group who are likely to be free of disease after a specified duration of time.</P>
</TD>
</TR>
<TR>
<TD>
<P>pTE</P>
</TD>
<TD>
<P>Purified extracts from animal thymus glands containing peptide mixtures</P>
</TD>
</TR>
<TR>
<TD>
<P>sTP</P>
</TD>
<TD>
<P>Synthetically produced single thymic peptides.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-12-18 12:15:14 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-12-18 12:14:32 +0000" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-12-18 12:15:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>PubMed - CENTRAL - MEDLINE</B>
</P>
<P>These databases were searched with 37 terms that referred to Thymyc/Peptide extracts.</P>
<P>Search terms used to identify interventions were:</P>
<OL>
<LI>Thymostimulin or thymoxtimulin</LI>
<LI>TF5</LI>
<LI>Thymosin</LI>
<LI>Thymosin fraction 5</LI>
<LI>T&#945;1 or Talpha1 or Thymosin alfa one or thymalfasin or zadaxin</LI>
<LI>Thymic serum factors</LI>
<LI>T&#946;4 or thymosin beta four</LI>
<LI>T&#947; or thymosin gamma</LI>
<LI>TFX or thymomodulin or thymic factor x or TFX-Polfa</LI>
<LI>TFX-Jelfa</LI>
<LI>TP-1</LI>
<LI>Thym-uvocal or Thymuvocal</LI>
<LI>Thymoject/thymojekt</LI>
<LI>Biosin</LI>
<LI>Thymex-L or thymex l</LI>
<LI>Thymophisin/Thymophysin</LI>
<LI>Zellmedin-thymus or THX</LI>
<LI>Neytumourin Sol</LI>
<LI>NeyThymun</LI>
<LI>Thymuskin</LI>
<LI>Thymushydrolysate</LI>
<LI>Solcothymosin</LI>
<LI>Thymowied</LI>
<LI>Leucotrofina</LI>
<LI>
<I>FTS-Zn  </I>
</LI>
<LI>Thymulin</LI>
<LI>Thymic serum factor</LI>
<LI>
<I>THF</I>&#947;</LI>
<LI>Thymic humoral factor</LI>
<LI>HTH or Homeostatic thymic hormone</LI>
<LI>Thymopoietin (I and II) or TP5 or Thymopentin</LI>
<LI>Prothymosin &#945;</LI>
<LI>Thymus peptide</LI>
<LI>LSH</LI>
<LI>Lymphocytopoietic factor</LI>
<LI>Wobe-Mugos</LI>
<LI>t-activin or tactivin</LI>
</OL>
<P>PubMed limits to identify the type of study: </P>
<UL>
<LI>Humans</LI>
<LI>Type of Article:  Clinical Trial OR Meta-Analysis OR Randomized Controlled Trial OR Review</LI>
<LI>More Publication Types: Clinical Trial, Phase I OR  Clinical Trial, Phase II OR  Clinical Trial, Phase III OR Clinical Trial, Phase IV OR Controlled Clinical Trial OR Multicenter Study</LI>
<LI>Topics: Cancer OR Complementary Medicine OR  Systematic Reviews OR Toxicology</LI>
<LI>Age : All Adult: 19+ years OR  Young Adult: 19-24 years OR Adult: 19-44 years OR Middle Aged: 45-64 years OR Middle Aged + Aged: 45+ years OR Aged: 65+ years80 and over: 80+ years</LI>
</UL>
<P>
<B>Example of search:</B>
</P>
<P>("thymostimulin"[Substance Name] <B>OR</B> "thymostimulin"[All Fields])</P>
<P>
<B>AND</B>
</P>
<P> ("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields])</P>
<P>
<B>AND </B>
</P>
<P>("humans"[MeSH Terms])</P>
<P>
<B>AND </B>
</P>
<P>(Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Clinical Trial, Phase I[ptyp] OR Clinical Trial, Phase II[ptyp] OR Clinical Trial, Phase III[ptyp] OR Clinical Trial, Phase IV[ptyp] OR Controlled Clinical Trial[ptyp] OR Multicenter Study[ptyp])</P>
<P>
<B>AND </B>
</P>
<P>(cancer[sb] OR cam[sb] OR systematic[sb] OR tox[sb] OR medline[sb] OR pubmed pmc local[sb]) AND ("adult"[MeSH Terms] OR "young adult"[MeSH Terms] OR "adult"[MeSH Terms:noexp] OR "middle aged"[MeSH Terms] OR ("middle aged"[MeSH Terms] OR "aged"[MeSH Terms]) OR "aged"[MeSH Terms] OR "aged, 80 and over"[MeSH Terms]))</P>
<P>
<B>EMBASE SEARCH:</B>
</P>
<P>The same 37 above mentioned PubMed terms were also searched in EMBASE.</P>
<P>EMBASE limits to identify the type of study:</P>
<UL>
<LI>human</LI>
<LI>article or "review"</LI>
<LI>adult &lt;18 to 64 years&gt; or aged &lt;65+ years&gt;</LI>
<LI>intramuscular or subcutaneous</LI>
</UL>
<P>
<B>Example of search:</B>
</P>
<P>Thymic extracts <B>OR</B> Thymus extracts <B>OR</B> Thymos* <B>OR</B> Thym*</P>
<P>
<B>AND</B>
</P>
<P>Cancer).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>
<B>OTHER DATABASE SEARCHES</B>
</P>
<P>The other databases were searched using the following specific terms as text words combined by the Boolean operator "OR":</P>
<P>thymus therapy; thymic peptide; thymic hormone; Thymustherapie; thymosin; thymosin fraction 5: thymosin fraction V; thymulin; thymusfactor; thymopentin; thymostimulin; thymic extracts; Ney-Tumorin; Neythymun; Solcothymosin; Thymex; Thymowied; Thym-Uvocal; Thymoject; thymophysin; Zellmedin-Thymus; THX; TF5; TP-1;THF;TFX;TP5.</P>
<P>These following terms were used to identify the study design:</P>
<P>"therapy"; "treatment"; clinical trial; randomised clinical trial as MeSH terms.</P>
<P>These following terms were used to identify cancer patients:</P>
<P>"cancer"; "tumours"; "neoplasms" as MeSH terms.</P>
<P>
<B>Date of last search 10.3.2010</B>
</P>
<P>
<B>All databases were searched from their inception until March 2010</B>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-12-08 14:07:04 +0000" MODIFIED_BY="Clare Jess" NO="3">
<TITLE MODIFIED="2010-06-15 15:32:10 +0100" MODIFIED_BY="Clare Jess">Kirkwood formulae</TITLE>
<APPENDIX_BODY MODIFIED="2010-06-15 15:32:48 +0100" MODIFIED_BY="Clare Jess">
<P>Survival Time (t)=S(t)=exp(-&#654;t). This transforms for the median survival time to T<SUB>med</SUB> = - ln (0.5) / &#654;. The number E<SUB>CG</SUB> of events in the control group given N<SUB>CG</SUB> patients in the control group at median survival time of the intervention group T<SUB>med</SUB>(M<SUB>IG</SUB>) can now be calculated via E<SUB>CG</SUB> = N<SUB>CG</SUB> * (1-EXP(-T<SUB>med</SUB>(M<SUB>IG</SUB>)*ln(2)/ T<SUB>med</SUB>(M<SUB>CG</SUB>)). Obviously, the number of events in the intervention group is E<SUB>IG=</SUB> 0.5*N<SUB>IG</SUB>. Of note, these calculations assume no censoring of patients up to median follow-up time. With these numbers a relative risk with an approximate 95% CI can be calculated as implemented in standard meta-analysis software.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>